Prior Art Document

```
 (FILE 'HOME' ENTERED AT 14:16:53 ON 24 APR 2007)

     FILE 'REGISTRY' ENTERED AT 14:17:45 ON 24 APR 2007
L1            76 S EEEAYGW'NLE'DF/SQSFP

     FILE 'CAPLUS' ENTERED AT 14:18:39 ON 24 APR 2007
L2            55 S L1

     FILE 'REGISTRY' ENTERED AT 14:18:54 ON 24 APR 2007
L3        114425 S ALAL/SQSP
L4         17544 S ALALA/SQSP
L5         14925 S VLALA/SQSP
L6         31615 S FALA/SQSP

     FILE 'CAPLUS' ENTERED AT 14:23:02 ON 24 APR 2007
L7         14743 S L3
L8          3622 S L4
L9          2348 S L5
L10         5282 S L6
L11            2 S L2 AND (L7 OR L8 OR L9 OR L10)
                 SEL L11 2 RN
L12       388792 S E1-E13

     FILE 'REGISTRY' ENTERED AT 14:29:11 ON 24 APR 2007
L13           13 S E1-E13
L14            2 S L13 AND L1
L15            3 S L13 AND (L3 OR L4 OR L5 OR L6)
                 E CEMADOTIN/CN
L16            1 S E3

     FILE 'CAPLUS' ENTERED AT 14:43:15 ON 24 APR 2007
L17           30 S L16
L18            0 S L2 AND L17

     FILE 'REGISTRY' ENTERED AT 14:46:34 ON 24 APR 2007
                 E HEMIASTERLIN/CN
L19            1 S E3
                 E ESPERAMICIN C/CN
L20            1 S E3
                 E NEOCARZINOSTATIN/CN
L21            1 S E3
                 E MAYTANSINOID DM1/CN
L22            1 S E2
                 E RHIZOXIN/CN
L23            1 S E3

     FILE 'CAPLUS' ENTERED AT 14:51:33 ON 24 APR 2007
L24           39 S L19
L25           21 S L20
L26          877 S L21
L27           63 S L22
L28          167 S L23
L29            0 S L2 AND (L24 OR L25 OR L26 OR L27 OR L28)
```

Prior Art Document

```
(FILE 'HOME' ENTERED AT 15:59:44 ON 24 APR 2007)

     FILE 'REGISTRY' ENTERED AT 15:59:58 ON 24 APR 2007
L1         31615 S FALA/SQSP

     FILE 'CAPLUS' ENTERED AT 16:00:16 ON 24 APR 2007
L2          5282 S L1
L3        122699 S CONJUGAT?/OBI
               E ANTITUMOR AGENTS/CT
               E E3+ALL
L4        239331 S ANTITUMOR AGENTS+OLD/CT
L5        176451 S LIGAND#/OBI

=> s l2 and l4 and l5
L6           31 L2 AND L4 AND L5

=> s l6 and py<2002
L7            8 L6 AND PY<2002

=>
=> d l7 1-8 ibib abs hitstr hitseq

L7   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:310866  CAPLUS
DOCUMENT NUMBER:          140:337887
TITLE:                    Alpha-2 macroglobulin receptor as heat shock protein
                          receptor for screening compounds useful for diagnosis
                          and treatment of autoimmune, proliferative, and
                          infectious diseases
INVENTOR(S):              Srivastava, Pramod K.
PATENT ASSIGNEE(S):       University of Connecticut Health Center, USA
SOURCE:                   U.S. Pat. Appl. Publ., 185 pp., Cont.-in-part of U.S.
                          Ser. No. 668,724.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2004072993         A1    20040415    US 2000-750972           20001228
     US 7179462            B2    20070220
     US 7186515            B1    20070306    US 2000-625137           20000725
     CA 2410736            A1    20011206    CA 2001-2410736          20010604 <--
     WO 2001092474         A1    20011206    WO 2001-US18041          20010604 <--
         W:  AU, CA, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     EP 1290140            A1    20030312    EP 2001-941889           20010604
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2004514113         T     20040513    JP 2002-500668           20010604
PRIORITY APPLN. INFO.:                       US 2000-209095P      P  20000602
                                             US 2000-625137       A2 20000725
                                             US 2000-668724       A2 20000922
                                             US 2000-750972       A  20001228
                                             WO 2001-US18041      W  20010604
AB   The present invention relates to the use of α2 macroglobulin
```

Prior Art Document

("α2M") receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other mols. that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compds. that interact with the α2M receptor, and modulate the interaction of the α2M receptor with its ligand, such as HSPs, and methods for using compns. comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

IT **680295-94-7**, α2-macroglobulin (human precursor)
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; α2 macroglobulin receptor as heat shock protein receptor for screening compds. useful for diagnosis and treatment of autoimmune, proliferative, and infectious diseases)
RN 680295-94-7 CAPLUS
CN α2-macroglobulin (human precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **680295-94-7**, α2-macroglobulin (human precursor)
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; α2 macroglobulin receptor as heat shock protein receptor for screening compds. useful for diagnosis and treatment of autoimmune, proliferative, and infectious diseases)
RN 680295-94-7 CAPLUS
CN α2-macroglobulin (human precursor) (9CI) (CA INDEX NAME)

SEQ

```
      1 MGKNKLLHPS LVLLLLVLLP TDASVSGKPQ YMVLVPSLLH TETTEKGCVL
     51 LSYLNETVTV SASLESVRGN RSLFTDLEAE NDVLHCVAFA VPKSSSNEEV
    101 MFLTVQVKGP TQEFKKRTTV MVKNEDSLVF VQTDKSIYKP GQTVKFRVVS
    151 MDENFHPLNE LIPLVYIQDP KGNRIAQWQS FQLEGGLKQF SFPLSSEPFQ
    201 GSYKVVVQKK SGGRTEHPFT VEEFVLPKFE VQVTVPKIIT ILEEEMNVSV
    251 CGLYTYGKPV PGHVTVSICR KYSDASDCHG EDSQAFCEKF SGQLNSHGCF
    301 YQQVKTKVFQ LKRKEYEMKL HTEAQIQEEG TVVELTGRQS SEITRTITKL
    351 SFVKVDSHFR QGIPFFGQVR LVDGKGVPIP NKVIFIRGNE ANYYSNATTD
    401 EHGLVQFSIN TTNVMGTSLT VRVNYKDRSP CYGYQWVSEE HEEAHHTAYL
    451 VFSPSKSFVH LEPMSHELPC GHTQTVQAHY ILNGGTLLGL KKLSFYYLIM
    501 AKGGIVRTGT HGLLVKQEDM KGHFSISIPV KSDIAPVARL LIYAVLPTGD
    551 VIGDSAKYDV ENCLANKVDL SFSPSQSLPA SHAHLRVTAA PQSVCALRAV
    601 DQSVLLMKPD AELSASSVYN LLPEKDLTGF PGPLNDQDDE DCINRHNVYI
    651 NGITYTPVSS TNEKDMYSFL EDMGLKAFTN SKIRKPKMCP QLQQYEMHGP
    701 EGLRVGFYES DVMGRGHARL VHVEEPHTET VRKYFPETWI WDLVVVNSAG
    751 VAEVGVTVPD TITEWKAGAF CLSEDAGLGI SSTASLRAFQ PFFVELTMPY
    801 SVIRGEAFTL KATVLNYLPK CIRVSVQLEA SPAFLAVPVE KEQAPHCICA
    851 NGRQTVSWAV TPKSLGNVNF TVSAEALESQ ELCGTEVPSV PEHGRKDTVI
    901 KPLLVEPEGL EKETTFNSLL CPSGGEVSEE LSLKLPPNVV EESARASVSV
    951 LGDILGSAMQ NTQNLLQMPY GCGEQNMVLF APNIYVLDYL NETQQLTPEV
   1001 KSKAIGYLNT GYQRQLNYKH YDGSYSTFGE RYGRNQGNTW LTAFVLKTFA
   1051 QARAYIFIDE AHITQALIWL SQRQKDNGCF RSSGSLLNNA IKGGVEDEVT
   1101 LSAYITIALL EIPLTVTHPV VRNALFCLES AWKTAQEGDH GSHVYTKALL
   1151 AYAFALAGNQ DKRKEVLKSL NEEAVKKDNS VHWERPQKPK APVGHFYEPQ
   1201 APSAEVEMTS YVLLAYLTAQ PAPTSEDLTS ATNIVKWITK QQNAQGGFSS
   1251 TQDTVVALHA LSKYGAATFT RTGKAAQVTI QSSGTFSSKF QVDNNNRLLL
   1301 QQVSLPELPG EYSMKVTGEG CVYLQTSLKY NILPEKEEFP FALGVQTLPQ
   1351 TCDEPKAHTS FQISLSVSYT GSRSASNMAI VDVKMVSGFI PLKPTVKMLE
   1401 RSNHVSRTEV SSNHVLIYLD KVSNQTLSLF FTVLQDVPVR DLKPAIVKVY
```

Prior Art Document

1451 DYYETDEFAI AEYNAPCSKD LGNA

REFERENCE COUNT: 155 THERE ARE 155 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:759252 CAPLUS
DOCUMENT NUMBER: 139:275728
TITLE: Human PRO polypeptides, polynucleotides, and antibodies for agonist/antagonist screening and diagnosis and treatment of cartilage diseases, diabetes mellitus and cancers
INVENTOR(S): Eaton, Dan L.; Filvaroff, Ellen; Gerritsen, Mary E.; Goddard, Audrey; Godowski, Paul J.; Grimaldi, J. Christopher; Gurney, Austin L.; Watanabe, Colin K.; Wood, William I.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 396 pp., Cont.-in-part of U.S. Ser. No. 6,867.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 152
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003181669	A1	20030925	US 2002-63570	20020502
AT 310810	T	20051215	AT 2001-127791	19980916
ES 2253320	T3	20060601	ES 2001-127791	19980916
NZ 528704	A	20050225	NZ 1999-528704	19990308
CA 2450824	A1	20000420	CA 1999-2450824	19991005 <--
EP 1466977	A1	20041013	EP 2004-7618	19991202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NZ 523206	A	20041224	NZ 2000-523206	20000211
NZ 523207	A	20041224	NZ 2000-523207	20000211
NZ 523208	A	20041224	NZ 2000-523208	20000211
NZ 523209	A	20041224	NZ 2000-523209	20000211
WO 2000070050	A1	20001123	WO 2000-US7532	20000321 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2481685	A1	20010308	CA 2000-2481685	20000824 <--
CA 2481691	A1	20010308	CA 2000-2481691	20000824 <--
CA 2481731	A1	20010308	CA 2000-2481731	20000824 <--
CA 2481756	A1	20010308	CA 2000-2481756	20000824 <--
CA 2481788	A1	20010308	CA 2000-2481788	20000824 <--
US 2002102723	A1	20020801	US 2001-870574	20010530
US 6551799	B2	20030422		
EP 1657251	A2	20060517	EP 2005-24036	20010601

Prior Art Document

EP 1657251		A3	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR					
AU 758921		B2	20030403	AU 2001-57764	20010801
AU 759004		B2	20030403	AU 2001-57765	20010801
CA 2420193		A1	20020228	CA 2001-2420193	20010823
JP 2004520810		T	20040715	JP 2002-522275	20010823
US 2003073129		A1	20030417	US 2001-946374	20010904
US 2003207803		A1	20031106	US 2001-143026	20011019
US 2003199021		A1	20031023	US 2001-13924	20011025
EP 1397383		A2	20040317	EP 2001-990229	20011213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AU 772759		B2	20040506	AU 2002-14767	20020201
AU 772723		B2	20040506	AU 2002-14769	20020201
AU 772734		B2	20040506	AU 2002-14771	20020201
AU 778585		B2	20041209	AU 2002-14753	20020201
CA 2449602		A1	20021219	CA 2002-2449602	20020403
WO 2002101069		A2	20021219	WO 2002-US10513	20020403
WO 2002101069		A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1402260		A2	20040331	EP 2002-731246	20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005500030		T	20050106	JP 2003-503819	20020403
US 2003190669		A1	20031009	US 2002-63521	20020501
US 2003191287		A1	20031009	US 2002-63561	20020502
US 2003190716		A1	20031009	US 2002-63617	20020503
US 2003191288		A1	20031009	US 2002-63618	20020503
US 2003191284		A1	20031009	US 2002-63664	20020507
US 2003191290		A1	20031009	US 2002-63668	20020507
US 2003190698		A1	20031009	US 2002-63718	20020508
US 2004058411		A1	20040325	US 2002-63745	20020509
US 2003148438		A1	20030807	US 2002-145821	20020514
US 2003170788		A1	20030911	US 2002-145634	20020514
US 2003166084		A1	20030904	US 2002-146793	20020515
US 2003134380		A1	20030717	US 2002-147509	20020516
US 2004214269		A1	20041028	US 2002-147518	20020516
US 2003180875		A1	20030925	US 2002-147505	20020517
US 2003199027		A1	20031023	US 2002-152396	20020520
US 2005074837		A1	20050407	US 2002-158788	20020530
US 2003068695		A1	20030410	US 2002-192012	20020709
US 2003068696		A1	20030410	US 2002-192014	20020709
US 2003049743		A1	20030313	US 2002-194394	20020711
US 2003049745		A1	20030313	US 2002-194485	20020711
US 2003064446		A1	20030403	US 2002-194460	20020711
US 2003153037		A1	20030814	US 2002-194457	20020711
US 2003059879		A1	20030327	US 2002-194456	20020712
US 2003064448		A1	20030403	US 2002-194484	20020712
US 2003049747		A1	20030313	US 2002-195899	20020715

Prior Art Document

US 2003064449	A1	20030403	US 2002-195884	20020715
US 2003063112	A1	20030403	US 2002-195896	20020715
US 2003068705	A1	20030410	US 2002-195886	20020715
US 2003068706	A1	20030410	US 2002-195891	20020715
US 2003071834	A1	20030417	US 2002-195898	20020715
US 2003049749	A1	20030313	US 2002-196750	20020716
US 2003065159	A1	20030403	US 2002-196757	20020716
US 2003068710	A1	20030410	US 2002-196761	20020716
US 2003207398	A1	20031106	US 2002-198759	20020718
US 2003215910	A1	20031120	US 2002-199463	20020718
US 2003180881	A1	20030925	US 2002-202475	20020723
US 2003064462	A1	20030403	US 2002-206919	20020726
US 2003064463	A1	20030403	US 2002-206922	20020726
US 2003068756	A1	20030410	US 2002-206912	20020726
US 2003068759	A1	20030410	US 2002-206920	20020726
US 2003068760	A1	20030410	US 2002-206921	20020726
US 2003073183	A1	20030417	US 2002-206917	20020726
US 2003096359	A1	20030522	US 2002-205910	20020726
US 2004048334	A1	20040311	US 2002-205890	20020726
US 2003068766	A1	20030410	US 2002-207917	20020729
US 2003068769	A1	20030410	US 2002-207920	20020729
US 2003068773	A1	20030410	US 2002-208023	20020729
US 2003068774	A1	20030410	US 2002-208026	20020729
US 2003073184	A1	20030417	US 2002-207923	20020729
US 2003073185	A1	20030417	US 2002-207924	20020729
US 2003215912	A1	20031120	US 2002-207915	20020729
US 2004048335	A1	20040311	US 2002-208024	20020729
US 2003120056	A1	20030626	US 2002-289498	20021105
US 2003144498	A1	20030731	US 2002-289527	20021105
US 2004249141	A1	20041209	US 2002-289490	20021105
US 2003211576	A1	20031113	US 2002-298993	20021118
US 2003224984	A1	20031204	US 2002-305654	20021126
US 2003186306	A1	20031002	US 2003-410374	20030408
US 2003199044	A1	20031023	US 2003-410552	20030408
AU 2003248191	A1	20031106	AU 2003-248191	20030919
AU 2003257515	A1	20031120	AU 2003-257515	20031023
AU 2003259607	A1	20031127	AU 2003-259607	20031031
US 2004258710	A1	20041223	US 2004-791618	20040302
US 2005019823	A1	20050127	US 2004-931886	20040831
US 2005187382	A1	20050825	US 2004-950374	20040923
US 2005153396	A1	20050714	US 2004-955952	20040929
US 2005153348	A1	20050714	US 2004-20604	20041221
US 2005176041	A1	20050811	US 2004-26279	20041230
US 2005214819	A1	20050929	US 2005-30464	20050105
US 2005164266	A1	20050728	US 2005-36582	20050113
US 2005170396	A1	20050804	US 2005-36869	20050114
US 2005202475	A1	20050915	US 2005-38328	20050118
US 2005176046	A1	20050811	US 2005-46650	20050128
US 2005176104	A1	20050811	US 2005-52503	20050204
US 2005136515	A1	20050623	US 2005-56802	20050211
US 2005136475	A1	20050623	US 2005-60652	20050216
US 2005158830	A1	20050721	US 2005-80062	20050314
US 2005214846	A1	20050929	US 2005-117757	20050427
AU 2005205752	A1	20050922	AU 2005-205752	20050831
AU 2005205754	A1	20050922	AU 2005-205754	20050831
AU 2005205755	A1	20050922	AU 2005-205755	20050831
AU 2005205758	A1	20050922	AU 2005-205758	20050831
US 2006068439	A1	20060330	US 2005-265966	20051103
JP 2007037551	A	20070215	JP 2006-221327	20060814

Prior Art Document

PRIORITY APPLN. INFO.:

US	1999-397342	A1 19990915
WO	2000-US7532	A 20000321
US	2001-870574	A1 20010530
US	2001-869599	A2 20010629
US	1997-63128P	P 19971024
US	1998-82704P	P 19980422
US	1998-83742P	P 19980430
US	1998-84366P	P 19980505
US	1998-85339P	A1 19980513
US	1998-87106P	P 19980528
US	1998-88326P	P 19980604
US	1998-88217P	P 19980605
US	1998-88655P	P 19980609
US	1998-89947P	P 19980619
US	1998-90676P	P 19980625
US	1998-91982P	P 19980707
US	1998-94651P	A1 19980730
US	1998-97022P	P 19980818
US	1998-97954P	P 19980826
US	1998-97974P	P 19980826
US	1998-97979P	P 19980826
AU	1998-93881	A3 19980914
US	1998-101279P	P 19980922
AU	1998-93178	A3 19981002
US	1998-105169P	P 19981022
US	1998-63561P	P 19981028
US	1998-114223P	P 19981230
AU	1999-30721	A3 19990308
US	1999-129674P	P 19990416
US	1999-131293P	P 19990427
US	1999-133459P	P 19990511
US	1999-134287P	P 19990514
US	1999-140650P	P 19990622
US	1999-149395P	P 19990817
US	1999-151689P	P 19990831
CA	1999-2344465	A3 19991005
AU	2000-17482	A3 19991130
AU	2000-17499	A3 19991202
EP	1999-960644	A3 19991202
US	1999-169495P	P 19991207
US	2000-198121P	P 20000418
US	2000-198585P	P 20000418
US	2000-199397P	P 20000425
US	2000-199550P	P 20000425
US	2000-201516P	P 20000503
US	2000-204675P	P 20000517
WO	2000-US14042	W 20000522
US	2000-227133P	P 20000822
CA	2000-2380355	A3 20000824
WO	2000-US23328	W 20000824
US	2000-232887P	P 20000915
US	2000-690189	A3 20001016
JP	2002-576286	A3 20010322
US	2001-816920	B1 20010322
EP	2001-939834	A3 20010601
EP	2004-5726	A3 20010601
US	2001-880457	A 20010612
US	2001-882636	B1 20010614
US	2001-927796	B1 20010809

Prior Art Document

WO 2001-US26626	W	20010823
US 2001-990711	A1	20011114
US 2001-992521	B1	20011114
WO 2001-US48938	W	20011213
US 2002-52586	A1	20020115
WO 2002-US10513	W	20020403
US 2002-123155	A1	20020415
US 2002-127825	A1	20020422
US 2002-127966	B1	20020423
US 2002-141703	A1	20020508
US 2002-145627	A1	20020514
US 2002-145751	A	20020514
US 2002-146793	A1	20020515
US 2002-197703	B1	20020717
US 2002-197708	A1	20020717
US 2002-199666	A1	20020718
US 2002-199464	B1	20020719
US 2002-211858	A1	20020802
AU 2003-261484	A	20031106
US 2004-797366	A1	20040309

AB The present invention is directed to novel PRO polypeptides, and to nucleic acid mols. encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide mols. comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antisense oligonucleotide probes and antibodies which bind to the polypeptides of the present invention, and to methods for producing the polypeptides of the present invention. The PRO polypeptides, polynucleotides and antibodies are useful for screening of agonists and antagonists, as well as for diagnosis and treatment of PRO protein-associated diseases, such as sports-related joint problems, articular cartilage defects, osteoarthritis, rheumatoid arthritis, diabetes, hyper- or hypoinsulinemia, lung cancer, rectal cancer, melanoma, stomach cancer, and esophageal cancer.

IT **604019-94-5P**
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human PRO polypeptides, polynucleotides, and antibodies for agonist/antagonist screening and diagnosis and treatment of cartilage diseases, diabetes mellitus and cancers)

RN 604019-94-5 CAPLUS

CN Protein PRO3435 (human clone DNA85066-2534) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **604019-94-5P**
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human PRO polypeptides, polynucleotides, and antibodies for agonist/antagonist screening and diagnosis and treatment of cartilage diseases, diabetes mellitus and cancers)

RN 604019-94-5 CAPLUS

CN Protein PRO3435 (human clone DNA85066-2534) (9CI) (CA INDEX NAME)

SEQ 1 MLLLLLEYNF PIENNCQHLK TTHTFRVKNL NPKKFSIHDQ DHKVLVLDSG
51 NLIAVPDKNY IRPEIFFALA SSLSSASAEK GSPILLGVSK GEFCLYCDKD

Prior Art Document

101 KGQSHPSLQL KKEKLMKLAA QKESARRPFI FYRAQVGSWN MLESAAHPGW
151 FICTSCNCNE PVGVTDKFEN RKHIEFSFQP VCKAEMSPSE VSD

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:281945 CAPLUS
DOCUMENT NUMBER: 138:285609
TITLE: cDNA encoding CTTP transmembrane protein and their use in diagnosis and treatment of cancer
INVENTOR(S): Lasek, Amy K. W.; Baughn, Mariah R.; Azimzai, Yalda
PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of Appl. No. PCT/US00/07817.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003068311	A1	20030410	US 2002-187657	20020701
US 7105315	B2	20060912		
WO 2000056891	A2	20000928	WO 2000-US7817	20000322 <--
WO 2000056891	A3	20010405		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2006275314	A1	20061207	US 2006-498712	20060804

PRIORITY APPLN. INFO.:

US 1999-139565P	P	19990616
WO 2000-US7817	A2	20000322
US 1999-125537P	P	19990322
US 2002-187657	A3	20020701

AB The invention provides a transmembrane protein that is differentially expressed in neoplastic disorders. It also provides for the use of the protein, a cDNA encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of a neoplastic disorder.

IT **505104-88-1**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cDNA encoding CTTP transmembrane protein and their use in diagnosis and treatment of cancer)
RN 505104-88-1 CAPLUS
CN Transmembrane protein (human clone 4901066CD1 gene CTTP) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **505104-88-1**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cDNA encoding CTTP transmembrane protein and

their use in diagnosis and treatment of cancer)
RN 505104-88-1 CAPLUS
CN Transmembrane protein (human clone 4901066CD1 gene CTTP) (9CI) (CA INDEX NAME)

SEQ
```
  1 MTLWNGVLPF YPQPRHAAGF SVPLLIVILV FLALAASFLL ILPGIRGHSR
 51 WFWLVRVLLS LFIGAEIVAV HFSAEWFVGT VNTNTSYKAF SAARVTARVG
101 LLVGLEGINI TLTGTPVHQL NETIDYNEQF TWRLKENYAA EYANALEKGL
151 PDPVLYLAEK FTPSSPCGLY HQYHLAGHYA SATLWVAFCF WLLSNVLLST
201 PAPLYGGLAL LTTGAFALFG VFALASISSV PLCPLRLGSS ALTTQYGAAF
251 WVTLATGVLC LFLGGAVVSL QYVRPSALRT LLDQSAKDCS QERGGSPLIL
301 GDPLHKQAAL PDLKCITTNL
```

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:886449 CAPLUS
DOCUMENT NUMBER: 136:36328
TITLE: Alpha 2 macroglobulin receptors as a heat shock protein receptor and uses thereof
INVENTOR(S): Srivastava, Pramod K.
PATENT ASSIGNEE(S): University of Connecticut Health Center, USA
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001092474	A1	20011206	WO 2001-US18041		20010604 <--
W: AU, CA, JP					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
US 7186515	B1	20070306	US 2000-625137		20000725
US 2004072993	A1	20040415	US 2000-750972		20001228
US 7179462	B2	20070220			
CA 2410736	A1	20011206	CA 2001-2410736		20010604 <--
EP 1290140	A1	20030312	EP 2001-941889		20010604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
JP 2004514113	T	20040513	JP 2002-500668		20010604
PRIORITY APPLN. INFO.:			US 2000-209095P	P	20000602
			US 2000-625137	A	20000725
			US 2000-668724	A	20000922
			US 2000-750972	A	20001228
			WO 2001-US18041	W	20010604

AB The present invention relates to the use of alpha (2) macroglobulin ("α2M") receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other mols. that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compds. that interact with the α2M receptor, and modulate the interaction of the α2M receptor with its ligand, such as HSPs, and methods for using compns. comprising

Prior Art Document

α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

IT **96880-40-9**, α2-Macroglobulin (human precursor protein moiety reduced)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; α2 macroglobulin receptors as heat shock protein receptor for screening antagonists or agonists and for immunotherapy of autoimmune disease, infection, proliferative disease or cancer)

RN 96880-40-9 CAPLUS

CN α2-Macroglobulin (human precursor protein moiety reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **96880-40-9**, α2-Macroglobulin (human precursor protein moiety reduced)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; α2 macroglobulin receptors as heat shock protein receptor for screening antagonists or agonists and for immunotherapy of autoimmune disease, infection, proliferative disease or cancer)

RN 96880-40-9 CAPLUS

CN α2-Macroglobulin (human precursor protein moiety reduced) (9CI) (CA INDEX NAME)

SEQ

```
      1 MGKNKLLHPS LVLLLLVLLP TDASVSGKPQ YMVLVPSLLH TETTEKGCVL
     51 LSYLNETVTV SASLESVRGN RSLFTDLEAE NDVLHCVAFA VPKSSSNEEV
    101 MFLTVQVKGP TQEFKKRTTV MVKNEDSLVF VQTDKSIYKP GQTVKFRVVS
    151 MDENFHPLNE LIPLVYIQDP KGNRIAQWQS FQLEGGLKQF SFPLSSEPFQ
    201 GSYKVVVQKK SGGRTEHPFT VEEFVLPKFE VQVTVPKIIT ILEEEMNVSV
    251 CGLYTYGKPV PGHVTVSICR KYSDASDCHG EDSQAFCEKF SGQLNSHGCF
    301 YQQVKTKVFQ LKRKEYEMKL HTEAQIQEEG TVVELTGRQS SEITRTITKL
    351 SFVKVDSHFR QGIPFFGQVR LVDGKGVPIP NKVIFIRGNE ANYYSNATTD
    401 EHGLVQFSIN TTNVMGTSLT VRVNYKDRSP CYGYQWVSEE HEEAHHTAYL
    451 VFSPSKSFVH LEPMSHELPC GHTQTVQAHY ILNGGTLLGL KKLSFYYLIM
    501 AKGGIVRTGT HGLLVKQEDM KGHFSISIPV KSDIAPVARL LIYAVLPTGD
    551 VIGDSAKYDV ENCLANKVDL SFSPSQSLPA SHAHLRVTAA PQSVCALRAV
    601 DQSVLLMKPD AELSASSVYN LLPEKDLTGF PGPLNDQDDE DCINRHNVYI
    651 NGITYTPVSS TNEKDMYSFL EDMGLKAFTN SKIRKPKMCP QLQQYEMHGP
    701 EGLRVGFYES DVMGRGHARL VHVEEPHTET VRKYFPETWI WDLVVVNSAG
    751 VAEVGVTVPD TITEWKAGAF CLSEDAGLGI SSTASLRAFQ PFFVELTMPY
    801 SVIRGEAFTL KATVLNYLPK CIRVSVQLEA SPAFLAVPVE KEQAPHCICA
    851 NGRQTVSWAV TPKSLGNVNF TVSAEALESQ ELCGTEVPSV PEHGRKDTVI
    901 KPLLVEPEGL EKETTFNSLL CPSGGEVSEE LSLKLPPNVV EESARASVSV
    951 LGDILGSAMQ NTQNLLQMPY GCGEQNMVLF APNIYVLDYL NETQQLTPEV
   1001 KSKAIGYLNT GYQRQLNYKH YDGSYSTFGE RYGRNQGNTW LTAFVLKTFA
   1051 QARAYIFIDE AHITQALIWL SQRQKDNGCF RSSGSLLNNA IKGGVEDEVT
   1101 LSAYITIALL EIPLTVTHPV VRNALFCLES AWKTAQEGDH GSHVYTKALL
   1151 AYAFALAGNQ DKRKEVLKSL NEEAVKKDNS VHWERPQKPK APVGHFYEPQ
   1201 APSAEVEMTS YVLLAYLTAQ PAPTSEDLTS ATNIVKWITK QQNAQGGFSS
   1251 TQDTVVALHA LSKYGAATFT RTGKAAQVTI QSSGTFSSKF QVDNNNRLLL
   1301 QQVSLPELPG EYSMKVTGEG CVYLQTSLKY NILPEKEEFP FALGVQTLPQ
   1351 TCDEPKAHTS FQISLSVSYT GSRSASNMAI VDVKMVSGFI PLKPTVKMLE
   1401 RSNHVSRTEV SSNHVLIYLD KVSNQTLSLF FTVLQDVPVR DLKPAIVKVY
   1451 DYYETDEFAI AEYNAPCSKD LGNA
```

Prior Art Document

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:798427 CAPLUS
DOCUMENT NUMBER: 135:353806
TITLE: Human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them
INVENTOR(S): Vernet, Corine A. M.; Fernandes, Elma R.; Gerlach, Valerie; Shimkets, Richard A.; Malyankar, Uriel M.; Boldog, Ferenc L.; Zerhusen, Bryan D.; Spytek, Kimberly A.; Majumder, Kumud; Tchernev, Velizar T.; Padigaru, Muralidhara; Patturajan, Meera; Burgess, Catherine E.; Gangolli, Esha A.; Smithson, Glennda; Rastelli, Luca; MacDougall, John R.; Taupier, Raymond J., Jr.; Grosse, William M.; Szekeres, Edward S., Jr.; Alsoborook, John P., II
PATENT ASSIGNEE(S): Curagen Corp., USA
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001081578	A2	20011101	WO 2001-US13578		20010426 <--
WO 2001081578	A3	20030313			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2407494	A1	20011101	CA 2001-2407494		20010426 <--
EP 1309683	A2	20030514	EP 2001-928927		20010426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2006501801	T	20060119	JP 2001-578649		20010426
PRIORITY APPLN. INFO.:			US 2000-200158P	P	20000426
			US 2000-200780P	P	20000428
			US 2000-201006P	P	20000501
			US 2000-201007P	P	20000501
			US 2000-201236P	P	20000501
			US 2000-201238P	P	20000501
			US 2000-201474P	P	20000503
			US 2000-201508P	P	20000503
			US 2000-220591P	P	20000725
			US 2000-232678P	P	20000915
			US 2001-263217P	P	20010122
			US 2001-265160P	P	20010130
			US 2000-200613P	P	20000428
			US 2000-201186P	P	20000502

Prior Art Document

US 2001-842758 A 20010425
WO 2001-US13578 W 20010426

AB Disclosed herein are 15 nucleic acid sequences that encode human G protein-coupled receptor-related polypeptides, designated MOL1 to MOL10b. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. Nearest neighbor sequence homologies, protein domains, tissue expression profiles, and chromosomal location are also provided. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IT **372021-42-6**
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them)
RN 372021-42-6 CAPLUS
CN Protein MOL3 (human clone 82254077.0.1 precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **372023-58-0**
RL: PRP (Properties)
(unclaimed sequence; human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them)
RN 372023-58-0 CAPLUS
CN 34: PN: WO0181578 PAGE: 11-13 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **372021-42-6**
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them)
RN 372021-42-6 CAPLUS
CN Protein MOL3 (human clone 82254077.0.1 precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **372023-58-0**
RL: PRP (Properties)
(unclaimed sequence; human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them)
RN 372023-58-0 CAPLUS
CN 34: PN: WO0181578 PAGE: 11-13 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ
```
  1 MVLRRRTLHP LSLLVQAAVL AETLALGTLP AFLPCELKPH GLVDCNWLFL
 51 KSVPRFSAAA SCSNITRLSL ISNRIHHLHN SDFVHLSNLR QLNLKWNCPP
101 TGLSPLHFSC HMTIEPRTFL AMRTLEELNL SYNGITTVPR LPSSLVNLSL
151 SHTNILVLDA NSLAGLYSLR VLFMDGNCYY KNPCTGAVKV TPGALLGLSN
201 LTHLSLKYNN LTKVPRQLPP SLEYLLVSYN LIVKLGPEDL ANLTSLRVLD
251 VGGNCRRCDH APNPCIECGQ KSLHLHPETF HHLSHLEGLV LKDSSLHTLN
301 SSWFQGLVNL SVLDLSENFL YESINHTNAF QNLTRLRKLN LSFNYRKKVS
351 FARLHLASSF KNLVSLQELN MNGIFFRSLN KYTLRWLADL PKLHTLHLQM
401 NFINQAQLSI FGTFRALRFV DLSDNRISGP STLSEATPEE ADDAEQEELL
451 SADPHPAPLS TPASKNFMDR CKNFKFTMDL SPNNLVTIKP EMFVNLSRLQ
```

Prior Art Document

```
  501 CLSLSHNSIA QAVNGSQFLP LTNLQVLDLS HNKLDLYHWK SFSELPQLQA
  551 LDLGYNSQPF SIKGIGHNFS FVAHLSMLHS LSLAHNDIHT RVSSHLNSNS
  601 VRFLDFSGNG MGRMWDEGGL YLHFFQGLSG LLKLDLSQNN LHILRPQNLD
  651 NLPKSLKLLS LRDNYLSFFN WTSLSFLPNL EVLDLAGNQL KALTNGTLPN
  701 GTLLQKLDVS SNSIVSVVPA FFALAVELKE VNLSHNILKT VDRSWFGPIV
  751 MNLTVLDVRS NPLHCACGAA FVDLLLEVQT KVPGLANGVK CGSPGQLQGR
  801 SIFAQDLRLC LDEVLSWDCF GLSLLAVAVG MVVPILHHLC GWDVWYCFHL
  851 CLAWLPLLAR SRRSAQALPY DAFVVFDKAQ SAVADWVYNE LRVRLEGRRG
  901 RRALRLCLED RDWLPGQTLF ENLWASIYGS RKTLFVLAHT DRVSGLLRTS
  951 FLLAQQRLLE DRKDVVVLVI LRPDAHRSRY VRLRQRLCRQ SVLFWPQQPN
 1001 GQGGFWAQLS TALTRDNRHF YNQNFCRGPT AE
```

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:741929 CAPLUS
DOCUMENT NUMBER: 133:317569
TITLE: Antisense modulation of Fas-mediated signaling
INVENTOR(S): Dean, Nicholas M.; Marcusson, Eric G.
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 324
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061150	A1	20001019	WO 2000-US9540	20000410 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9726244	A	19971106	AU 1997-26244	19970624 <--
AU 713740	B2	19991209		
US 6232463	B1	20010515	US 1998-128508	19980804 <--
US 6204055	B1	20010320	US 1999-290640	19990412 <--
EP 1176965	A1	20020206	EP 2000-923209	20000410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:		
US 1999-290640	A	19990412
AU 1993-38025	A3	19930225
US 1997-948151	A1	19971009
WO 2000-US9540	W	20000410

AB Compds., compns., and methods are provided for inhibiting Fas-mediated signaling. The compns. comprise antisense compds. targeted to nucleic acids encoding Fas, Fas ligand (FasL) and Fap-1. Methods of using these antisense compds. for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.

IT **154338-70-2**
RL: PRP (Properties)

Prior Art Document

(unclaimed protein sequence; antisense modulation of Fas-mediated signaling)
RN 154338-70-2 CAPLUS
CN Phosphatase, phosphoprotein (phosphotyrosine) (human KU812E cell isoenzyme 1 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **154338-70-2**
RL: PRP (Properties)
(unclaimed protein sequence; antisense modulation of Fas-mediated signaling)
RN 154338-70-2 CAPLUS
CN Phosphatase, phosphoprotein (phosphotyrosine) (human KU812E cell isoenzyme 1 reduced) (9CI) (CA INDEX NAME)

SEQ
```
   1 MHVSLAEALE VRGGPLQEEE IWAVLNQSAE SLQELFRKVS LADPAALGFI
  51 ISPWSLLLLP SGSVSFTDEN ISNQDLRAFT APEVLQNQSL TSLSDVEKIH
 101 IYSLGMTLYW GADYEVPQSQ PIKLGDHLNS ILLGMCEDVI YARVSVRTVL
 151 DACSAHIRNS NCAPSFSYVK HLVKLVLGNL SGTDQLSCNS EQKPDRSQAI
 201 RDRLRGKGLP TGRSSTSDVL DIQKPPLSHQ TFLNKGLSKS MGFLSIKDTQ
 251 DENYFKDILS DNSGREDSEN TFSPYQFKTS GPEKKPIPGI DVLSKKKIWA
 301 SSMDLLCTAD RDFSSGETAT YRRCHPEAVT VRTSTTPRKK EARYSDGSIA
 351 LDIFGPQKMD PIYHTRELPT SSAISSALDR IRERQKKLQV LREAMNVEEP
 401 VRRYKTYHGD VFSTSSESPS IISSESDFRQ VRRSEASKRF ESSSGLPGVD
 451 ETLSQGQSQR PSRQYETPFE GNLINQEIML KRQEEELMQL QAKMALRQSR
 501 LSLYPGDTIK ASMLDITRDP LREIALETAM TQRKLRNFFG PEFVKMTIEP
 551 FISLDLPRSI LTKKGKNEDN RRKVNIMLLN GQRLELTCDT KTICKDVFDM
 601 VVAHIGLVEH HLFALATLKD NEYFFVDPDL KLTKVAPEGW KEEPKKKTKA
 651 TVNFTLFFRI KFFMDDVSLI QHTLTCHQYY LQLRKDILEE RMHCDDETSL
 701 LLASLALQAE YGDYQPEVHG VSYFRMEHYL PARVMEKLDL SYIKEELPKL
 751 HNTYVGASEK ETELEFLKVC QRLTEYGVHF HRVHPEKKSQ TGILLGVCSK
 801 GVLVFEVHNG VRTLVLRFPW RETKKISFSK KKITLQNTSD GIKHGFQTDN
 851 SKICQYLLHL CSYQHKFQLQ MRARQSNQDA QDIERASFRS LNLQAESVRG
 901 FNMGRAISTG SLASSTLNKL AVRPLSVQAE ILKRLSCSEL SLYQPLQNSS
 951 KEKNDKASWE EKPREMSKSY HDLSQASLYP HRKNVIVNME PPPQTVAELV
1001 GKPSHQMSRS DAESLAGVTK LNNSKSVASL NRSPERRKHE SDSSSIEDPG
1051 QAYVLGMTMH SSGNSSSQVP LKENDVLHKR WSIVSSPERE ITLVNLKKDA
1101 KYGLGFQIIG GEKMGRLDLG IFISSVAPGG PADLDGCLKP GDRLISVNSV
1151 SLEGVSHHAA IEILQNAPED VTLVISQPKE KISKVPSTPV HLTNEMKNYM
1201 KKSSYMQDSA IDSSSKDHHW SRGTLRHISE NSFGPSGGLR EGSLSSQDSR
1251 TESASLSQSQ VNGFFASHLG DQTWQESQHG SPSPSVISKA TEKETFTDSN
1301 QSKTKKPGIS DVTDYSDRGD SDMDEATYSS SQDHQTPKQE SSSSVNTSNK
1351 MNFKTFSSSP PKPGDIFEVE LAKNDNSLGI SVTGGVNTSV RHGGIYVKAV
1401 IPQGAAESDG RIHKGDRVLA VNGVSLEGAT HKQAVETLRN TGQVVHLLLE
1451 KGQSPTSKEH VPVTPQCTLS DQNAQGQGPE KVKKTTQVKD YSFVTEENTF
1501 EVKLFKNSSG LGFSFSREDN LIPEQINASI VRVKKLFPGQ PAAESGKIDV
1551 GDVILKVNGA SLKGLSQQEV ISALRGTAPE VFLLLCRPPP GVLPEIDTAL
1601 LTPLQSPAQV LPNSSKDSSQ PSCVEQSTSS DENEMSDKSK KQCKSPSRRD
1651 SYSDSSGSGE DDLVTAPANI SNSTWSSALH QTLSNMVSQA QSHHEAPKSQ
1701 EDTICTMFYY PQKIPNKPEF EDSNPSPLPP DMAPGQSYQP QSESASSSSM
1751 DKYHIHHISE PTRQENWTPL KNDLENHLED FELEVELLIT LIKSEKGSLG
1801 FTVTKGNQRI GCYVHDVIQD PAKSDGRLKP GDRLIKVNDT DVTNMTHTDA
1851 VNLLRAASKT VRLVIGRVLE LPRIPMLPHL LPDITLTCNK EELGFSLCGG
1901 HDSLYQVVYI SDINPRSVAA IEGNLQLLDV IHYVNGVSTQ GMTLEEVNRA
1951 LDMSLPSLVL KATRNDLPVV PSSKRSAVSA PKSTKGNGSY SVGSCSQPAL
2001 TPNDSFSTVA GEEINEISYP KGKCSTYQIK GSPNLTLPKE SYIQEDDIYD
2051 DSQEAEVIQS LLDVVDEEAQ NLLNENNAAG YSCGPGTLKM NGKLSEERTE
2101 DTDCDGSPLP EYFTEATKMN GCEEYCEEKV KSESLIQKPQ EKKTDDDEIT
```

Prior Art Document

```
2151 WGNDELPIER TNHEDSDKDH SFLTNDELAV LPVVKVLPSG KYTGANLKSV
2201 IRVLRGLLDQ GIPSKELENL QELKPLDQCL IGQTKENRRK NRYKNILPYD
2251 ATRVPLGDEG GYINASFIKI PVGKEEFVYI ACQGPLPTTV GDFWQMIWEQ
2301 KSTVIAMMTQ EVEGEKIKCQ RYWPNILGKT TMVSNRLRLA LVRMQQLKGF
2351 VVRAMTLEDI QTREVRHISH LNFTAWPDHD TPSQPDDLLT FISYMRHIHR
2401 SGPIITHCSA GIGRSGTLIC IDVVLGLISQ DLDFDISDLV RCMRLQRHGM
2451 VQTEDQYIFC YQVILYVLTR LQAEEEQKQQ PQLLK
```

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:675103 CAPLUS
DOCUMENT NUMBER: 129:286410
TITLE: Hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and in inducing sterility
INVENTOR(S): Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William; Koonce, Kenneth L.; McCann, Samuel M.; Yu, Wen H.; Melrose, Patricia A.; Foil, Lane D.; Elzer, Philip H.
PATENT ASSIGNEE(S): Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9842365	A1	19981001	WO 1998-US6114		19980327 <--
W: CA, JP, US, US, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2283630	A1	19981001	CA 1998-2283630		19980327 <--
EP 975354	A1	20000202	EP 1998-913218		19980327 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2000514836	T	20001107	JP 1998-546026		19980327 <--
CA 2302392	A1	19990311	CA 1998-2302392		19980901 <--
WO 9911282	A1	19990311	WO 1998-US18117		19980901 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9892138	A	19990322	AU 1998-92138		19980901 <--
JP 2001514231	T	20010911	JP 2000-508384		19980901 <--
US 6635740	B1	20031021	US 1999-381879		19990924
US 6680058	B1	20040120	US 2000-486143		20000222
US 2004018967	A1	20040129	US 2003-617561		20030711
PRIORITY APPLN. INFO.:			US 1997-41009P	P	19970327
			US 1997-869153	A2	19970604

Prior Art Document

US 1997-57456P	P	19970903
US 1997-92112P	P	19970604
WO 1998-US6114	W	19980327
WO 1998-US18117	W	19980901
US 1999-381879	A1	19990924

AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compds. are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components -the ligand and the lytic peptide- may optionally be administered as a fusion peptide, or they may be administered sep., with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compds. may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

IT **214061-23-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and in inducing sterility)

RN 214061-23-1 CAPLUS

CN D-Leucine, D-phenylalanyl-D-alanyl-D-leucyl-D-alanyl-D-leucyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Prior Art Document

PAGE 1-A



PAGE 2-A



Prior Art Document

PAGE 3-A



PAGE 4-A



PAGE 5-A



IT **133084-63-6** **214142-46-8** **214142-48-0**
214142-49-1 **214208-15-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Prior Art Document

(hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and inducing sterility)

RN 133084-63-6 CAPLUS

CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



Prior Art Document

PAGE 3-A



PAGE 4-A



PAGE 5-A



RN 214142-46-8 CAPLUS

CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-

alanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 214142-48-0 CAPLUS
CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 214142-49-1 CAPLUS
CN L-Leucine, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-histidyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 214208-15-8 CAPLUS
CN L-Arginine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-seryl-L-tyrosyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-seryl-L-cysteinyl-L-glutaminyl-L-cysteinyl-L-alanyl-L-leucyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **214061-23-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and in inducing sterility)
RN 214061-23-1 CAPLUS
CN D-Leucine, D-phenylalanyl-D-alanyl-D-leucyl-D-alanyl-D-leucyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl-D-leucyl-D-lysyl-D-lysyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Prior Art Document

PAGE 1-A



PAGE 2-A



Prior Art Document

PAGE 3-A



PAGE 4-A



PAGE 5-A



IT **133084-63-6** **214142-46-8** **214142-48-0**
214142-49-1 **214208-15-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Prior Art Document

(hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and inducing sterility)

RN 133084-63-6 CAPLUS

CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 FALALKALKK ALKKLKKALK KAL

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



Prior Art Document

PAGE 3-A



PAGE 4-A



PAGE 5-A



RN 214142-46-8 CAPLUS

CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-

alanyl- (9CI) (CA INDEX NAME)

SEQ 1 QHWSYGLRPG FALALKALKK ALKKLKKALK KAL

RN 214142-48-0 CAPLUS
CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 FALALKALKK ALKKLKKALK KALQHWSYGL RPG

RN 214142-49-1 CAPLUS
CN L-Leucine, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-histidyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 XHWSHDWKPG FALALKALKK ALKKLKKALK KAL

RN 214208-15-8 CAPLUS
CN L-Arginine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-seryl-L-tyrosyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-seryl-L-cysteinyl-L-glutaminyl-L-cysteinyl-L-alanyl-L-leucyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 FALALKALKK ALKKLKKALK KALSYAVALS CQCALCRR

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:672481 CAPLUS
DOCUMENT NUMBER: 129:293890
TITLE: **Ligand**/lytic peptide compositions and methods of use
INVENTOR(S): Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William B.; Koonce, Kenneth L.; Foil, Lane D.
PATENT ASSIGNEE(S): Demeter Biotechnologies, Ltd., USA; Louisiana State University and Agricultural and Mechanical College
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

Prior Art Document

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842364	A1	19981001	WO 1998-US6013	19980326 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865879	A	19981020	AU 1998-65879	19980326 <--
EP 988048	A1	20000329	EP 1998-912077	19980326 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CA 2302392	A1	19990311	CA 1998-2302392	19980901 <--
WO 9911282	A1	19990311	WO 1998-US18117	19980901 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9892138	A	19990322	AU 1998-92138	19980901 <--
JP 2001514231	T	20010911	JP 2000-508384	19980901 <--
US 6680058	B1	20040120	US 2000-486143	20000222
PRIORITY APPLN. INFO.:			US 1997-41009P	P 19970327
			US 1997-869153	A 19970604
			US 1997-57456P	P 19970903
			WO 1998-US6013	W 19980326
			WO 1998-US18117	W 19980901

AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compds. are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components - the ligand and the lytic peptide - may optionally be administered as a fusion peptide, or they may be administered sep., with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compds. may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide

hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

IT **133084-63-6**, Hecate
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)

RN 133084-63-6 CAPLUS

CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



Prior Art Document

PAGE 3-A



PAGE 4-A



PAGE 5-A



IT **214142-46-8** **214142-48-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns: for contraceptive and

therapeutic use)
RN 214142-46-8 CAPLUS
CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 214142-48-0 CAPLUS
CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **133084-63-6**, Hecate
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)
RN 133084-63-6 CAPLUS
CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Prior Art Document

PAGE 2-A



PAGE 3-A



PAGE 4-A





IT **214142-46-8 214142-48-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)

RN 214142-46-8 CAPLUS

CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 QHWSYGLRPG FALALKALKK ALKKLKKALK KAL

RN 214142-48-0 CAPLUS

CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 FALALKALKK ALKKLKKALK KALQHWSYGL RPG

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg; d ide 1-2
FILE 'REGISTRY' ENTERED AT 16:51:23 ON 22 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 MAR 2007  HIGHEST RN 927866-99-7
DICTIONARY FILE UPDATES:  21 MAR 2007  HIGHEST RN 927866-99-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L19  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   172837-41-1  REGISTRY
ED   Entered STN:  01 Feb 1996
CN   L-Prolinamide, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-N-
     (phenylmethyl)-, monohydrochloride (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Cemadotin hydrochloride
FS   PROTEIN SEQUENCE; STEREOSEARCH
MF   C35 H56 N6 O5 . Cl H
SR   CA
LC   STN Files:  CA, CAPLUS, CASREACT, IMSRESEARCH, TOXCENTER, USPATFULL
CRN  (159776-69-9)

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

Absolute stereochemistry.  Rotation (-).
```



● HCl

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 159776-69-9 REGISTRY
ED Entered STN: 23 Dec 1994
CN L-Prolinamide, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Cemadotin**
CN LU 103793
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C35 H56 N6 O5
CI COM
SR World Health Organization (WHO)
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, PHAR, PROMT, PROUSDDR, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

27 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
28 REFERENCES IN FILE CAPLUS (1907 TO DATE)

STRUCTURE AND SEQUENCE SEARCHES

=> => fil reg; d stat que l4; d stat que l13; d que l11; d que l48
FILE 'REGISTRY' ENTERED AT 17:06:20 ON 22 MAR 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2007 HIGHEST RN 927866-99-7
DICTIONARY FILE UPDATES: 21 MAR 2007 HIGHEST RN 927866-99-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

Uploading L1.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46 47 48 49 50 51 52 53 54 55 56 57 60 61 62 63 64 65 66 67
68 69 70 71 72 73 74 75 76 77 78 79 80 84
chain bonds :
1-2 2-3 2-41 3-4 3-40 4-5 5-6 5-43 6-7 6-39 7-8 8-9 8-45 9-10 9-38
10-11 11-12 11-47 12-13 12-37 13-14 14-15 14-48 15-16 15-36 16-17 17-18
18-19 18-35 19-20 20-21 20-51 21-22 21-34 22-23 23-24 23-53 24-33 24-25
25-26 26-27 26-54 27-28 27-32 28-29 29-30 29-56 30-31 41-42 43-44 45-46

```
48-49  49-50  51-52  54-55  56-57  60-75  60-61  60-80  61-62  61-72  62-63  63-64
63-77  64-65  64-73  65-66  66-67  66-78  67-68  67-74  68-69  69-70  69-79  70-71
75-76
exact/norm bonds :
1-2  2-41  3-4  3-40  4-5  5-43  6-7  6-39  7-8  8-45  9-10  9-38  10-11  12-13
12-37  13-14  15-16  15-36  16-17  18-19  18-35  19-20  21-22  21-34  22-23  24-33
24-25  25-26  26-54  27-28  27-32  28-29  30-31  41-42  43-44  45-46  49-50  51-52
54-55  60-80  61-62  61-72  62-63  64-65  64-73  65-66  67-68  67-74  68-69  70-71
exact bonds :
2-3  5-6  8-9  11-12  11-47  14-15  14-48  17-18  20-21  20-51  23-24  23-53  26-27
29-30  29-56  48-49  56-57  60-75  60-61  63-64  63-77  66-67  66-78  69-70  69-79
75-76


G1:[*1],[*2]

Connectivity :
41:2 E exact RC ring/chain  43:2 E exact RC ring/chain  45:2 E exact RC ring/chain
54:2 E exact RC ring/chain
Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:CLASS  11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS
18:CLASS  19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS
26:CLASS  27:CLASS  28:CLASS  29:CLASS  30:CLASS  31:CLASS  32:CLASS  33:CLASS
34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS  39:CLASS  40:CLASS  41:CLASS
42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS  49:CLASS
50:CLASS  51:CLASS  52:Atom  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS
60:CLASS  61:CLASS  62:CLASS  63:CLASS  64:CLASS  65:CLASS  66:CLASS  67:CLASS
68:CLASS  69:CLASS  70:CLASS  71:CLASS  72:CLASS  73:CLASS  74:CLASS  75:CLASS
76:CLASS  77:CLASS  78:CLASS  79:CLASS  80:CLASS  84:CLASS
Generic attributes :
52:
Saturation              : Unsaturated
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : Exactly 1
Type of Ring System     : Polycyclic

Element Count :
Node 52: Limited
    C,C8
    N,N1




L4          102 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  526064 ITERATIONS                          102 ANSWERS
SEARCH TIME: 00.00.27



L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP


L11          76 SEA FILE=REGISTRY ABB=ON  EEEAYGW'NLE'DF/SQSFP
```

```
L1              STR
L4          102 SEA FILE=REGISTRY SSS FUL L1
L6              STR
L10         102 SEA FILE=REGISTRY SUB=L4 SSS FUL L6
L11          76 SEA FILE=REGISTRY ABB=ON  EEEAYGW'NLE'DF/SQSFP
L12     1918813 SEA FILE=REGISTRY ABB=ON  FALA/SQSFP
L48           0 SEA FILE=REGISTRY ABB=ON  L11 AND (L12 OR L10)
```

INVENTOR SEARCH

```
=> => fil capl; d que nos l28; d que nos l55
FILE 'CAPLUS' ENTERED AT 17:07:17 ON 22 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Mar 2007  VOL 146 ISS 13
FILE LAST UPDATED: 21 Mar 2007  (20070321/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE


L24 (       457)SEA FILE=CAPLUS ABB=ON  TARASOVA N?/AU
L25 (       165)SEA FILE=CAPLUS ABB=ON  MICHEJDA C?/AU
L26 (        32)SEA FILE=CAPLUS ABB=ON  DYBA M?/AU
L27 (         5)SEA FILE=CAPLUS ABB=ON  COHRAN C?/AU
L28           2 SEA FILE=CAPLUS ABB=ON  (L27 OR L26) AND (L24 OR L25)


L1              STR
L4            102 SEA FILE=REGISTRY SSS FUL L1
L11            76 SEA FILE=REGISTRY ABB=ON  EEEAYGW'NLE'DF/SQSFP
L13         31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L15            55 SEA FILE=CAPLUS ABB=ON  L11
L17          5237 SEA FILE=CAPLUS ABB=ON  L13
L44           108 SEA FILE=CAPLUS ABB=ON  L4
L51           457 SEA FILE=CAPLUS ABB=ON  TARASOVA N?/AU
L52           165 SEA FILE=CAPLUS ABB=ON  MICHEJDA C?/AU
L53            32 SEA FILE=CAPLUS ABB=ON  DYBA M?/AU
L54             5 SEA FILE=CAPLUS ABB=ON  COHRAN C?/AU
L55             3 SEA FILE=CAPLUS ABB=ON  (L51 OR L52 OR L53 OR L54) AND (L44 OR
                  L17 OR L15)


=> s l28,155 or (l28,155 and 144,117,115)
L56             4 (L28 OR L55) OR ((L28 OR L55) AND (L44 OR L17 OR L15))

=> d ibib ed abs hitstr 1-4

L56  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:383220  CAPLUS  Full-text
DOCUMENT NUMBER:          143:70991
```

author

SEA FILE OR LINKUP

TITLE: Transmembrane Inhibitors of P-Glycoprotein, an ABC Transporter

AUTHOR(S): **Tarasova, Nadya I.**; Seth, Rishi; Tarasov, Sergey G.; Kosakowska-Cholody, Teresa; Hrycyna, Christine A.; Gottesman, Michael M.; **Michejda, Christopher J.**

CORPORATE SOURCE: Molecular Aspects of Drug Design Section, Structural Biophysics Laboratory, Frederick, MD, 21702, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(11), 3768-3775
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:70991

ED Entered STN: 05 May 2005

AB Drug resistance mediated by ABC transporters such as P-glycoprotein (P-gp) continues to be a major impediment to effective cancer chemotherapy. We have developed a panel of highly specific peptide inhibitors of P-gp based on the structure of the transmembrane domains of the transporter. These peptides are thought to exert their inhibitory action by disrupting the proper assembly of P-gp. A novel 96-well-plate assay based on the efflux of fluorescent P-gp substrate DiOC2 (3-ethyl-2-[3-(3-ethyl-2(3H)- benzoxazolylidene)-1-propenyl]benzoxazoliumiodide) was developed and used for structure-functional characterization of transporter inhibitors. The studies strongly suggest that potent and selective inhibitors of ABC transporters can now be developed solely on the basis of the primary structures of the target proteins. The inhibition of P-gp with transmembrane peptides was shown to be chirality-independent. A 25-residue long retroinverso D-analog of transmembrane domain 5 inhibited the efflux of the fluorescent P-gp substrate with an IC50 of 500 nM. Transmembrane peptides effectively sensitized resistant cancer cells to doxorubicin in vitro without demonstrating any cell toxicity of their own. The newly synthesized P-gp antagonists appear to be promising nontoxic drug resistance inhibitors that merit further development.

IT **855444-60-9**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of transmembrane inhibitors of P-glycoprotein, an ABC transporter in HCT115 human colon carcinoma cells)

RN 855444-60-9 CAPLUS

CN D-Leucine, N-(3-carboxy-1-oxopropyl)-D-α-aspartyl-D-α-aspartyl-D-serylglycyl-D-α-glutamylglycyl-D-seryl-D-leucyl-D-valyl-D-leucyl-D-threonyl-D-threonylglycyl-D-tyrosyl-D-tryptophyl-D-phenylalanyl-D-alanyl-D-leucyl-D-alanyl-D-tyrosyl-D-seryl-D-alanyl-D-tyrosyl-D-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



PAGE 3-B



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:514451 CAPLUS Full-text
DOCUMENT NUMBER: 141:33239
TITLE: Small molecule toxins targeting tumor receptors
AUTHOR(S): **Dyba, Marcin; Tarasova, Nadya I.; Michejda, Christopher J.**
CORPORATE SOURCE: Molecular Aspects of Drug Design Section, Structural

Biophysics Laboratory, NCI-Frederick, Frederick, MD, 21702, USA
SOURCE: Current Pharmaceutical Design (2004), 10(19), 2311-2334
CODEN: CPDEFP; ISSN: 1381-6128
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
ED Entered STN: 25 Jun 2004
AB A review. Targeting toxic therapeutics to tumors through receptors overexpressed on the surface of cancer cells can reduce systemic toxicity and increase the effectiveness of the targeted compds. Small mol. targeted therapeutics have a number of advantages over toxic immunoconjugates including better tumor penetration, lack of neutralizing host immune response, and superior flexibility in selection of drug components with optimal specificity, potency, and stability in circulation. Three major components of the targeted drug, the toxic warhead, tumor-specific ligand, and the linker can influence the properties of each other and thus have to be optimized for each system. All receptor-targeted drugs are delivered inside the cells through endocytosis and undergo processing liberating the toxins in endosomes and lysosomes. Common delivery route defines a number of general requirements for each drug component. The review addresses currently known possible receptor targets and their ligands along with toxins that were used and that have a potential to be successfully applied in tumor targeting. Linkers that are stable in circulation, but efficiently cleaved in lysosomes constitute an essential component of receptor-targeted drugs and are evaluated in greater detail.
REFERENCE COUNT: 249 THERE ARE 249 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:697040 CAPLUS Full-text
DOCUMENT NUMBER: 139:231000
TITLE: Conjugates of ligand, linker and cytotoxic agent, related compositions, and methods for their use
INVENTOR(S): **Tarasova, Nadya I.; Michejda, Christopher J.; Dyba, Marcin; Cohran, Carolyn**
PATENT ASSIGNEE(S): The Government of the United States of America, Represented by the Secretary Department of Health and Human Services, USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072754	A2	20030904	WO 2003-US6344	20030227
WO 2003072754	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

Applicant's PCT.

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003224644	A1	20030909	AU 2003-224644	20030227
EP 1531846	A2	20050525	EP 2003-721323	20030227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005171014	A1	20050804	US 2003-505239	20030227

PRIORITY APPLN. INFO.: US 2002-360543P P 20020227 } Provisional
US 2002-370189P P 20020405 }
WO 2003-US6344 W 20030227

ED Entered STN: 05 Sep 2003

GI



I

AB The invention discloses conjugates comprising a ligand, a linker, and a cytotoxic agent, in which the linker is a peptide fragment FALA, VLALA, ALAL, ALALA, ChaLALA, ChaChaLAL, NalChaLAL or NalLALA. Compns. containing the conjugates deliver a cytotoxic agent in a cell-specific manner for treating cancer in a mammal. Thus, peptide derivative I (R = VLALAEEEAYGW-Nle-DF-NH2) was prepared by the solid-phase method and showed relatively low cytotoxic activity (IC50 = 1 μM when tested on gastrin receptor-expressing 3T3 cells).

IT **591750-18-4P 591750-24-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugates of ligand, linker and cytotoxic agent, related compns., and methods for their use)

RN 591750-18-4 CAPLUS

CN L-Phenylalaninamide, [N,β,β-trimethyl-L-phenylalanyl-3-methyl-L-valyl-(2E,4S)-2,5-dimethyl-4-(methylamino)-2-hexenoyl]-L-valyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Me

PAGE 2-A



PAGE 2-B

RN 591750-24-2 CAPLUS

CN L-Phenylalaninamide, N,β,β-trimethyl-L-phenylalanyl-3-methyl-L-valyl-(2E,4S)-2,5-dimethyl-4-(methylamino)-2-hexenoyl-3-cyclohexyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



IT **591750-16-2D**, protected derivative **591750-19-5D**, protected derivative
RL: RCT (Reactant); RACT (Reactant or reagent)
(conjugates of ligand, linker and cytotoxic agent, related compns., and methods for their use)

RN 591750-16-2 CAPLUS

CN L-Phenylalanine, L-valyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

RN 591750-19-5 CAPLUS

CN L-Phenylalanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **591750-15-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(conjugates of ligand, linker and cytotoxic agent, related compns., and methods for their use)
RN 591750-15-1 CAPLUS
CN L-Phenylalaninamide, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolyl-L-valyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **594846-97-6**
RL: PRP (Properties)
(unclaimed sequence; conjugates of ligand, linker and cytotoxic agent, related compns., and methods for their use)
RN 594846-97-6 CAPLUS
CN L-Alanine, L-phenylalanyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:649171 CAPLUS Full-text
DOCUMENT NUMBER: 130:20325
TITLE: Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug
AUTHOR(S): Czerwinski, Grzegorz; **Tarasova, Nadya I.**; **Michejda, Christopher J.**
CORPORATE SOURCE: Molecular Aspects of Drug Design Section, Macromolecular Structure Laboratory, Advanced BioScience Laboratories-Basic Research Program, Frederick Cancer Research and Development Center, National Cancer Institute, Frederick, MD, 21702, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(20), 11520-11525
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 14 Oct 1998

AB In principle, cell surface receptors that are overexpressed in tumor tissue could serve as targets for anticancer drugs attached to receptor ligands. The purpose of this paper is to identify the necessary elements for a successful receptor-targeted drug. We used the gastrin/cholecystokinin type B receptor as a model delivery system, and we report on the synthesis, trafficking, and in vitro and in vivo evaluation of heptagastrin, the C-terminal heptapeptide of gastrin, linked via an appropriate linker to a potently cytotoxic ellipticine derivative, 1-[3-[N-(3-aminopropyl)-N-methylamino]propyl]amino-9-methoxy-5,11-dimethyl- 6H-pyrido[4,3-b]carbazole. These data, and previous work from our laboratory, show that the drug-complexed ligand is sorted to lysosomes whereas the receptor is recycled to the plasma membrane. The lysosomal processing of the ligand/drug construct depends on the linker between the ligand sequence and the cytotoxic moiety. We show that heptagastrin linked to ellipticine via a succinoyl-substituted pentapeptide, AlaLeuAlaLeuAla, is at least 103 more toxic to cholecystokinin type B receptor-pos. NIH/3T3 cells than to isogenic NIH/3T3 cells lacking the receptor. The conjugated drug eradicated all receptor-pos. tumor cells in vivo without producing any general toxicity. The data indicate that the d. of the cell surface receptor, the properties of the cytotoxic moiety, and the correct processing of the drug-conjugated ligand in lysosomes are crucial to the effectiveness of a receptor-targeted drug.

IT **216220-15-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(requirements for cytotoxic agents directed to peptide hormone receptors)
RN 216220-15-4 CAPLUS
CN 2-17-Gastrin-17 I (human), N-[[[3-[[3-[(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)amino]propyl]methylamino]propyl]amino]carbonyl]-15-L-norleucine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C



IT **134998-07-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(requirements for cytotoxic agents directed to peptide hormone receptors)
RN 134998-07-5 CAPLUS
CN 19-34-Gastrin I (swine), 22-L-leucine-32-L-norleucine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCES FOR STRUCTURE/SEQUENCE SEARCH

```
=> fil capl; d que nos 149
FILE 'CAPLUS' ENTERED AT 17:08:19 ON 22 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Mar 2007  VOL 146 ISS 13
FILE LAST UPDATED: 21 Mar 2007  (20070321/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

SEQ 1 AND SEQ 20 IN SAME RECORD
L1              STR
L4          102 SEA FILE=REGISTRY SSS FUL L1
L11          76 SEA FILE=REGISTRY ABB=ON  EEEAYGW'NLE'DF/SQSFP
L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L15          55 SEA FILE=CAPLUS ABB=ON  L11
L17        5237 SEA FILE=CAPLUS ABB=ON  L13
L44         108 SEA FILE=CAPLUS ABB=ON  L4
L49           1 SEA FILE=CAPLUS ABB=ON  (L44 OR L17) AND L15


=> s l49 not l56
L57           0 L49 NOT L56

=> d que nos 150
SEQ 1 OR SEQ 20 PLUS CEMADOTIN
L1              STR
L4          102 SEA FILE=REGISTRY SSS FUL L1
L11          76 SEA FILE=REGISTRY ABB=ON  EEEAYGW'NLE'DF/SQSFP
L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L15          55 SEA FILE=CAPLUS ABB=ON  L11
L17        5237 SEA FILE=CAPLUS ABB=ON  L13
L19           2 SEA FILE=REGISTRY ABB=ON  CEMADOTIN?/CN
L20          35 SEA FILE=CAPLUS ABB=ON  L19
L22          29 SEA FILE=CAPLUS ABB=ON  (CEMADOTIN# OR LU103793 OR LU 103793)/B
                I
L44         108 SEA FILE=CAPLUS ABB=ON  L4
L50           0 SEA FILE=CAPLUS ABB=ON  (L44 OR L17 OR L15) AND (L20 OR L22)


=> d que l45 nos ; d que nos 146; d que nos 147
L1              STR
```

```
SEQ 1 AS LINKER WITH CONJUGATE
L4          102 SEA FILE=REGISTRY SSS FUL L1
L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L17        5237 SEA FILE=CAPLUS ABB=ON  L13
L30      121882 SEA FILE=CAPLUS ABB=ON  CONJUGAT?/OBI
L35      127191 SEA FILE=CAPLUS ABB=ON  LINK?/OBI
L44         108 SEA FILE=CAPLUS ABB=ON  L4
L45          20 SEA FILE=CAPLUS ABB=ON  (L44 OR L17) AND L30 AND L35


SEQ 1 AS LINKER WITH CYTOTOXIC AGENT
L1              STR
L4          102 SEA FILE=REGISTRY SSS FUL L1
L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L17        5237 SEA FILE=CAPLUS ABB=ON  L13
L34      237035 SEA FILE=CAPLUS ABB=ON  ANTITUMOR AGENTS+OLD/CT
L35      127191 SEA FILE=CAPLUS ABB=ON  LINK?/OBI
L44         108 SEA FILE=CAPLUS ABB=ON  L4
L46          24 SEA FILE=CAPLUS ABB=ON  (L44 OR L17) AND L34 AND L35


SEQ 1 AND (LINKER OR CONJUGATE) AND CYTOTOXIC AGENT AND LINGAND
L1              STR
L4          102 SEA FILE=REGISTRY SSS FUL L1
L13       31235 SEA FILE=REGISTRY ABB=ON  FALA/SQSP
L17        5237 SEA FILE=CAPLUS ABB=ON  L13
L30      121882 SEA FILE=CAPLUS ABB=ON  CONJUGAT?/OBI
L34      237035 SEA FILE=CAPLUS ABB=ON  ANTITUMOR AGENTS+OLD/CT
L35      127191 SEA FILE=CAPLUS ABB=ON  LINK?/OBI
L42      175275 SEA FILE=CAPLUS ABB=ON  LIGAND#/OBI
L44         108 SEA FILE=CAPLUS ABB=ON  L4
L47          10 SEA FILE=CAPLUS ABB=ON  (L44 OR L17) AND L34 AND (L35 OR L30)
                AND L42


=> s l45,l46,l47 not l56
L58          35 (L45 OR L46 OR L47) NOT L56

=> d ibib ed abs hitstr hitseq l58 1

L58  ANSWER 1 OF 35  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1332341  CAPLUS  Full-text
DOCUMENT NUMBER:          146:95362
TITLE:                    Identification of genes modulating signal transduction
                          by the JAK/STAT pathway by genome-wide RNAi screening
INVENTOR(S):              Boutros, Michael; Zeidler, Martin; Mueller, Patrick
PATENT ASSIGNEE(S):       Deutsches Krebsforschungszentrum Stiftung des
                          Oeffentlichen Rechts, Germany; Max-Planck-Gesellschaft
                          zur Foerderung der Wissenschaften e.V.
SOURCE:                   PCT Int. Appl., 67pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006133931         A2    20061221    WO 2006-EP5744          20060614
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1734118 A1 20061220 EP 2005-12934 20050615

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

PRIORITY APPLN. INFO.: EP 2005-12934 A 20050615

ED Entered STN: 21 Dec 2006

AB A reporter gene method of identifying genes involved in modulating the activity of the JAK/STAT signaling pathway and to the use of different JAK/STAT pathway components as targets for modulation of the JAK/STAT pathway is described. Furthermore, the present invention pertains to a pharmaceutical composition and to the use of different JAK/STAT pathway components and/or effector mols. thereof for the manufacture of such composition for the diagnosis, prevention or treatment of a JAK/STAT pathway associated disorder. A reporter gene is placed under control of a promoter regulated by the JAK/STAT pathway and animal or cell lines carrying the gene are established. Animals or cells are then exposed to siRNAs derived from a large number of genes and the effects of the exposure to levels and patterns of gene expression are analyzed. The screening of 20,000 dsRNAs corresponding to 91% of the Drosophila melanogaster genome is reported. The data from the screen were used in combination with genetic assays to confirm the roles of genes.

IT **917518-14-0**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; identification of genes modulating signal transduction by JAK/STAT pathway by genome-wide RNAi screening)

RN 917518-14-0 CAPLUS

CN Protein (human clone WO2006/133931-SEQID-82 JAK/STAT signal transduction pathway-regulating) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **917518-14-0**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; identification of genes modulating signal transduction by JAK/STAT pathway by genome-wide RNAi screening)

RN 917518-14-0 CAPLUS

CN Protein (human clone WO2006/133931-SEQID-82 JAK/STAT signal transduction pathway-regulating) (CA INDEX NAME)

SEQ

```
  1 MAPPSEETPL IPQRSCSLLS TEAGALHVLL PARGPGPPQR LSFSFGDHLA
 51 EDLCVQAAKA SGILPVYHSL FALATEDLSC WFPPSHIFSV EDASTQVLLY
101 RIRFYFPNWF GLEKCHRFGL RKDLASAILD LPVLEHLFAQ HRSDLVSGRL
151 PVGLSLKEQG ECLSLAVLDL ARMAREQAQR PGELLKTVSY KACLPPSLRD
201 LIQGLSFVTR RRIRRTVRRA LRRVAACQAD RHSLMAKYIM DLERLDPAGA
251 AETFHVGLPG ALGGHDGLGL LRVAGDGGIA WTQGEQEVLQ PFCDFPEIVD
301 ISIKQAPRVG PAGEHRLVTV TRTDNQILEA EFPGLPEALS FVALVDGYFR
351 LTTDSQHFFC KEVAPPRLLE EVAEQCHGPI TLDFAINKLK TGGSRPGSYV
401 LRRSPQDFDS FLLTVCVQNP LGPDYKGCLI RRSPTGTFLL VGLSRPHSSL
```

```
 451 RELLATCWDG GLHVDGVAVT LTSCCIPRPK EKSNLIVVQR GHSPPTSSLV
 501 QPQSQYQLSQ MTFHKIPADS LEWHENLGHG SFTKIYRGCR HEVVDGEARK
 551 TEVLLKVMDA KHKNCMESFL EAASLMSQVS YRHLVLLHGV CMAGDSTMVQ
 601 EFVHLGAIDM YLRKRGHLVP ASWKLQVVKQ LAYALNYLED KGLPHGNVSA
 651 RKVLLAREGA DGSPPFIKLS DPGVSPAVLS LEMLTDRIPW VAPECLREAQ
 701 TLSLEADKWG FGATVWEVFS GVTMPISALD PAKKLQFYED RQQLPAPKWT
 751 ELALLIQQCM AYEPVQRPSF RAVIRDLNSL ISSDYELLSD PTPGALAPRD
 801 GLWNGAQLYA CQNPTEFEER HLKYISQLGK GNFGSVELCR YDPLGDNTGA
 851 LVAVKQLQHS GPDQQRDFQR EIQILKALHS DFIVKYRGVS YGPGRQSLRL
 901 VMEYLPSGCL RDFLQRHRAR LDASRLLLYS SQICKGMEYL GSRRCVHRDL
 951 AARNILVESE AHVKIADFGL AKLLPLDKDY YVVREPGQSP IFWYAPESLS
1001 DNIFSRQSDV WSFGVVLYEL FTYCDKSCSP SAEFLRMMGC ERDVPALCRL
1051 LELLEEGQRL PAPPACPAEV HELMKLCWAP SPQDRPSFSA LGPQLDMLWS
1101 GSRGCETHAF TAHPEGKHHS LSFS
```

```
=> d ibib ed abs hitstr hitseq l58 2-35; fil hom

L58  ANSWER 2 OF 35  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1311334  CAPLUS  Full-text
DOCUMENT NUMBER:          146:80384
TITLE:                    Human interferon comprising non-natural amino acid
                          modified with water soluble polymer for improving serum
                          half-life and reducing side effects
INVENTOR(S):              Hays, Anna-Maria; Kimmel, Bruce E.; Cho, Ho Sung; Sim,
                          Bee-Cheng; Litzinger, David C.; Mariani, Roberto;
                          Kraynov, Vadim; Knudsen, Nick; Daniel, Thomas O.;
                          Koder, Alan; Bussell, Stuart; Liu, Junjie; Miao,
                          Zhenwei; Morrow, Theresa
PATENT ASSIGNEE(S):       Ambrx, Inc., USA
SOURCE:                   PCT Int. Appl., 337pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2006133089         A2    20061214    WO 2006-US21738          20060602
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       US 2005-687173P     P  20050603
                                             US 2005-753375P     P  20051221
OTHER SOURCE(S):          MARPAT 146:80384
ED   Entered STN:  15 Dec 2006
```

AB Modified human interferon polypeptides and uses thereof are provided. The human interferon is IFN, IFNα, IFNε, IFNγ, IFNω, IFNα-1a, IFNα-1b, IFNα-2a, IFNα-2b, IFNβ-1a, IFNβ-1b and IFNγ-1a. The human IFNs and mutants are modified with non-natural amino acid containing carbonyl, aminooxy, hydrazide, hydrazine, semicarbazide, azide or alkyne group, and conjugated with water-soluble branched or multiarmed polymer to improve biol. and/or pharmacol. properties e.g. to increase such as serum half-life, to reduce side effect such as immunogenicity or hematopoietic toxicity, and to enhance therapeutic activity such as antiviral activity.

IT **916779-24-3**
RL: PRP (Properties)
(unclaimed protein sequence; human interferon comprising non-natural amino acid modified with water soluble polymer for improving serum half-life and reducing side effects)
RN 916779-24-3 CAPLUS
CN 23: PN: WO2006133089 SEQID: 23 unclaimed protein (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **916779-24-3**
RL: PRP (Properties)
(unclaimed protein sequence; human interferon comprising non-natural amino acid modified with water soluble polymer for improving serum half-life and reducing side effects)
RN 916779-24-3 CAPLUS
CN 23: PN: WO2006133089 SEQID: 23 unclaimed protein (CA INDEX NAME)

SEQ
```
  1 MLPVHLFLVG GVMLSCSPAS SLDSGKSGSL HLERSETARF LAELRSVPGH
 51 QCLRDRTDFP CPWKEGTNIT PMTLGETTSC YSQTLKQVLH LFDTEASRAA
101 WHERALDQLL SSLWRELQVL KRPREQGQSC PLPFALAIRT YFRGFFRYLK
151 AKAYSACSWE IVRVQLQVDL PAFPLSARRG PR
```

L58 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1093210 CAPLUS Full-text
DOCUMENT NUMBER: 145:443875
TITLE: Polymer-based compositions and **conjugates** of antimicrobial agents
INVENTOR(S): Bossard, Mary J.; Mitchell, Stacy
PATENT ASSIGNEE(S): Nektar Therapeutics AL, Corporation, USA
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110776	A2	20061019	WO 2006-US13548	20060411

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006239960 A1 20061026 US 2006-402641 20060411
PRIORITY APPLN. INFO.: US 2005-671000P P 20050412
ED Entered STN: 19 Oct 2006
AB Water-soluble polymer conjugates and polymer-based compns. of antimicrobial agents are provided. Also provided are methods for synthesizing and administering such conjugates and compns. Thus, the PEGylation of lysostaphin with the degradable PEG reagent, mPEG SBC at pH 6.95 resulted in a mono-PEGylated (1-mer) conjugate MeO(CH2CH2O)nCH2CH2NHCOC6H4OCONH-LY (NH-LY representing a residue of lysostaphin). The yield of mono-PEGylated conjugate was .apprx.44.7%. The half-life for mPEG-lysostaphin 1-mer conjugate was estimated to be 17.5 h.
IT **912858-56-1**
RL: PRP (Properties)
(unclaimed protein sequence; polymer-based compns. and **conjugates** of antimicrobial agents)
RN 912858-56-1 CAPLUS
CN 1: PN: WO2006110776 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **912858-56-1**
RL: PRP (Properties)
(unclaimed protein sequence; polymer-based compns. and **conjugates** of antimicrobial agents)
RN 912858-56-1 CAPLUS
CN 1: PN: WO2006110776 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
1 MKKTKNNYYT RPLAIGLSTF ALASIVYGGI QNETHASEKS NMDVSKKVAE
51 VETSKAPVEN TAEVETSKAP VENTAEVETS KAPVENTAEV ETSKAPVENT
101 AEVETSKAPV ENTAEVETSK APVENTAEVE TSKALVQNRT ALRAATHEHS
151 AQWLNNYKKG YGYGPYPLGI NGGMHYGVDF FMNIGTPVKA ISSGKIVEAG
201 WSNYGGGNQI GLIENDGVHR QWYMHLSKYN VKVGDYVKAG QIIGWSGSTG
251 YSTAPHLHFQ RMVNSFSNST AQDPMPFLKS AGYGKAGGTV TPTPNTGWKT
301 NKYGTLYKSE SASFTPNTDI ITRTTGPFRS MPQSGVLKAG QTIHYDEVMK
351 QDGHVWVGYT GNSGQRIYLP VRTWNKSTNT LGVLWGTIK

L58 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1031869 CAPLUS Full-text
DOCUMENT NUMBER: 145:416030
TITLE: Astrocyte-specific gene expression profiles for the identification, assessment, prevention, and therapy of neurological diseases, disorders and conditions
INVENTOR(S): Bachoo, Robert M.
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA
SOURCE: PCT Int. Appl., 528pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2006105417 A2 20061005 WO 2006-US11960 20060331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2005-667922P P 20050331
ED Entered STN: 05 Oct 2006
AB The present invention is based on the identification of correlations between certain expressed markers (e.g., nucleic acid markers and protein markers) involved in neural cell survival and neural cell homeostasis, e.g., markers differentially expressed in astrocytes and in subjects suffering from neurol. diseases, disorders, or conditions. RNA isolated from murine embryonic neural stem cells differentiated into astrocytes, primary cortical astrocyte cultures from postnatal mice, pure neuronal cultures, and gray matter, corpus callosum, and glial limitans microdissected from the telencephalon of postnatal and adult mice was hybridized to Affymetrix U74 oligonucleotide microarrays. Differentially expressed genes were analyzed by (i) unsupervised hierarchical clustering, (ii) R-SVM, and (iii) threshold criteria, and genes differentially expressed by neurons were subtracted from the data. Candidate genes were validated by RNA in situ hybridization combined with immunohistochem. Finally, a novel clustering algorithm was used to identify addnl. astrocyte-specific genes that tightly cluster with the validated astrocyte genes. The identified differentially expressed transcripts and their encoded proteins can be used in compns., kits, and methods for detecting, characterizing, preventing, and treating human neurol. diseases, disorders, or diseases, and in the generation of a mouse model of neuroblastoma.
IT **911731-84-5 911731-88-9 911731-93-6**
911733-19-2 911734-12-8 911734-54-8
RL: PRP (Properties)
(unclaimed sequence; astrocyte-specific gene expression profiles for the identification, assessment, prevention, and therapy of neurol. diseases, disorders and conditions)
RN 911731-84-5 CAPLUS
CN 459: PN: WO2006105417 PAGE: 323/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 911731-88-9 CAPLUS
CN 463: PN: WO2006105417 PAGE: 324/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 911731-93-6 CAPLUS
CN 468: PN: WO2006105417 PAGE: 325/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 911733-19-2 CAPLUS
CN 594: PN: WO2006105417 PAGE: 348/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 911734-12-8 CAPLUS
CN 691: PN: WO2006105417 PAGE: 363/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 911734-54-8 CAPLUS
CN 733: PN: WO2006105417 PAGE: 372/395 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **911731-84-5 911731-88-9 911731-93-6**
911733-19-2 911734-12-8 911734-54-8
RL: PRP (Properties)
(unclaimed sequence; astrocyte-specific gene expression profiles for the identification, assessment, prevention, and therapy of neurol. diseases, disorders and conditions)
RN 911731-84-5 CAPLUS
CN 459: PN: WO2006105417 PAGE: 323/395 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ
1 MASEIHMSEP MCLIENTEAQ LVINQEALRI LSAITQPVVV VAIVGLYRTG
51 KSYLMNKLAG KRTGFSLGST VQSHTKGIWM WCVPHPKKAG QTLVLLDTEG
101 LEDVEKGDNQ NDCWIFALAV LLSSTFIYNS IGTINQQAMD QLHYVTELTD
151 LIKSKSSPDQ SGVDDSANFV GFFPTFVWTL RDFSLELEVN GKPVTSDEYL
201 EHSLTLKKGA DKKTKSFNEP RLCIRKFFPK RKCFIFDRPA QRKQLSKLET
251 LREEELCGEF VEQVAEFTSY ILSYSSVKTL CGGIIVNGPR LKSLVQTYVG
301 AISNGSLPCM ESAVLTLAQI ENSAAVQKAI THYEEQMNQK IQMPTETLQE
351 LLDLHRPIES EAIEVFLKNS FKDVDQKFQT ELGNLLVAKR DAFIKKNMDV
401 SSARCSDLLE DIFGPLEEEV KLGTFSKPGG YYLFLQMRQE LEKKYNQAPG
451 KGLQAEAMLK NYFDSKADVV ETLLQTDQSL TEAAKEVEEE RTKAEAAEAA
501 NRELEKKQKE FELMMQQKEK SYQEHVKKLT EKMKDEQKQL LAEQENIIAA
551 KLREQEKFLK EGFENESKKL IREIDTLKQN KSSGKCTIL

RN 911731-88-9 CAPLUS
CN 463: PN: WO2006105417 PAGE: 324/395 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ
1 MGKRWLPSLA LLPLPPPLLL LLLLLLPTNA SAPQKPIYMV MVPSLLHAGT
51 PEKGCLLFNH LNETVTVKVS MESVRGNQSL FTDLVVDKDL FHCASFIVPQ
101 SSSNEVMFLT VQVKGPTHEF RRRSTVLIKT KESLVFAQTD KPIYKPGQMV
151 RFRWVSLDEN FHPLNELIPL LYIQDSKKNR IAQWQNFRLE GGLKQLSFPL
201 SSEPTQGSYK VVIRTESGRT VEHPFSVKEF VLPKFEVKVA VPETITILEE
251 EMNVSVCGIY TYGKPVPGHV TVNICRKYSN PSSCFGEESL AFCEKFSQQL
301 DGRGCFSQLV KTKSFQLKRQ EYEMQLDVNA KIQEEGTGVE ETGKGLTKIT
351 RTITKLSFVN VDTHFGQGIP FVGQVLLVDG RGTPIPYEMI FIGADEANQN
401 INTTTDKNGL ARFSINTDDI MGTSLTVRAK YKDSNVCYGF RWLTEENVEA
451 WRTANAVFSP SRSFVHLESL PYKLRCEQTL AVQAHYILND EAVLERKELV
501 FYYLMMAKGG IVRAGTHVLP VTQGHKKGHF SILISMETDL APVARLVLYT
551 ILPNGEVVGD TVKYEIEKCL ANKVDLVFHP NIGLPATRAF LSVMASPQSL
601 CGLRAVDQSV LLTKPEAELS ASLVYDLLPV KDLTGFPKGV NQQEEDTNGC
651 LKQNDTYIRN PVLPRQNTNE EDMYGFLKDM GLKVFTNLNI RKPKVCERLG
701 VNKIPAAYHL VSQGHMDAFL ESSESPTETT RSYFPETWIW DLVIVDSTGV
751 AEMEVTVPDT ITEWKAGAFC LSNDTGLGLS PVIDFQAFQP FFVDLTMPYS
801 VIRGEAFTLK ATVLNYLQTC IRVGVQLEAS PDFLATPEEK EQKSHCICMN
851 ERHTMSWAVI PKSLGNVNFT VSAEALDSKE LCRNEVPVVP ERGKKDTIIK
901 SLLVEPEGLE NEVTFNSLLC PTGAEVSEQI SLKLPSDVVE ESARASVTVL

```
 951 GDILGSAMQN TQDLLKMPYG CGEQNMVLFA PNIYVLDYLN ETEQLTQEIK
1001 TKAITYLNTG YQRQLNYKHR DGSYSTFGDK PGRSHANTWL TAFVLKSFAQ
1051 ARRYIFIDES HITQALTWLS QQQKDNGCFR SSGSLLNNAM KGGVEDEVTL
1101 SAYITIALLE MSLPVTHPVV RNALFCLDTA WKSARRGASG NHVYTKALLA
1151 YAFALAGNQD TKKEILKSLD EEAVKEDNSV HWTRAQKPRV PADLWYQPQA
1201 PSAEVEMTAY VLLAYLTTEL VPTREDLTAA MLIVKWLTKQ QNSHGGFSST
1251 QDTVVALHAL SKYGAATFTR AKKAAHVTIQ SSGAFYTKFQ VNNDNQLLLQ
1301 RVTLPTVPGD YTAKVAGEGC VYLQTSLKYS VLPREKEFPF ALVVQTLPGT
1351 CEDLKAHTTF QISLNISYIG SRSDSNMAIA DVKMVSGFIP LKPTVKMLER
1401 SVHVSRTEVS NNHVLIYLDK VSNQMLTLFF MVQQDIPVRD LKPAIVKVYD
1451 YYEKDEFAVA KYSAPCSAGY GNA
```

RN 911731-93-6 CAPLUS
CN 468: PN: WO2006105417 PAGE: 325/395 unclaimed sequence (9CI) (CA INDEX NAME)

```
SEQ    1 MAAATPTETP APEGSGLGMD ARLDQETAQW LRWDQNPLTS ESVKQLIAGG
      51 NKEELRKCFG ARMEFGTAGL RAPMGAGISR MNDLTIIQTT QGFCRYLEKQ
     101 FSDLKQRGVV ISFDARAHPA SGGSSRRFAR LAATAFITQG VPVYLFSDIT
     151 PTPFVPYTVS HLKLCAGIMI TASHNPKQDN GYKVYWDNGA QIISPHDRGI
     201 SQAIEENLEP WPQAWEESLV DSSPLLHNPS ASIGNDYFED LKKYCFHRTV
     251 NKESKVKFVH TSVHGVGHEF VQLAFKAFDL APPEAVPQQK DPDPEFPTVK
     301 YPNPEEGKGV LTLSFALADK IKAKIVLAND PDADRLAVAE KQDSGEWRVF
     351 SGNELGALLG WWLFTSWKEK NQDQSNLKDT YMLSSTVSSK ILRAIALKEG
     401 FHFEETLTGF KWMGNRAQQL GDQGKTVLFA FEEAIGYMCC PFVLDKDGVS
     451 AAVICAELAS FLATKNLSLS QQLNAIYVEY GYHITTASYF ICHDQGTIQN
     501 LFGNLRNYDG KNNYPKMCGK FEISAIRDLT TGYDDSQPDK KAVLPTSKSS
     551 QMITFTFANG GVATMRTSGT EPKIKYYAEL CAPPGNSDPE HLKKELDELV
     601 GAIEEHFFQP QKYNLQPKAE
```

RN 911733-19-2 CAPLUS
CN 594: PN: WO2006105417 PAGE: 348/395 unclaimed sequence (9CI) (CA INDEX NAME)

```
SEQ    1 MATAMTVSSK LRGLLMQQLR GTSQLYFNIS LRSLSSSAQE ASKRAPEEVS
      51 DHNYESIQVT SAQKHVLHVQ LNRPEKRNAM NRAFWRELVE CFQKISKDSD
     101 CRAVVVSGAG KMFTSGIDLM DMASELMQPS GDDAARIAWY LRDLISKYQK
     151 TFTVIEKCPK PVIAAIHGGC IGGGVDLVSA CDIRYCTQDA FFQIKEVDMG
     201 LAADVGTLQR LPKVIGNQSL VNELTFSARK MMADEALDSG LVSRVFQDKD
     251 AMLNAAFALA ADISSKSPVA VQGSKINLIY SRDHSVDESL DYMATWNMSM
     301 LQTQDIIKSV QAAMEKRDTK SITFSKL
```

RN 911734-12-8 CAPLUS
CN 691: PN: WO2006105417 PAGE: 363/395 unclaimed sequence (9CI) (CA INDEX NAME)

```
SEQ    1 MAKPLTDSER QKQISVRGIA GLGDVAEVRK SFNRHLHFTL VKDRNVATPR
      51 DYFFALAHTV RDHLVGRWIR TQQHYYERDP KRIYYLSLEF YMGRTLQNTM
     101 VNLGLQTACD EATYQLGLDL EELEEIEEDA GLGNGGLGRL AACFLDSMAT
     151 LGLAAYGYGI RYEFGIFNQK IVNGWQVEEA DDWLRYGNPW EKARPEYMLP
     201 VHFYGRVEHT PDGVLWLDTQ VVLAMPYDTP VPGYKNNTVN TMRLWSAKAP
```

```
  251 NDFKLKDFNV GDYIEAVLDR NLAENISRVL YPNDNFFEGK ELRLKQEYFV
  301 VAATLQDIIR RFKSSRFGCR DPVRTCFETF PDKVAIQLND THPALSIPEL
  351 MRILVDVEKV DWDKAWEITK KTCAYTNHTV LPEALERWPV SMFEKLLPRH
  401 LEIIYAINQR HLDHVAALFP GDVDRLRRMS VIEEGDCKRI NMAHLCVIGS
  451 HAVNGVARIH SEIVKQSVFK DFYELEPEKF QNKTNGITPR RWLLLCNPGL
  501 AEIIVERIGE GFLTDLSQLK KLLSLVDDEA FIRDVAKVKQ ENKLKFSAQL
  551 EKEYKVKINP ASMFDVHVKR IHEYKRQLLN CLHIITLYNR IKKDPAKAFV
  601 PRTVMIGGKA APGYHMAKMI IKLVTSIGDV VNHDPVVGDR LRVIFLENYR
  651 VSLAEKVIPA ADLSQQISTA GTEASGTGNM KFMLNGALTI GTMDGANVEM
  701 AEEAGEENLF IFGMRVEDVE ALDQKGYNAR EFYERLPELR QAVDQISSGF
  751 FSPKDPDCFK DVVNMLMYHD RFKVFADYEA YIQCQAQVDR LYRNSKEWTK
  801 KVIRNIACSG KFSSDRTITE YAREIWGVEP SDLQIPPPNL PKD
```

RN 911734-54-8 CAPLUS

CN 733: PN: WO2006105417 PAGE: 372/395 unclaimed sequence (9CI) (CA INDEX NAME)

```
SEQ     1 MHVSLAEALE VRGGPLQEEE IWAVLNQSAE SLQEVFRRVS IADPAALGFI
       51 ISPWSLLLLP SGSVSFTDEN VSNQDLRAST APEVLQSHSL TSLADVEKIH
      101 IYSLGMTLYW GADHEVPQSQ PIKLGDHLNS ILLGMCEDVI YARVSVRTVL
      151 DACSAHIRNS NCAPSFSNVK QLVKLVLGNI SGTDPLSRSS EQKPDRSQAI
      201 RDRLRGKGLP TGRSSTSDAL DTHEAPLSQQ TFVNKGLSKS MGFLSIRDTR
      251 DEEDYLKDTP SDNNSRHEDS ETFSSPYQFK TSTPQMDALS KKKTWASSMD
      301 LLCAANRDIS GETGRYQRCD PKTVTGRTSI TPRKKEGRYS DGSIALDIFG
      351 PQKVEPVIHT RELPTSTAVS SALDRIRERQ QKLQVLREAM NVEEPVRRYK
      401 TYHSDIFSIS SESPSVISSE SDFRQVRKSE ASKRFESSSG LPGVDETGQT
      451 RPSRQYETSL EGNLINQDIM LRRQEEEMMQ LQARMALRQS RLSLYPGDTV
      501 KASMLDISRD PLREMALETA MTQRKLRNFF GPEFVKMTVE PFVSLDLPRS
      551 ILSQTKKGKS EDQRRKVNIR LLSGQRLELT CDTKTICKDV FDMVVAHIGL
      601 VEHHLFALAT RKENEYFFVD PDLKLTKVAP EGWKEEPKRK GKAAVDFTLF
      651 FRIKFFMDDV SLIQHDLTCH QYYLQLRKDL LDERVHCDDE AALLLASLAL
      701 QAEYGDYQPE VHGVSYFRLE HYLPARVMEK LDVSYIKEEL PKLHNTYAGA
      751 SEKETELEFL KVCQRLTEYG VHFHRVHPEK KSQTGILLGV CSKGVLVFEV
      801 HNGVRALVLR FPWRETKKIS FSKKKITLQN TSDGIKHAFQ TDSSKACQYL
      851 LHLCSSQHKF QLQMRARQSN QDAQDIERAS FRSLNLQAES VRGFNMGRAI
      901 STGSLASSTI NKLAVRPLSV QAEILKRLSS SEWSLYQPLQ NSSKEKTDKA
      951 SWEEKPRGMS KSYHDLSQAS LCPHRKQVIN MEALPQAFAE LVGKPLYPMA
     1001 RSDTESLAGL PKLDNSKSVA SLNRSPERRN HESDSSTEDP GQAYVVGMSL
     1051 PSSGKSSSQV PFKDNDTLHK RWSIVSSPER EITLVNLKKD PKHGLGFQII
     1101 GGEKMGRLDL GVFISAVTPG GPADLDGCLK PGDRLISVNS VSLEGVSHHA
     1151 AVDILQNAPE DVTLVISQPK EKPSKVPSTP VHFANGMKSY TKKPAYMQDS
     1201 AMDPSEDQPW PRGTLRHIPE SPFGLSGGLR EGSLSSQDSR TESASLSQSQ
     1251 VNGFFASHLG DRGWQEPQHS SPSPSVTTKV NEKTFSDSNR SKAKRRGISD
     1301 LIEHLDCADS DKDDSTYTSS QDHQTSKQEP SSSLSTSNKT SFPTSSASPP
     1351 KPGDTFEVEL AKTDGSLGIS VTGGVNTSVR HGGIYVKAII PKGAAESDGR
     1401 IHKGDRVLAV NGVSLEGATH KQAVETLRNT GQVVHLLLEK GQVPTSRERD
     1451 PAGPQSPPPD QDAQRQAPEK VAKKHPMSKT TALLLKIIFE VKLFKNSSGT
     1501 GFSFSREDNL IPEQINGSIV RVKKLFPGQP AAESGKIDVG DVILKVNGAP
     1551 LKGLSQQDVI SALRGTAPEV SLLLCRPAPG VLPEIDTTFL NPLYSPANSF
     1601 LNSSKETSQP SSSVEQGASS DDNGVSGKTK NHCRAPSRRE SYSDHSESGE
     1651 DDSVRAPAKM PNVTRVAAFP HEAPRSQEES ICAMFYLPRK IPGKLESESS
     1701 HPPPLDVSPG QTCQPPAECA PSDATGKHFT HLASQLSKEE NITTLKNDLG
     1751 NHLEDSELEV ELLITLVKSE KGSLGFTVTK GSQSIGCYVH DVIQDPAKGD
     1801 GRLKAGDRLI KVNDTDVTNM THTDAVNLLR AAPKTVRLVL GRILELPRMP
     1851 VFPHLLPDIT VTCHGEELGF PLSGGQGSPH GVVYISDINP RSAAAVDGSL
     1901 QLLDIIHYVN GVSTQGMTLE DANRALDLSL PSVVLKVTRD GCPVVPTTRA
     1951 AISAPRFTKA NGLTSMEPSG QPALMPKNSF SKVNGEGVHE AVCPAGEGSS
```

2001 SQMKESAGLT ETKESNSRDD DIYDDPQEAE VIQSLLDVVD EEAQNLLNQR
2051 HATRRACSPD PLRTNGEAPE EGDTDYDGSP LPEDVPESVS SGEGKVDLAS
2101 LTAASQEEKP IEEDATQESR NSTTETTDGE DSSKDPPFLT NEELAALPVV
2151 RVPPSGKYTG TQLQATIRTL QGLLDQGIPS KELENLQELK PLDQCLIGQT
2201 KENRRKNRYK NILPYDTTRV PLGDEGGYIN ASFIRIPVGT QEFVYIACQG
2251 PLPTTVGDFW QMVWEQNSTV IAMMTQEVEG EKIKCQRYWP SILGTTTMAN
2301 ERLRLALLRM QQLKGFIVRV MALEDIQTGE VRHISHLNFT AWPDHDTPSQ
2351 PDDLLTFISY MRHIRRSGPV ITHCSAGIGR SGTLICIDVV LGLISQDLEF
2401 DISDLVRCMR LQRHGMVQTE GQYVFCYQVI LYVLTHLQAE EQKAQQGSHS
2451 DAEQPPKAPP

L58 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:769222 CAPLUS Full-text
DOCUMENT NUMBER: 145:180970
TITLE: Abasic oligonucleotides as carrier platform for antigens and immunostimulatory agonists and antagonists, and their therapeutic use
INVENTOR(S): Lipford, Grayson B.; Forsbach, Alexandra; Uhlmann, Eugen; Wagner, Hermann
PATENT ASSIGNEE(S): Coley Pharmaceutical GmbH, Germany
SOURCE: PCT Int. Appl., 83pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006080946	A2	20060803	WO 2005-US20225	20050608
WO 2006080946	A3	20061221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005326144	A1	20060803	AU 2005-326144	20050608
CA 2567789	A1	20060803	CA 2005-2567789	20050608
EP 1753453	A2	20070221	EP 2005-856794	20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

PRIORITY APPLN. INFO.: US 2004-577813P P 20040608
WO 2005-US20225 W 20050608

ED Entered STN: 04 Aug 2006
AB Compns. and methods are provided for enhancing delivery of therapeutic agents. More specifically, compns. and methods are provided for improving antigen delivery to antigen-presenting cells. Conjugates between abasic oligonucleotides and antigen are provided, along with methods for their use in vaccination and in the treatment of cancer, infection, and allergy and asthma.

Also provided are conjugates between abasic oligonucleotides and various immunostimulatory nucleic acids, including CpG oligonucleotides, as well as methods of use thereof. Also provided are conjugates between abasic oligonucleotides and various other agonists and antagonists of immunostimulation, as well as methods of use thereof.

IT **363639-78-5**, GENBANK AAK29625 **415177-29-6**, GENBANK AAK28488 **483531-45-9**, GenBank BAB19260
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(abasic oligonucleotides as carrier platform for antigens and immunostimulatory agonists and antagonists, and therapeutic use)

RN 363639-78-5 CAPLUS
CN Receptor TLR-9 (Toll-like receptor-9) (Mus musculus RAW264.7 cell gene Tlr9) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 415177-29-6 CAPLUS
CN Receptor TLR-9 (Toll-like receptor-9) (Mus musculus strain BALB/c spleen gene Tlr9 precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 483531-45-9 CAPLUS
CN GenBank BAB19260 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **363639-78-5**, GENBANK AAK29625 **415177-29-6**, GENBANK AAK28488 **483531-45-9**, GenBank BAB19260
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(abasic oligonucleotides as carrier platform for antigens and immunostimulatory agonists and antagonists, and therapeutic use)

RN 363639-78-5 CAPLUS
CN Receptor TLR-9 (Toll-like receptor-9) (Mus musculus RAW264.7 cell gene Tlr9) (9CI) (CA INDEX NAME)

SEQ

```
      1 MVLRRRTLHP LSLLVQAAVL AETLALGTLP AFLPCELKPH GLVDCNWLFL
     51 KSVPRFSAAA SCSNITRLSL ISNRIHHLHN SDFVHLSNLR QLNLKWNCPP
    101 TGLSPLHFSC HMTIEPRTFL AMRTLEELNL SYNGITTVPR LPSSLVNLSL
    151 SHTNILVLDA NSLAGLYSLR VLFMDGNCYY KNPCTGAVKV TPGALLGLSN
    201 LTHLSLKYNN LTKVPRQLPP SLEYLLVSYN LIVKLGPEDL ANLTSLRVLD
    251 VGGNCRRCDH APNPCIECGQ KSLHLHPETF HHLSHLEGLV LKDSSLHTLN
    301 SSWFQGLVNL SVLDLSENFL YESINHTNAF QNLTRLRKLN LSFNYRKKVS
    351 FARLHLASSF KNLVSLQELN MNGIFFRSLN KYTLRWLADL PKLHTLHLQM
    401 NFINQAQLSI FGTFRALRFV DLSDNRISGP STLSEATPEE ADDAEQEELL
    451 SADPHPAPLS TPASKNFMDR CKNFKFTMDL SRNNLVTIKP EMFVNLSRLQ
    501 CLSLSHNSIA QAVNGSQFLP LTNLQVLDLS HNKLDLYHWK SFSELPQLQA
    551 LDLSYNSQPF SMKGIGHNFS FVAHLSMLHS LSLAHNDIHT RVSSHLNSNS
    601 VRFLDFSGNG MGRMWDEGGL YLHFFQGLSG LLKLDLSQNN LHILRPQNLD
    651 NLPKSLKLLS LRDNYLSFFN WTSLSFLPNL EVLDLAGNQL KALTNGTLPN
    701 GTLLQKLDVS SNSIVSVVPA FFALAVELKE VNLSHNILKT VDRSWFGPIV
    751 MNLTVLDVRS NPLHCACGAA FVDLLLEVQT KVPGLANGVK CGSPGQLQGR
    801 SIFAQDLRLC LDEVLSWDCF GLSLLAVAVG MVVPILHHLC GWDVWYCFHL
    851 CLAWLPLLAR SRRSAQALPY DAFVVFDKAQ SAVADWVYNE LRVRLEERRG
    901 RRALRLCLED RDWLPGQTLF ENLWASIYGS RKTLFVLAHT DRVSGLLRTS
    951 FLLAQQRLLE DRKDVVVLVI LRPDAHRSRY VRLRQRLCRQ SVLFWPQQPN
   1001 GQGGFWAQLS TALTRDNRHF YNQNFCRGPT AE
```

RN 415177-29-6 CAPLUS
CN Receptor TLR-9 (Toll-like receptor-9) (Mus musculus strain BALB/c spleen gene Tlr9 precursor) (9CI) (CA INDEX NAME)

SEQ
1 MVLRRRTLHP LSLLVQAAVL AETLALGTLP AFLPCELKPH GLVDCNWLFL
51 KSVPRFSAAA SCSNITRLSL ISNRIHHLHN SDFVHLSNLR QLNLKWNCPP
101 TGLSPLHFSC HMTIEPRTFL AMRTLEELNL SYNGITTVPR LPSSLVNLSL
151 SHTNILVLDA NSLAGLYSLR VLFMDGNCYY KNPCTGAVKV TPGALLGLSN
201 LTHLSLKYNN LTKVPRQLPP SLEYLLVSYN LIVKLGPEDL ANLTSLRVLD
251 VGGNCRRCDH APNPCIECGQ KSLHLHPETF HHLSHLEGLV LKDSSLHTLN
301 SSWFQGLVNL SVLDLSENFL YESINHTNAF QNLTRLRKLN LSFNYRKKVS
351 FARLHLASSF KNLVSLQELN MNGIFFRSLN KYTLRWLADL PKLHTLHLQM
401 NFINQAQLSI FGTFRALRFV DLSDNRISGP STLSEATPEE ADDAEQEELL
451 SADPHPAPLS TPASKNFMDR CKNFKFTMDL SRNNLVTIKP EMFVNLSRLQ
501 CLSLSHNSIA QAVNGSQFLP LTNLQVLDLS HNKLDLYHWK SFSELPQLQA
551 LDLGYNSQPF SIKGIGHNFS FVAHLSMLHS LSLAHNDIHT RVSSHLNSNS
601 VRFLDFSGNG MGRMWDEGGL YLHFFQGLSG LLKLDLSQNN LHILRPQNLD
651 NLPKSLKLLS LRDNYLSFFN WTSLSFLPNL EVLDLAGNQL KALTNGTLPN
701 GTLLQKLDVS SNSIVSVVPA FFALAVELKE VNLSHNILKT VDRSWFGPIV
751 MNLTVLDVRS NPLHCACGAA FVDLLLEVQT KVPGLANGVK CGSPGQLQGR
801 SIFAQDLRLC LDEVLSWDCF GLSLLAVAVG MVVPILHHLC GWDVWYCFHL
851 CLAWLPLLAR SRRSAQALPY DAFVVFDKAQ SAVADWVYNE LRVRLEGRRG
901 RRALRLCLED RDWLPGQTLF ENLWASIYGS RKTLFVLAHT DRVSGLLRTS
951 FLLAQQRLLE DRKDVVVLVI LRPDAHRSRY VRLRQRLCRQ SVLFWPQQPN
1001 GQGGFWAQLS TALTRDNRHF YNQNFCRGPT AE

RN 483531-45-9 CAPLUS
CN GenBank BAB19260 (9CI) (CA INDEX NAME)

SEQ
1 MVLRRRTLHP LSLLVQAAVL AETLALGTLP AFLPCELKPH GLVDCNWLFL
51 KSVPRFSAAA SCSNITRLSL ISNRIHHLHN SDFVHLSNLR QLNLKWNCPP
101 TGLSPLHFSC HMTIEPRTFL AMRTLEELNL SYNGITTVPR LPSSLVNLSL
151 SHTNILVLDA NSLAGLYSLR VLFMDGNCYY KNPCTGAVKV TPGALLGLSN
201 LTHLSLKYNN LTKVPRQLPP SLEYLLVSYN LIVKLGPEDL ANLTSLRVLD
251 VGGNCRRCDH APNPCIECGQ KSLHLHPETF HHLSHLEGLV LKDSSLHTLN
301 SSWFQGLVNL SVLDLSENFL YESINHTNAF QNLTRLRKLN LSFNYRKKVS
351 FARLHLASSF KNLVSLQELN MNGIFFRSLN KYTLRWLADL PKLHTLHLQM
401 NFINQAQLSI FGTFRALRFV DLSDNRISGP STLSEATPEE ADDAEQEELL
451 SADPHPAPLS TPASKNFMDR CKNFKFTMDL SRNNLVTIKP EMFVNLSRLQ
501 CLSLSHNSIA QAVNGSQFLP LTNLQVLDLS HNKLDLYHWK SFSELPQLQA
551 LDLSYNSQPF SMKGIGHNFS FVTHLSMLQS LSLAHNDIHT RVSSHLNSNS
601 VRFLDFSGNG MGRMWDEGGL YLHFFQGLSG LLKLDLSQNN LHILRPQNLD
651 NLPKSLKLLS LRDNYLSFFN WTSLSFLPNL EVLDLAGNQL KALTNGTLPN
701 GTLLQKLDVS SNSIVSVVPA FFALAVELKE VNLSHNILKT VDRSWFGPIV
751 MNLTVLDVRS NPLHCACGAA FVDLLLEVQT KVPGLANGVK CGSPGQLQGR
801 SIFAQDLRLC LDEVLSWDCF GLSLLAVAVG MVVPILHHLC GWDVWYCFHL
851 CLAWLPLLAR SRRSAQTLPY DAFVVFDKAQ SAVADWVYNE LRVRLEERRG
901 RRALRLCLED RDWLPGQTLF ENLWASIYGS RKTLFVLAHT DRVSGLLRTS
951 FLLAQQRLLE DRKDVVVLVI LRPDAHRSRY VRLRQRLCRQ SVLFWPQQPN
1001 GQGGFWAQLS TALTRDNRHF YNQNFCRGPT AE

L58 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:101085 CAPLUS Full-text

DOCUMENT NUMBER: 144:164292
TITLE: Guanylate binding protein (GBP-1) as cell proliferation inhibitor and cellular differentiation marker, vectors expressing the same, and therapeutic uses
INVENTOR(S): Sturzl, Michael; Cornali, Emmanuelle
PATENT ASSIGNEE(S): Sturzl, Michael, Germany
SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 791,502.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006025362	A1	20060202	US 2005-59292	20050216
WO 2000012737	A1	20000309	WO 1999-EP6148	19990823
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9955184	A	20000321	AU 1999-55184	19990823
EP 1736547	A1	20061227	EP 2006-116437	19990823
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 2002115138	A1	20020822	US 2001-791502	20010223
US 6894157	B2	20050517		

PRIORITY APPLN. INFO.:		
DK 1998-1081	A	19980826
DK 1998-1241	A	19981001
WO 1999-EP6148	A2	19990823
US 2001-791502	A2	20010223
EP 1999-941654	A3	19990823
WO 1999-DK6148	W	19990823

ED Entered STN: 03 Feb 2006

AB The present invention relates to a recombinant protein consisting of Guanylate Binding Protein-1 (GBP-1), or one or more functional parts thereof, linked to a shuttle protein, such as HIV-1-tat transduction domain. The present invention provides an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said vector comprising said gene or parts thereof in sense or antisense orientation into cells can be used to induce phenotypical changes of said cells and can, thus, be used for modulation of cell differentiation. The invention is based on the discovery that GBP-1 plays roles in cell adhesion and proliferation. Differential display RT-PCR demonstrates that GBP-1 mRNA expression is induced by interferon-γ, interleukin-1β, and tumor necrosis factor-α, but not by angiogenic factors in HDMVEC (human dermis microvascular endothelial cells). Vascular endothelial growth factor and basic fibroblast growth factor inhibit interleukin-1β induction of GBP-1 mRNA in HDMVEC and also inhibit the binding of U937 monocytes to interleukin-1β or interferon-γ-activated HDMVEC. Thus, the present invention provides GBP-1-expressing vectors for the treatment of cancer, sarcoma, lymphoma, hemangioma, atherosclerosis or restenosis, but also the treatment of inflammatory diseases like chronic ulcerative diseases, psoriasis, insect bites, freezing or burning injuries, wound healing, or

Morbus Crohn. Addnl., the present invention provides, inter alia, a method for determination of the stage of cellular differentiation by using GBP-1 gene expression as a marker.

IT **874689-74-4DP**, fusion products
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; guanylate binding protein (GBP-1) as cell proliferation inhibitor and cellular differentiation marker, vectors expressing same, and therapeutic uses)
RN 874689-74-4 CAPLUS
CN Protein GBP-1 (guanylate-binding protein 1) (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **874689-74-4DP**, fusion products
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; guanylate binding protein (GBP-1) as cell proliferation inhibitor and cellular differentiation marker, vectors expressing same, and therapeutic uses)
RN 874689-74-4 CAPLUS
CN Protein GBP-1 (guanylate-binding protein 1) (human) (9CI) (CA INDEX NAME)

SEQ
```
  1 MASEIHMTGP MCLIENTNGR LMANPEALKI LSAITQPMVV VAIVGLYRTG
 51 KSYLMNKLAG KKKGFSLGST VQSHTKGIWM WCVPHPKKPG HILVLLDTEG
101 LGDVEKGDNQ NDSWIFALAV LLSSTFVYNS IGTINQQAMD QLYYVTELTH
151 RIRSKSSPDE NENEVEDSAD FVSFFPDFVW TLRDFSLDLE ADGQPLTPDE
201 YLTYSLKLKK GTSQKDETFN LPRLCIRKFF PKKKCFVFDR PVHRRKLAQL
251 EKLQDEELDP EFVQQVADFC SYIFSNSKTK TLSGGIQVNG PRLESLVLTY
301 VNAISSGDLP CMENAVLALA QIENSAAVQK AIAHYEQQMG QKVQLPTETL
351 QELLDLHRDS EREAIEVFIR SSFKDVDHLF QKELAAQLEK KRDDFCKQNQ
401 EASSDRCSAL LQVIFSPLEE EVKAGIYSKP GGYRLFVQKL QDLKKKYYEE
451 PRKGIQAEEI LQTYLKSKES MTDAILQTDQ TLTEKEKEIE VERVKAESAQ
501 ASAKMLQEMQ RKNEQMMEQK ERSYQEHLKQ LTEKMENDRV QLLKEQERTL
551 ALKLQEQEQL LKEGFQKESR IMKNEIQDLQ TKMRRRKACT IS
```

L58 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1313893 CAPLUS Full-text
DOCUMENT NUMBER: 144:67422
TITLE: Gene expression profile for diagnosing transport stress in horses
INVENTOR(S): Brandon, Richard Bruce; Thomas, Mervyn Rees
PATENT ASSIGNEE(S): Genomics Research Partners Pty Ltd, Australia
SOURCE: PCT Int. Appl., 445 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118810	A1	20051215	WO 2005-AU794	20050603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005250056	A1	20051215	AU 2005-250056	20050603
CA 2568967	A1	20051215	CA 2005-2568967	20050603
PRIORITY APPLN. INFO.:			US 2004-576285P	P 20040603
			AU 2004-903003	A 20040604
			WO 2005-AU794	W 20050603

ED Entered STN: 16 Dec 2005

AB The present invention is predicated on the discovery that horses subjected to stress have aberrant expression of certain genes or certain alleles of genes, referred to as stress marker genes, as compared to horses not subjected to stress. One hundred thirty-four stress marker genes are identified by GeneChip anal. of blood obtained from normal horses and from 20 horses subjected to transport stress over 48 h. Of the 134 marker genes, 96 have full-length or substantially full-length coding sequences and the remaining 38 have partial sequence information at one or both of their 5' and 3' ends. Significant genes were ranked according to an Empirical Bayes approach, and the gene sequences were compared against the GenBank database using the BLAST algorithm. The identified stress marker genes include 38 previously uncharacterized equine genes. The sequences of isolated nucleic acids find utility inter alia as hybridization probes or amplification primers. Thus, the present invention provides mols. and assays for qual. or quant. determining the effect of stress on the immune system, the susceptibility to developing disease or illness through immune system dysfunction as a result of stress, and for monitoring the ability of an animal to cope with stress. The invention is useful inter alia in measuring response to immunomodulatory therapies, and monitoring the immune response to natural disease under stressful conditions, especially those in athletic training, in measuring the effects of aging on the ability to respond to external stressors, and in enabling better treatment and management decisions to be made in animals at risk of exposure to disease, or susceptible to disease through the effects of stress.

IT **871612-63-4 871612-81-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profile for diagnosing transport stress in horses)

RN 871612-63-4 CAPLUS
CN Protein (Equus caballus gene WBC013G08 protein FLJ16386 sequence homolog) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 871612-81-6 CAPLUS
CN Protein (Equus caballus gene BM781012 immunoglobulin IgG γ1-chain constant region sequence homolog) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **871612-63-4 871612-81-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profile for diagnosing transport stress in horses)
RN 871612-63-4 CAPLUS
CN Protein (Equus caballus gene WBC013G08 protein FLJ16386 sequence homolog) (9CI) (CA INDEX NAME)

SEQ
1 MESGPKMLAP VCLVENNNEQ LLVNQQAIQI LEKISQPVVV VAIVGLYRTG
51 KSYLMNHLAG QNHGFPLGST VQSETKGIWM WCVPHPSKPN HTLVLLDTEG
101 LGDVEKGDPK NDSWIFALAV LLCSTFVYNS MSTINHQALE QLHYVTELTE
151 LIRAKSSPRP DEVQDSTEFV SFFPDFIWTV RDFTLELKLD GHPITEDEYL
201 ENALKLIPGK NPKVQASNLP RECIRLFFPK RKCFVFDRPI NDKALLADIE
251 NVSENELDSK FQEQINKFCS HIFTHARPKT LREGIMVTGN RLRTLVVTYV
301 DTINTGAVPC LENAVRTLAQ LENSVAMQKA ADHYSEQMAE KLKLPTDTLQ
351 ELLDVHTACE REAIAFFMEH SFKDENQEFQ KKFMETTMNK KGDFLLQNEE
401 SSVQYCQAKL NELSKGLMES ISAGSFSVPG GHKLYMETKE RIEQDYWQVP
451 RKGVKAKEVF QRFLESQMVI EESILQSDKA LTDREKAVAV DRAKKEAAEK
501 EQELLKQKLQ EQQQQMEAQD KSRKENIAQL KEKLQMEREH LLREQIMMLE
551 HTQKVQNDWL HEGFKKKYEE MNAEISQFKR MIDTTKNDDT PWIARTLDNL
601 ADELTAILSA PAKLIGHGVK GVSSLFKKHK LPF

RN 871612-81-6 CAPLUS
CN Protein (Equus caballus gene BM781012 immunoglobulin IgG γ1-chain constant region sequence homolog) (9CI) (CA INDEX NAME)

SEQ
1 ASTTAPKVFA LAPGCGTTSD STVALGCLVS GYFPEPVKVS WNSGSLTSGV
51 HTFPSVLQSS GFYSLSSMVT VPASTWTSET YICNVVHAAS NFKVDKRIEP
101 IPDNHQKVCD MSKCPKCPAP ELLGGPSVFI FPPNPKDTLM ITRTPEVTCV
151 VVDVSQENPD VKFNWYMDGV EVRTATTRPK EEQFNSTYRV VSVLRIQHQD
201 WLSGKEFKCK VNNQALPQPI ERTITKTKGR SQEPQVYVLA PHPDELSKSK
251 VSVTCLVKDF YPPEINIEWQ SNGQPELETK YSTTQAQQDS DGSYFLYSKL
301 SVDRNRWQQG TTFTCGVMHE ALHNHYTQKN VSKNPGK

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1218484 CAPLUS Full-text
DOCUMENT NUMBER: 143:453990
TITLE: Membrane-associated proteins for the diagnosis and therapy of hyperproliferative or autoimmune disorders and their identification using a custom microarray
INVENTOR(S): Betchel, Pamela; Daniels, Mark; McLachkan, Karen; Zhai, Yufeng; Colson, Benjamin L.; O'Brien, Nicole W.
PATENT ASSIGNEE(S): Biogen Idec MA Inc., USA
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108415	A2	20051117	WO 2005-US15207	20050502

WO 2005108415 A8 20060518
WO 2005108415 A3 20061130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2004-567187P P 20040430
ED Entered STN: 17 Nov 2005
AB The present invention is directed to novel methods of treating, identifying, or diagnosing a hyperproliferative disorder. The methods of the invention include administering to a patient a composition comprising a binding mol. which binds to a cell surface-expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding mol., for example an antibody or immunospecific fragment thereof, which specifically binds to a membrane-associated mol., variant polypeptide or fragment thereof. The present invention is based, at least in part, on the discovery of membrane-associated proteins, i.e., nucleic acid mols. which encode membrane proteins and the use of these mols. to generate custom arrays to screen for markers associated with various diseases and disorders, e.g., cancer, e.g., lung, colon, pancreatic, and ovarian cancer and autoimmune diseases or disorders. The invention further relates to various methods, reagents and kits for diagnosing, staging, prognosing, monitoring, and treating hyperproliferative diseases or disorders such as cancer, e.g., lung, colon, pancreatic, and ovarian cancer and autoimmune diseases or disorders.
IT **869168-94-5 869169-59-5 869170-18-3 869170-37-6 869170-84-3 869171-06-2 869171-27-7 869172-19-0 869172-58-7 869173-67-1 869175-12-2 869175-13-3 869244-27-9**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; membrane-associated proteins for diagnosis and therapy of hyperproliferative or autoimmune disorders and their identification using custom microarray)
RN 869168-94-5 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1277 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869169-59-5 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1341 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869170-18-3 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1400 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869170-37-6 CAPLUS

CN Membrane protein (human clone WO2005108415-SEQID-1419 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869170-84-3 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1466 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869171-06-2 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1488 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869171-27-7 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1509 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869172-19-0 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1601 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869172-58-7 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1640 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869173-67-1 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1749 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869175-12-2 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1895 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869175-13-3 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1896 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 869244-27-9 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-2091 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **869168-94-5 869169-59-5 869170-18-3**
869170-37-6 869170-84-3 869171-06-2
869171-27-7 869172-19-0 869172-58-7
869173-67-1 869175-12-2 869175-13-3
869244-27-9
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; membrane-associated proteins for diagnosis and therapy of hyperproliferative or autoimmune disorders and their identification using custom microarray)

RN 869168-94-5 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1277 fragment) (9CI) (CA INDEX NAME)

SEQ
1 MMHFKSGLEL TELQNMTVPE DDNISNDSND FTEVENGQIN SKFISDRESR
51 RSLTNSHLEK KKCDEYIPGT TSLGMSVFNL SNAIMGSGIL GLAFALANTG
101 ILLFLVLLTS VTLLSIYSIN LLLICSKETG CMVYEKLGEQ VFGTTGKFVI
151 FGATSLQNTG AMLSYLFIVK NELPSAIKFL MGKEETFSAW YVDGRVLVVI
201 VTFGIILPLC LLKNLGYLGY TSGFSLSCMV FFLIVVIYKK FQIPCIVPEL
251 NSTISANSTN ADTCTPKYVT FNSKTVYALP TIAFAFVCHP SVLPIYSELK
301 DRSQKKMQMV SNISFFAMFV MYFLTAIFGY LTFYDNVQSD LLHKYQSKDD
351 ILILTVRLAV IVAVILTVPV LFFTVRSSLF ELAKKTKFNL CRHTVVTCIL
401 LVVINLLVIF IPSMKDIFGV VGVTSANMLI FILPSSLYLK ITDQDGDKGT
451 QRIWAALFLG LGVLFSLVSI PLVIYDWACS SSSDEGH

RN 869169-59-5 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1341 fragment) (9CI) (CA INDEX NAME)

SEQ
1 KRPSPPAPTA GCPGHGAALG GWEHGRGARA AASRAHRAVG RGRGPGAGLR
51 AGARSRAAAA GTPGPGLAAG AAFQLLNLLG NVGLFLRSDP SIRGVMLAGR
101 GLGQGWAYCY QCQSQVPPRS GHCSACRVCI LRRDHHCRLL GRCVGFGNYR
151 PFLCLLLHAA GVLLHVSVLL GPALSALLRA HTPLHMAALL LLPWLMLLTG
201 RVSLAQFALA FVTDTCVAGA LLCGAGLLFH GMLLLRGQTT WEWARGQHSY
251 DLGPCHNLQA ALGPRWALVW LWPFLASPLP GDGITFQTTA DVGHTAS

RN 869170-18-3 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1400 fragment) (9CI) (CA INDEX NAME)

SEQ
1 MAPGRAVAGL LLLAAAGLGG VAEGPGLAFS EDVLSVFGAN LSLSAAQLQH
51 LLEQMGAASR VGVPEPGQLH FNQCLTAEEI FSLHGFSNAT QITSSKFSVI
101 CPAVLQQLNF HPCEDRPKHK TRPSHSEVWG YGFLSVTIIN LASLLGLILT
151 PLIKKSYFPK ILTFFVGLAI GTLFSNAIFQ LIPEAFGFDP KVDSYVEKAV
201 AVFGGFYLLF FFERMLKMLL KTYGQNGHTH FGNDNFGPQE KTHQPKALPA
251 INGVTCYANP AVTEANGHIH FDNVSVVSLQ DGKKEPSSCT CLKGPKLSEI
301 GTIAWMITLC DALHNFIDGL AIGASCTLSL LQGLSTSIAI LCEEFPHELG
351 DFVILLNAGM STRQALLFNF LSACSCYVGL AFGILVGNNF APNIIFALAG
401 GMFLYISLAD MFPEMNDMLR EKVTGRKTDF TFFMIQNAGM LTGFTAILLI
451 TLYAGEIELE

RN 869170-37-6 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1419 fragment) (9CI) (CA INDEX NAME)

SEQ
1 MLALRVARGS WGALRGAAWA PGTRPSKRRA CWALLPPVPC CLGCLAERWR
51 LRPAALGLRL PGIGQRNHCS GAGKAAPRPA AGAGAAAEAP GGQWGPASTP
101 SLYENPWTIP NMLSMTRIGL APVLGYLIIE EDFNIALGVF ALAGLTDLLD
151 GFIARNWANQ RSALGSALDP LADKILISIL YVSLTYADLI PVPLTYMIIS
201 RDVMLIAAVF YVRYRTLPTP RTLAKYFNPC YATARLKPTF ISKVNTAVQL

```
       251 ILVAASLAAP VFNYADSIYL QILWCFTAFT TAASAYSYYH YGRKTVQVIK
       301 D


RN   869170-84-3  CAPLUS
CN   Membrane protein (human clone WO2005108415-SEQID-1466 fragment) (9CI)  (CA
     INDEX NAME)


SEQ      1 MEPGDAARPG SGRATGAPPP RLLLLPLLLG WGLRVAAAAS ASSSGAAAED
        51 SSAMEELATE KEAEESHRQD SVSLLTFILL LTLTILTIWL FKHRRVRFLH
       101 ETGLAMIYGL IVGVILRYGT PATSGRDKSL SCTQEDRAFS TLLVNVSGKF
       151 FEYTLKGEIS PGKINSVEQN DMLRKVTFDP EVFFNILLPP IIFHAGYSLK
       201 KRHFFRNLGS ILAYAFLGTA VSCFIIGNLM YGVVKLMKIM GQLSDKFYYT
       251 DCLFFGAIIS ATDPVTVLAI FNELHADVDL YALLFGESVL NDAVAIVLSS
       301 SIVAYQPAGL NTHAFDAAAF FKSVGIFLGI FSGSFTMGAV TGVNANVTKF
       351 TKLHCFPLLE TALFFLMSWS TFLLAEACGF TGVVAVLFCG ITQAHYTYNN
       401 LSVESRSRTK QLFEVLHFLA ENFIFSYMGL ALFTFQKHVF SPIFIIGAFV
       451 AIFLGRAAHI YPLSFFLNLG RRHKIGWNFQ HMMMFSGLRG AMAFALAIRD
       501 TASYARQMMF TTTLLIVFFT VWIIGGGTTP MLSWLNIRVG VEEPSEEDQN
       551 EHHWQYFRVG VDPDQDPPPN NDSFQVLQGD GPDSARGNRT KQESAWIFRL
       601 WYSFDHNYLK PILTHSGPPL TTTLPAWCGL LARCLTSPQV YDNQEPLREE
       651 DSDFILTEGD LTLTYGDSTV TANGSSSSHT ASTSLEGSRR TKSSSEEVLE
       701 RDLGMGDQKV SSRGTRLVFP LEDNA


RN   869171-06-2  CAPLUS
CN   Membrane protein (human clone WO2005108415-SEQID-1488 fragment) (9CI)  (CA
     INDEX NAME)


SEQ      1 MDDFISISLL SLAMLVGCYV AGIIPLAVNF SEERLKLVTV LGAGLLCGTA
        51 LAVIVPEGVH ALYEDILEGK HHQASETHNV IASDKAAEKS VVHEHEHSHD
       101 HTQLHAYIGV SLVLGFVFML LVDQIGNSHV HSTDDPEAAR SSNSKITTTL
       151 GLVVHAAADG VALGAAASTS QTSVQLIVFV AIMLHKAPAA FGLVSFLMHA
       201 GLERNRIRKH LLVFALAAPV MSMVTYLGLS KSSKEALSEV NATGVAMLFS
       251 AGTFLYVATV HVLPEVGGIG HSHKPDATGG RGLSRLEVAA LVLGCLIPLI
       301 LSVGHQH


RN   869171-27-7  CAPLUS
CN   Membrane protein (human clone WO2005108415-SEQID-1509 fragment) (9CI)  (CA
     INDEX NAME)


SEQ      1 MAASPHTLSS RLLTGCVGGS VWYLERRTIQ DSPHKFLHLL RNVNKQWITF
        51 QHFSFLKRMY VTQLNRSHNQ QVRPKPEPVA SPFLEKTSSG QAKAEIYEMR
       101 PLSPPSLSLS RKPNEKELIE LEPDSVIEDS IDVGKETKEE KRWKEMKLQV
       151 YDLPGILARL SKIKLTALVV STTAAGFALA PGPFDWPCFL LTSVGTGLAS
       201 CAANSINQFF EVPFDSNMNR TKNRPLVRGQ ISPLLAVSFA TCCAVPGVAI
       251 LTLGVNPLTG ALGLFNIFLY TCCYTPLKRI SIANTWVGAV VGAIPPVMGW
       301 TAATGSLDAG AFLLGGILYS WQFPHFNALS WGLREDYSRG GYCMMSVTHP
       351 GLCRRVALRH CLALLVLSAA APVLDITTWT FPIMALPINA YISYLGFRFY
       401 VDADRRSSRR LFFCSLWHLP LLLLLMLTCK RPSGGGDAGP PPS
```

RN 869172-19-0 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1601 fragment) (9CI) (CA INDEX NAME)

SEQ
1 MPSRKFADGE VVRGRWPGSS LYYEVEILSH DSTSQLYTVK YKDGTELELK
51 ENDIKPLTSF RQRKGGSTSS SPSRRRGSRS RSRSRSPGRP PKSARRSASA
101 SHQADIKEAR REVEVKLTPL ILKPFGNSIS RYNGEPEHIE RNDAPHKNTQ
151 EKFSLSQESS YIATQYSLRP RREEVKLKEI DSKEEKYVAK ELAVRTFEVT
201 PIRAKDLEFG GVPGVFLIMF GLPVFLFLLL LMCKQKDPSL LNFPPPLPAL
251 YELWETRVFG VYLLWFLIQV LFYLLPIGKV VEGTPLIDGR RLKYRLNGFY
301 AFILTSAVIG TSLFQGVEFH YVYSHFLQFA LAATVFCVVL SVYLYMRSLK
351 APRNDLSPAS SGNAVYDFFI GRELNPRIGT FDLKYFCELR PGLIGWVVIN
401 LVMLLAEMKI QDRAVPSLAM ILVNSFQLLY VVDALWNEEA LLTTMDIIHD
451 GFGFMLAFGD LVWVPFIYSF QAFYLVSHPN EVSWPMASLI IVLKLCGYVI
501 FRGANSQKNA FRKNPSDPKL AHLKTIHTST GKNLLVSGWW GFVRHPNYLG
551 DLIMALAWSL PCGFNHILPY FYIIYFTMLL VHREARDEYH CKKKYGVAWE
601 KYCQRVPYRI FPYIY

RN 869172-58-7 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1640 fragment) (9CI) (CA INDEX NAME)

SEQ
1 MRARPQVCEA LLFALALQTG VCYGIKWLAL SKTPSALALN QTQHCKQLEG
51 LVSAQVQLCR SNLELMHTVV HAAREVMKAC RRAFADMRWN CSSIELAPNY
101 LLDLERGTRE SAFVYALSAA AISHAIARAC TSGDLPGCSC GPVPGEPPGP
151 GNRWGGCADN LSYGLLMGAK FSDAPMKVKK TGSQANKLMR LHNSEVGRQA
201 LRASLEMKCK CHGVSGSCSI RTCWKGLQEL QDVAADLKTR YLSATKVVHR
251 PMGTRKHLVP KDLDIRPVKD SELVYLQSSP DFCMKNEKVG SHGTQDRQCN
301 KTSNGSDSCD LMCCGRGYNP YTDRVVERCH CKYHWCCYVT CRRCERTVER
351 YVCK

RN 869173-67-1 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1749 fragment) (9CI) (CA INDEX NAME)

SEQ
1 CAYVIILMAI YWCTEVIPLA VTSLMPVLLF PLFQILDSRQ VCVQYMKDTN
51 MLFLGGLIVA VAVERWNLHK RIALRTLLWV GAKPARLMLG FMGVTALLSM
101 WISNTATTAM MVPIVEAILQ QMEATSAATE AGLELVDKGK AKELPGEPLA
151 RALPGHNSSL PLPLLANALA TSFSLSASRS PPLNTHREKK IENTVVLSPT
201 LGQQEDQERK RLCKAMTLCI CYAASIGGTA TLTGTGPNVV LLGQMNELFP
251 DSKDLVNFAS WFAFAFPNML VMLLFAWLWL QFVYMRFNFK KSWGCGLESK
301 KNEKAALKVL QEEYRKLGPL SFAEINVLIC FFLLVILWFS RDPGFMPGWL
351 TVAWVEGETK YVSDATVAIF VATLLFIVPS QKPKFNFRSQ TEEERKTPFY
401 PPPLLDWKVT QEKVPWGIVL LLGGGFALAK GSEASGLSVW MGKQMEPLHA
451 VPPAAITLIL SLLVAVFTEC TSNVATTTLF LPIFASMSRS IGLNPLYIML
501 PCTLSASFAF MLPVATPPNA IVFTYGHLKV ADMVKTGVIM NIIGVFCVFL
551 AVNTWGRAIF DLDHFPDWAN VT

RN 869175-12-2 CAPLUS
CN Membrane protein (human clone WO2005108415-SEQID-1895 fragment) (9CI) (CA INDEX NAME)

```
SEQ      1 QSYIFVESSH IRDALTWLSQ GQKADGFFEG SGSLLNNAIK HAVVCSALSC
        51 LETAWSSTSE AQGSVVYTKA LLAYAFALAG NKVKRRELLE SLNREAMKEE
       101 DSIHWQRPGK LHEAKTLYSQ PWAPSVEVEM TSYVLLAYLT VQPAPSSEDL
       151 SVASRIVKWI TKQQNPQGGF SSTQDTVVAL QALSKYGTAT FTKSEKAALV
       201 TIKSSDTFSK DFQVDDGNCL VLQEVQLPEV PGEYSTTMSG SGCVYLQLQK
       251 QPQIQRTEVS TNHVPIYFEK LTHQTLHFSF FVEQDIQIKN LKPATVKAYD
       301 YYETGPCTQS TAKKENPKTL KSIVITHSVP EMNLQCMSYY HGNMSLTFFV
       351 SILCHLLVRI LKEMEK


RN   869175-13-3  CAPLUS
CN   Membrane protein (human clone WO2005108415-SEQID-1896 fragment) (9CI)  (CA
     INDEX NAME)

SEQ      1 MAPSLWKGLV GIGLFALAHA AFSAAQHRSY MRLTEKEDES LPIDIVLQTL
        51 LAFAVTCYGI VHIAGEFKDM DATSELKNKT FDTLRNHPSF YVFNHRGRVL
       101 FRPSDTANSS NQDALSSNTS LKLRKLESLR R


RN   869244-27-9  CAPLUS
CN   Membrane protein (human clone WO2005108415-SEQID-2091 fragment) (9CI)  (CA
     INDEX NAME)

SEQ      1 MPVQLTTALR VVGTSLFALA VLGGILAAYV TGYQFIHTEK HYLSFGLYGA
        51 ILGLHLLIQS LFAFLEHRRM RRAGQALKLP SPRRGSVALC IAAYQEDPDY
       101 LRKCLRSAQR ISFPDLKVVM VVDGNRQEDA YMLDIFHEVL GGTEQAGFFV
       151 WRSNFHEAGE GETEASLQEG MDRVRDVVRA STFSCIMQKW GGKREVMYTA
       201 FKALGDSVDY IQVCDSDTVL DPACTIEMLR VLEEDPQVGG VGGDVQPPGK
       251 GMAVEDDQVQ AAQVRATEAW SVHQRHVSRE Q


L58  ANSWER 9 OF 35  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:823914  CAPLUS  Full-text
DOCUMENT NUMBER:          143:227326
TITLE:                    Tumor marker genes for survival prognosis, and a
                          method for classifying a tumor cell sample using gene
                          expression profiling for diagnosis and therapy
INVENTOR(S):              Stratowa, Christian; Koenig, Ulrich; Steinlein, Peter;
                          Amatschek, Stefan; Auer, Herbert; Sommergruber,
                          Wolfgang; Schreiber, Martin; Gruenfelder, Agnes;
                          Pacher-Zavisin, Margit
PATENT ASSIGNEE(S):       Medizinische Universitaet Wien, Austria
SOURCE:                   PCT Int. Appl., 61 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005076005         A2    20050818    WO 2005-EP858            20050128
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2004-450020 A 20040130

ED Entered STN: 19 Aug 2005

AB An object of the present invention to provide efficient tools and markers for tumor diagnosis. Another object is providing tumor markers for good and poor prognosis in order to adopt an individual therapy scheme to a certain patient. The inventors conducted cDNA microarray gene expression profiling in cancer patients with long or short overall survival. Thus, the invention provides a method for classifying a cell sample as being a tumor cell comprising detecting a difference in the expression by said cell sample of at least one gene identified as a tumor marker gene for patient survival expectation relative to at least one control cell. The tumors to be classified according to the present invention are preferably selected from the group consisting of breast cancer (BC), lung squamous cell cancer (LSCC), lung adenocarcinoma (LAC) and renal cell cancer (RCC).

IT **391965-05-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; tumor marker genes for survival prognosis, and a method for classifying a tumor cell sample using gene expression profiling for diagnosis and therapy)

RN 391965-05-2 CAPLUS

CN Epidermal growth factor receptor substrate (human gene eps15) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **391965-05-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; tumor marker genes for survival prognosis, and a method for classifying a tumor cell sample using gene expression profiling for diagnosis and therapy)

RN 391965-05-2 CAPLUS

CN Epidermal growth factor receptor substrate (human gene eps15) (9CI) (CA INDEX NAME)

SEQ
```
      1 MAAAAQLSLT QLSSGNPVYE KYYRQVDTGN TGRVLASDAA AFLKKSGLPD
     51 LILGKIWDLA DTDGKGILNK QEFFVALRLV ACAQNGLEVS LSSLNLAVPP
    101 PRFHDTSSPL LISGTSAAEL PWAVKPEDKA KYDAIFDSLS PVNGFLSGDK
    151 VKPVLLNSKL PVDILGRVWE LSDIDHDGML DRDEFAVAMF LVYCALEKEP
    201 VPMSLPPALV PPSKRKTWVV SPAEKAKYDE IFLKTDKDMD GFVSGLEVRE
    251 IFLKTGLPST LLAHIWSLCD TKDCGKLSKD QFALAFHLIS QKLIKGIDPP
    301 HVLTPEMIPP SDRASLQKNI IGSSPVADFS AIKELDTLNN EIVDLQREKN
    351 NVEQDLKEKE DTIKQRTSEV QDLQDEVQRE NTNLQKLQAQ KQQVQELLDE
    401 LDEQKAQLEE QLKEVRKKCA EEAQLISSLK AELTSQESQI STYEEELAKA
    451 REELSRLQQE TAELEESVES GKAQLEPLQQ HLQDSQQEIS SMQMKLMEMK
    501 DLENHNSQLN WCSSPHSILV NGATDYCSLS TSSSETANLN EHVEGQSNLE
    551 SEPIHQESPA RSSPELLPSG VTDENEVTTA VTEKVCSELD NNRHSKEEDP
    601 FNVDSSSLTG PVADTNLDFF QSDPFVGSDP FKDDPFGKID PFGGDPFKGS
```

651 DPFASDCFFR QSTDPFATSS TDPFSAANNS SITSVETLKH NDPFAPGGTV
701 VAASDSATDP FASVFGNESF GGGFADFSTL SKVNNEDPFR SATSSSVSNV
751 VITKNVFEET SVKSEDEPPA LPPKIGTPTR PCPLPPGKRS INKLDSPDPF
801 KLNDPFQPFP GNDSPKEKDP EMFCDPFTSA TTTTNKEADP SNFANFSAYP
851 SEEDMIEWAK RESEREEEQR LARLNQQEQE DLELAIALSK SEISEA

L58 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:671727 CAPLUS Full-text
DOCUMENT NUMBER: 143:166667
TITLE: The curcuminoids- and anthocyanins-responsive genes in human adipocytes and their use in screenings of anti-obesity and anti-diabetes drugs
INVENTOR(S): Ueno, Yuki; Tsuda, Takanori; Takanori, Hitoshi; Yoshikawa, Toshikazu; Osawa, Toshihiko
PATENT ASSIGNEE(S): Biomarker Science Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 85 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005198640	A	20050728	JP 2004-53258	20040227
PRIORITY APPLN. INFO.:			JP 2003-394758 A	20031125

ED Entered STN: 29 Jul 2005
AB The curcuminoids- and anthocyanins-responsive gene expression profiles in adipocytes have been revealed. The curcuminoids- and anthocyanins- responsive genes are designed to be used as the index markers in the screenings of the substances that can affect the gene expression patterns in obesity and diabetes. These substances can be the candidates of anti-obesity and anti-diabetes drugs. Therefore, the groups of curcuminoids- and anthocyanins-responsive genes are intended to be used as markers in a form of kit such as DNA chip for the screening of anti-obesity and anti-diabetes drugs.
IT **483195-89-7 483554-45-6 487613-99-0**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; curcuminoids- and anthocyanins-responsive genes in human adipocytes and their use in screenings of anti-obesity and anti-diabetes drugs)
RN 483195-89-7 CAPLUS
CN Acyltransferase, acetyl coenzyme A (Rattus norvegicus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 483554-45-6 CAPLUS
CN Kinase (phosphorylating), choline (Rattus norvegicus strain Wistar gene CKR) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 487613-99-0 CAPLUS
CN Lysosomal acid lipase (Rattus sp. gene lysosomal acid lipase, LAL) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **483195-89-7 483554-45-6 487613-99-0**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; curcuminoids- and anthocyanins-responsive genes in human adipocytes and their use in screenings of anti-obesity and anti-diabetes drugs)

RN 483195-89-7 CAPLUS
CN Acyltransferase, acetyl coenzyme A (Rattus norvegicus) (9CI) (CA INDEX NAME)

SEQ
1 MHRLQVVLGH LAGRSESSSA LQAAPCSAGF PQASASDVVV VHGQRTPIGR
51 AGRGGFKDTT PDELLSAVLT AVLQDVKPKP ECLGDISVGN VLQPGAGAAM
101 ARIAQFLSGI PETVPLSAVN RQCSSGLQAV ANIAGGIRNG SYDIGMACGV
151 ESMTLSERGN PGNISSRLLE NEKARDCLIP MGITSENVAE RFGISRQKQD
201 AFALASQQKA ASAQSKGCFR AEIVPVTTTV LDDKGDRKTI TVSQDEGVRP
251 STTMEGLAKL KPAFKDGGST TAGNSSQVSD GAAAVLLARR SKAEELGLPI
301 LGVLRSYAVV GVPPDIMGIG PAYAIPAALQ KAGLTVNDID IFEINEAFAS
351 QALYCVEKLG IPAEKVNPLG GAIALGHPLG CTGARQVVTL LNELKRRGRR
401 AYGVVSMCIG TGMGAAAVFE YPGN

RN 483554-45-6 CAPLUS
CN Kinase (phosphorylating), choline (Rattus norvegicus strain Wistar gene CKR) (9CI) (CA INDEX NAME)

SEQ
1 MKTKFCTGGE AEPSPLGLLL SCGGSAAPTP GVGQQRDAAG ELESKQLGGR
51 SQPLALPPPP PPPLPLPPPP SPPLADEQPE PRTRRRAYLW CKEFLPGAWR
101 GLREDQFHIS VIRGGLSNML FQCSLPDSIA SVGDEPRKVL LRLYGAILKM
151 GAEAMVLESV MFAILAERSL GPKLYGIFPQ GRLEQFIPSR RLDTEELCLP
201 DISAEIAEKM ATFHGMKMPF NKEPKWLFGT MEKYLNQVLR LKFSREARVQ
251 QLHKFLSYNL PLELENLRSL LQYTRSPVVF CHNDCQEGNI LLLEGQENSE
301 KQKLMLIDFE YSSYNYRGFD IGNHFCEWMY DYTYEKYPFF RANIQKYPTR
351 KQQLHFISSY LTTFQNDFES LSSEEQSATK EDMLLEVNRF ALASHFLWGL
401 WSIVQAKISS IEFGYMEYAQ ARFDAYFDQK RKLGV

RN 487613-99-0 CAPLUS
CN Lysosomal acid lipase (Rattus sp. gene lysosomal acid lipase, LAL) (9CI) (CA INDEX NAME)

SEQ
1 MQLLGRVICF VVGILLSGGP TGTISAVDPE ANMNVTEIIM HWGYPEHSVQ
51 TGDGYILGVH RIPHGRKNQF DKGPKPVVYL QWRHGFLADS SNWVTNIDNN
101 SLGFILADAG FDVWMGNSRG NTWSRKHKTL SVSQDEYWAF SFDEMAKYDL
151 PASINYILNK TGQEQLYNVG HSQGCTIGFI AFSQMPELAK KVKMFFALAP
201 VLSLNFASGP MVKLGRLPDL LLEDLFGQKQ FLPQSAMVKW LSTHICTHVI
251 MKELCANIFF LICGFNEKNL NMSRVDVYTT HCPAGTSVQN MVHWTQVVKY
301 HKLQAFDWGS SDKNYFHYNQ SYPPLYSIKD MQLPTALWSG GKDWLADTSD
351 INILLTEIPT LVYHKNIPEW DHLDFIWGLD APWRLYNEVV SLMKKYQ

L58 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:546857 CAPLUS Full-text
DOCUMENT NUMBER: 143:76819
TITLE: Single chain Igs specific for various antigens

TITLE: including tumor and B cell antigens, recombinant production and immunological activities thereof
INVENTOR(S): Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha; Thompson, Peter A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 338 pp., Cont.-in-part of U.S. Ser. No. 53,530.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005136049	A1	20050623	US 2003-627556	20030726
US 2003133939	A1	20030717	US 2002-53530	20020117
CA 2533921	A1	20050224	CA 2003-2533921	20031224
WO 2005017148	A1	20050224	WO 2003-US41600	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300092	A1	20050307	AU 2003-300092	20031224
EP 1654358	A1	20060510	EP 2003-800349	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003018417	A	20060725	BR 2003-18417	20031224
CN 1852976	A	20061025	CN 2003-80110470	20031224
NO 2006000764	A	20060420	NO 2006-764	20060217

PRIORITY APPLN. INFO.:		
US 2001-367358P	P	20010117
US 2002-53530	A2	20020117
US 2003-627556	A	20030726
WO 2003-US41600	W	20031224

ED Entered STN: 24 Jun 2005

AB The invention provides recombinant single chain antibodies (scFvs) composed of: (a) variable regions of heavy or light chain Igs that may contain a linker sequence; (b) hinge regions of Igs; and (c) CH2 and CH3 constant regions of Igs. Specifically, the invention relates said scFvs may contain: (a) wild-type or mutant/variant variable region of Igs, wherein amino acid substitutions lead to an increase in stability and/or expression of scFvs; (b) wild-type or mutant hinge regions of IgG, IgA or IgE isolated from various organisms that contain zero, one, or two cysteine residues; and (c) wild-type or mutant/truncated IgG or IgA. The invention also relates that said recombinant scFv possess a variable region that bind specific antigens, such as tumor antigens, B cells antigens or B cell differentiation antigens, and that said scFvs are capable of at least one immunol. activity, such as antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC). The invention further relates that said recombinant scFvs may be coupled to a drug, toxin, immunomodulator, label and/or effector moiety. The invention also provides approx. 103 scFv constructs generated from the following hybridomas: murine 2H7 (anti-human CD20), 4.4.220 (anti-human CD40), 2e12 (anti-human CD28), 10A8 (anti-human CD152/CTLA-4), G19-4 (anti-human CD3), L6 (anti-carcinoma), FC2-2 (anti-CD16), UCHL-1 (anti-CD45RO), HD37

(anti-CD19), G19-4 (anti-CD3), and 5B9 (anti-human 4-1BB/CD137), and rat 1D8 (anti-murine 4-1BB/CD137). In the examples, the invention described the recombinant production of disclosed scFvs for various antigens. The sequences for various Ig regions used in construction of scFvs were presented. The immunol. activities of these scFvs were demonstrated.

IT **855047-13-1 855047-23-3**
RL: PRP (Properties)
(unclaimed protein sequence; single chain Igs specific for various antigens including tumor and B cell antigens, recombinant production and immunol. activities thereof)
RN 855047-13-1 CAPLUS
CN 152: PN: US20050136049 SEQID: 152 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 855047-23-3 CAPLUS
CN 162: PN: US20050136049 SEQID: 162 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **855047-13-1 855047-23-3**
RL: PRP (Properties)
(unclaimed protein sequence; single chain Igs specific for various antigens including tumor and B cell antigens, recombinant production and immunol. activities thereof)
RN 855047-13-1 CAPLUS
CN 152: PN: US20050136049 SEQID: 152 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
```
  1 GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
 51 YKTTPPVLDS DGSFALASKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
101 LSLSPGK
```

RN 855047-23-3 CAPLUS
CN 162: PN: US20050136049 SEQID: 162 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
```
  1 MDFQVQIFSF LLISASVIIA RGQIVLSQSP AILSASPGEK VTMTCRASSS
 51 VSYMHWYQQK PGSSPKPWIY APSNLASGVP ARFSGSGSGT SYSLTISRVE
101 AEDAATYYCQ QWSFNPPTFG AGTKLELKDG GGSGGGGSGG GGSSQAYLQQ
151 SGAELVRPGA SVKMSCKASG YTFTSYNMHW VKQTPRQGLE WIGAIYPGNG
201 DTSYNQKFKG KATLTVDKSS STAYMQLSSL TSEDSAVYFC ARVVYYSNSY
251 WYFDVWGTGT TVTVSSDQEP KSSDKTHTSP PSPAPELLGG PSVFLFPPKP
301 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
351 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
401 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV
451 LDSDGSFALA SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
```

L58 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:409130 CAPLUS Full-text
DOCUMENT NUMBER: 142:458903
TITLE: Sequences of KDR and VEGF/KDR binding peptides, peptide dimers, and multimeric complexes and their use in diagnosis and therapy
INVENTOR(S): Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert C.; Arbogast, Christophe; Bussat, Philippe; Fan, Hong; Khurana, Sudha; Linder, Karen E.;

Marinelli, Edmund R.; Nanjappan, Palaniappa; Nunn, Adrian D.; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam, Kondareddiar; Shrivastava, Ajay; Song, Bo; Swenson, Rolf E.; Von Wronski, Mathew A.
PATENT ASSIGNEE(S): Dyax Corporation, USA; Bracco International B. V.
SOURCE: U.S. Pat. Appl. Publ., 373 pp., Cont.-in-part of U.S. Ser. No. 382,082, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005100963	A1	20050512	US 2003-661156		20030911
WO 2003074005	A2	20030912	WO 2003-US6731		20030303
WO 2003074005	A8	20050721			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005250700	A1	20051110	US 2004-939890		20040913
PRIORITY APPLN. INFO.:			US 2002-360851P	P	20020301
			US 2003-440411P	P	20030115
			US 2003-382082	B2	20030303
			WO 2003-US6731	A2	20030303
			US 2003-661156	A2	20030911

OTHER SOURCE(S): MARPAT 142:458903
ED Entered STN: 13 May 2005
AB The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 μM), and dimer and multimeric constructs comprising these polypeptides.
IT **735282-02-7**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; sequences of KDR and VEGF/KDR binding peptides, peptide dimers, and multimeric complexes and their use in diagnosis and therapy)
RN 735282-02-7 CAPLUS
CN L-Proline, glycyl-L-seryl-L-threonyl-L-methionyl-L-methionyl-L-cysteinyl-L-tryptophyl-L-prolyl-L-alanyl-L-histidyl-L-tyrosylglycylglycyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A

PAGE 2-B





IT **735282-02-7**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; sequences of KDR and VEGF/KDR binding peptides, peptide dimers, and multimeric complexes and their use in diagnosis and therapy)
RN 735282-02-7 CAPLUS
CN L-Proline, glycyl-L-seryl-L-threonyl-L-methionyl-L-methionyl-L-cysteinyl-L-tryptophyl-L-prolyl-L-alanyl-L-histidyl-L-tyrosylglycylglycyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 GSTMMCWPAH YGGDECFALA P

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A

PAGE 2-B





L58 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:371373 CAPLUS Full-text
DOCUMENT NUMBER: 142:428781
TITLE: Binding domain-immunoglobulin fusion proteins for eliciting ADCC/CDC to treat cancer and autoimmune disease
INVENTOR(S): Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha S.; Thompson, Peter A.
PATENT ASSIGNEE(S): Trubion Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 522 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037989	A2	20050428	WO 2003-US24918	20030726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003264021 A1 20050505 AU 2003-264021 20030726
PRIORITY APPLN. INFO.: WO 2003-US24918 A 20030726
ED Entered STN: 29 Apr 2005
AB The invention relates to novel binding domain-Ig fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IgA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and Ig CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compns. and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
IT **850982-24-0P 850982-34-2P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; binding domain-Ig fusion proteins for eliciting ADCC/CDC to treat cancer and autoimmune disease)
RN 850982-24-0 CAPLUS
CN Immunoglobulin G1 (human clone WO2005/037989A2HuUgG1MTCH3A405A407 γ1-chain CH3 region derivative fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 850982-34-2 CAPLUS
CN Immunoglobulin, anti-(human CD20 (antigen)) (Mus musculus hybridoma 2H7 clone WO2005/037989A22H7scFvMTH(SSS)WTCH2MTCH3A405A407 single-chain) fusion protein with immunoglobulin G1 (human γ1-chain hinge-CH2-CH3 region derivative fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **850982-24-0P 850982-34-2P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; binding domain-Ig fusion proteins for eliciting ADCC/CDC to treat cancer and autoimmune disease)
RN 850982-24-0 CAPLUS
CN Immunoglobulin G1 (human clone WO2005/037989A2HuUgG1MTCH3A405A407 γ1-chain CH3 region derivative fragment) (9CI) (CA INDEX NAME)

SEQ
1 GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
51 YKTTPPVLDS DGSFALASKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
101 LSLSPGK

RN 850982-34-2 CAPLUS
CN Immunoglobulin, anti-(human CD20 (antigen)) (Mus musculus hybridoma 2H7

clone WO2005/037989A22H7scFvMTH(SSS)WTCH2MTCH3A405A407 single-chain) fusion protein with immunoglobulin G1 (human γ1-chain hinge-CH2-CH3 region derivative fragment) (9CI) (CA INDEX NAME)

```
SEQ      1 MDFQVQIFSF LLISASVIIA RGQIVLSQSP AILSASPGEK VTMTCRASSS
        51 VSYMHWYQQK PGSSPKPWIY APSNLASGVP ARFSGSGSGT SYSLTISRVE
       101 AEDAATYYCQ QWSFNPPTFG AGTKLELKDG GGSGGGGSGG GGSSQAYLQQ
       151 SGAELVRPGA SVKMSCKASG YTFTSYNMHW VKQTPRQGLE WIGAIYPGNG
       201 DTSYNQKFKG KATLTVDKSS STAYMQLSSL TSEDSAVYFC ARVVYYSNSY
       251 WYFDVWGTGT TVTVSSDQEP KSSDKTHTSP PSPAPELLGG PSVFLFPPKP
       301 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
       351 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
       401 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV
       451 LDSDGSFALA SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
```

L58 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:347145 CAPLUS Full-text
DOCUMENT NUMBER: 142:368792
TITLE: Cancer-**linked** genes and derived amino acid sequences and their use as targets for chemotherapy
INVENTOR(S): Cain, Colyn B.; Horrigan, Steven K.; Strovel, Jeffrey W.
PATENT ASSIGNEE(S): Avalon Pharmaceuticals, Inc, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035724	A2	20050421	WO 2004-US33072	20041007
WO 2005035724	A3	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-509515P P 20031008
ED Entered STN: 22 Apr 2005
AB Twenty cancer-linked gene transcript sequences are disclosed, along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.
IT **849581-12-0 849581-13-1 849581-14-2**
849581-15-3 849581-16-4 849581-17-5

849581-18-6 849581-19-7 849581-22-2
849581-24-4
RL: PRP (Properties)
(unclaimed protein sequence; cancer-**linked** genes and derived amino acid sequences and their use as targets for chemotherapy)
RN 849581-12-0 CAPLUS
CN 348: PN: WO2005035724 SEQID: 366 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-13-1 CAPLUS
CN 349: PN: WO2005035724 SEQID: 367 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-14-2 CAPLUS
CN 350: PN: WO2005035724 SEQID: 368 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-15-3 CAPLUS
CN 351: PN: WO2005035724 SEQID: 369 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-16-4 CAPLUS
CN 352: PN: WO2005035724 SEQID: 370 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-17-5 CAPLUS
CN 353: PN: WO2005035724 SEQID: 371 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-18-6 CAPLUS
CN 354: PN: WO2005035724 SEQID: 372 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-19-7 CAPLUS
CN 355: PN: WO2005035724 SEQID: 373 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-22-2 CAPLUS
CN 358: PN: WO2005035724 SEQID: 376 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 849581-24-4 CAPLUS
CN 360: PN: WO2005035724 SEQID: 378 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **849581-12-0 849581-13-1 849581-14-2**
849581-15-3 849581-16-4 849581-17-5
849581-18-6 849581-19-7 849581-22-2
849581-24-4
RL: PRP (Properties)
(unclaimed protein sequence; cancer-**linked** genes and derived amino acid sequences and their use as targets for chemotherapy)
RN 849581-12-0 CAPLUS
CN 348: PN: WO2005035724 SEQID: 366 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MEVEAVCGGA GEVEAQDSDP APAFSKAPGS AGHYELPWVE KYRPVKLNEI
51 VGNEDTVSRL EVFAREGNVP NIIIAGPPGT GKTTSILCLA RALLGPALKD
101 AMLELNASND RGIDVVRNKI KMFAQQKVTL PKGRHKIIIL DEADSMTDGA
151 QQALRRTMEI YSKTTRFALA CNASDKIIEP IQSRCAVLRY TKLTDAQILT

SEQ 201 RLMNVIEKER VPYTDDGLEA IIFTAQGDMR QALNNLQSTF SGFGFINSEN
251 VFKVCDEPHP LLVKEMIQHC VNANIDEAYK ILAHLWHLGY SPEDIIGNIF
301 RVCKTFQMAE YLKLEFIKEI GYTHMKIAEG VNSLLQMAGL LARLCQKTMA
351 PVAS

RN 849581-13-1 CAPLUS
CN 349: PN: WO2005035724 SEQID: 367 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 SEAWVAIRTR RRGGARMEVE AVCGGAGEVE AQDSDPAPAF SKAPGSAGHY
51 ELPWVEKYRP VKLNEIVGNE DTVSRLEVFA REGNVPNIII AGPPGTGKTT
101 SILCLARALL GPALKDAMLE LNASNDRGID VVRNKIKMFA QQKVTLPKGR
151 HKIIILDEAD SMTDGAQQAL RRTMEIYSKT TRFALACNAS DKIIEPIQSR
201 CAVLRYTKLT DAQILTRLMN VIEKERVPYT DDGLEAIIFT AQGDMRQALN
251 NLQSTFLRIW LH

RN 849581-14-2 CAPLUS
CN 350: PN: WO2005035724 SEQID: 368 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MEVEAVCGGA GEVEAQDSDP APAFSKAPGS AGHYELPWVE KYRPVKLNEI
51 VGNEDTVSRL EVFAREGNVP NIIIAGPPGT GKTTSILCLA RALLGPALKD
101 AMLELNASND RGIDVVRNKI KMFAQQKVTL PKGRHKIIIL DEADSMTDGA
151 QQALRRTMEI YSKTTRFALA CNASDKIIEP IQSRCAVLRY TKLTDAQILT
201 RLMNVIEKER VPYTDDGLEA IIFTAQGDMR QALNNLQSTF LRIWLH

RN 849581-15-3 CAPLUS
CN 351: PN: WO2005035724 SEQID: 369 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MEVEAVCGGA GEVEAQDSDP APAFSKAPGS AGHYELPWVE KYRPVKLNEI
51 VGNEDTVSRL EVFAREGNVP NIIIAGPPGT GKTTSILCLA RALLGPALKD
101 AMLELNASND SMTDGAQQAL RRTMEIYSKT TRFALACNAS DKIIEPIQSR
151 CAVLRYTKLT DAQILTRLMN VIEKERVPYT DDGLEAIIFT AQGDMRQALN
201 NLQSTFSGFG FINSENVFKV CDEPHPLLVK EMIQHCVNAN IDEAYKILAH
251 LWHLGYSPED IIGNIFRVCK TFQMAEYLKL EFIKEIGYTH MKIAEGVNSL
301 LQMAGLLARL CQKTMAPVAS

RN 849581-16-4 CAPLUS
CN 352: PN: WO2005035724 SEQID: 370 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MLELNASNDR GIDVVRNKIK MFAQQKVTLP KGRHKIIILD EADSMTDGAQ
51 QALRRTMEIY SKTTRFALAC NASDKIIEPI QSRCAVLRYT KLTDAQILTR
101 LMNVIEKERV PYTDDGLEAI IFTAQGDMRQ ALNNLQSTFL RIWLH

RN 849581-17-5 CAPLUS
CN 353: PN: WO2005035724 SEQID: 371 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MCPTSSLRGI DVVRNKIKMF AQQKVTLPKG RHKIIILDEA DSMTDGAQQA
51 LRRTMEIYSK TTRFALACNA SDKIIEPIQS RCAVLRYTKL TDAQILTRLM
101 NVIEKERVPY TDDGLEAIIF TAQGDMRQAL NNLQSTFLRI WLH

RN 849581-18-6 CAPLUS
CN 354: PN: WO2005035724 SEQID: 372 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MLELNASNDS MTDGAQQALR RTMEIYSKTT RFALACNASD KIIEPIQSRC
51 AVLRYTKLTD AQILTRLMNV IEKERVPYTD DGLEAIIFTA QGDMRQALNN
101 LQSTFLRIWL H

RN 849581-19-7 CAPLUS
CN 355: PN: WO2005035724 SEQID: 373 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MCPTSSLRMT DGAQQALRRT MEIYSKTTRF ALACNASDKI IEPIQSRCAV
51 LRYTKLTDAQ ILTRLMNVIE KERVPYTDDG LEAIIFTAQG DMRQALNNLQ
101 STFLRIWLH

RN 849581-22-2 CAPLUS
CN 358: PN: WO2005035724 SEQID: 376 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MEVEAVCGGA GEVEAQDSDP APAFSKAPGS AGHYELPWVE KYRPVKLNEI
51 VGNEDTVSRL EVFAREGNVP NIIIAGPPGT GKTTSILCLA RALLGPALKD
101 AMLELNASND RGIDVVRNKI KMFAQQKVTL PKGRHKIIIL DEADSMTDGA
151 QQALRRTMEI YSKTTRFALA CNASDKIIGA EQPAVHLSQD LASLTGENVF
201 KVCDEPHPLL VKGDDPALCE CQH

RN 849581-24-4 CAPLUS
CN 360: PN: WO2005035724 SEQID: 378 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 LNLCHEGLER TNSHKCDGSP CRSWFSMTDG AQQALRRTME IYSKTTRFAL
51 ACNASDKIIE PIQSRCAVLR YTKLTDAQIL TRLMNVIEKE RVPYTDDGLE
101 AIIFTAQGDM RQGIDVVRNK IKMFAQQKVT LPKGRHKIII LDEAD

L58 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:158798 CAPLUS Full-text
DOCUMENT NUMBER: 142:259970
TITLE: Immunoglobulin chimeric binding constructs and their immunotherapeutic applications
INVENTOR(S): Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha S.; Thompson, Peter A.
PATENT ASSIGNEE(S): Trubion Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 590 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005017148	A1	20050224	WO 2003-US41600	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005136049	A1	20050623	US 2003-627556	20030726
CA 2533921	A1	20050224	CA 2003-2533921	20031224
AU 2003300092	A1	20050307	AU 2003-300092	20031224
EP 1654358	A1	20060510	EP 2003-800349	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003018417	A	20060725	BR 2003-18417	20031224
CN 1852976	A	20061025	CN 2003-80110470	20031224
NO 2006000764	A	20060420	NO 2006-764	20060217
PRIORITY APPLN. INFO.:			US 2003-627556 A	20030726
			US 2001-367358P P	20010117
			US 2002-53530 A2	20020117
			WO 2003-US41600 W	20031224

ED Entered STN: 24 Feb 2005

AB The invention relates to novel binding domain-Ig fusion proteins that feature (1) a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, (2) a wild-type IgG, IgA or IgE hinge-acting region, or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and (3) Ig CH2 and CH3 domains. Parent monoclonal antibody Fv single-chain binding moieties include murine 2H7 (anti-human CD20), 40.2.220 (anti-human CD40), 2E12 (anti-human CD28), 10A8 (anti-human CD152/CTLA-4), G19-4 (anti-human CD3), L6 (anti-carcinoma), FC2-2 (anti-CD16), UCHL-1 (anti-CD45RO), HD37 (anti-CD19), G19-4 (anti-CD3), and 5B9 (anti-human 4-1BB/CD137), and rat 1D8 (anti-murine 4-1BB/CD137). The fusion proteins are capable of antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compns. and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

IT **845954-69-0 845954-71-4**
RL: PRP (Properties)
(unclaimed protein sequence; Ig chimeric binding constructs and their immunotherapeutic applications)

RN 845954-69-0 CAPLUS
CN 25: PN: WO2005017148 PAGE: 341 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 845954-71-4 CAPLUS
CN 35: PN: WO2005017148 PAGE: 346 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **845954-69-0 845954-71-4**
RL: PRP (Properties)
(unclaimed protein sequence; Ig chimeric binding constructs and their immunotherapeutic applications)
RN 845954-69-0 CAPLUS
CN 25: PN: WO2005017148 PAGE: 341 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
```
  1 GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
 51 YKTTPPVLDS DGSFALASKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
101 LSLSPGK
```

RN 845954-71-4 CAPLUS
CN 35: PN: WO2005017148 PAGE: 346 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
```
  1 MDFQVQIFSF LLISASVIIA RGQIVLSQSP AILSASPGEK VTMTCRASSS
 51 VSYMHWYQQK PGSSPKPWIY APSNLASGVP ARFSGSGSGT SYSLTISRVE
101 AEDAATYYCQ QWSFNPPTFG AGTKLELKDG GGSGGGGSGG GGSSQAYLQQ
151 SGAELVRPGA SVKMSCKASG YTFTSYNMHW VKQTPRQGLE WIGAYPGNGD
201 TSYNQKFKGK ATLTVDKSSS TAYMQLSSLT SEDSAVYFCA RVVYYSNSYW
251 YFDVWGTGTT VTVSSDQEPK SSDKTHTSPP SPAPELLGGP SVFLFPPKPK
301 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
351 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV
401 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
451 DSDGSFALAS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLS
```

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:139363 CAPLUS Full-text
Correction of: 2004:634055
DOCUMENT NUMBER: 142:213430
Correction of: 141:168996
TITLE: Polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy
INVENTOR(S): Nadler, Steven G.; Neubauer, Michael G.; Feder, John N.; Carman, Julie
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065577	A2	20040805	WO 2004-US798	20040113
WO 2004065577	A3	20060420		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW,
MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2004171823	A1	20040902	US 2004-755889	20040113
EP 1583820	A2	20051012	EP 2004-701762	20040113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2003-440068P	P	20030114
	US 2003-469757P	P	20030512
	WO 2004-US798	W	20040113

ED Entered STN: 18 Feb 2005

AB Polynucleotide and polypeptide sequences are identified that are associated with, regulated in, and/or regulate the NF-κB pathway in human THP-1 cell. The identification of such polynucleotides and polypeptides were identified utilizing subtraction library technol., PCR expression profiling, and microarray technol., and verified as being of functional relevance by antisense oligonucleotide methodol. and gene knockout studies. These polypeptides and proteins are an advancement toward discovering and identifying new drug targets for the treatment of NF-κB pathway-related diseases, disorders, and conditions. The invention further relates to compns. and methods for the treatment of diseases or disorders associated with the NF-κB signaling pathway using the sequences of the invention.

IT **459727-84-5**, Protein (human gene HPAST) **481132-72-3**
840690-75-7 840692-26-4
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy)

RN 459727-84-5 CAPLUS
CN Protein (human gene HPAST) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 481132-72-3 CAPLUS
CN Integral membrane protein (human gene BIGM103) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 840690-75-7 CAPLUS
CN Transcription factor NF-κB-associated protein (human clone WO2004065577-SEQID-184) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 840692-26-4 CAPLUS
CN Transcription factor NF-κB-associated protein (human clone WO2004065577-SEQID-336) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **459727-84-5**, Protein (human gene HPAST) **481132-72-3**
840690-75-7 840692-26-4
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy)

RN 459727-84-5 CAPLUS
CN Protein (human gene HPAST) (9CI) (CA INDEX NAME)

SEQ
1 MFSWVSKDAR RKKEPELFQT VAEGLRQLYA QKLLPLEEHY RFHEFHSPAL
51 EDADFDNKPM VLLVXQYSTG KTTFIRHLIE QDFPGMRIGP EPTTDSFIAV
101 MHGPTEGVVP GNALVVDPRR PFRKLNAFGN AFLNRFMCAQ LPNPVLDSIS
151 IIDTPGILSG EKQRISRGYD FAAVLEWFAE RVDRIILLFD AHKLDISDEF
201 SEVIKALKNH EDKIRVVLNK ADQIETQQLM RVYGALMWSL GKIINTPEVV
251 RVYIGSFWSH PLLIPDNRKL FEAEEQDLFK DIQSLPRNAA LRKLNDLIKR
301 ARLAKVHAYI ISSLKKEMPN VFGKESKKKE LVNNLGEIYQ KIEREHQISP
351 GDFPSLRKMQ ELLQTQDFSK FQALKPKLLD TVDDMLANDI ARLMVMVRQE
401 ESLMPSQVVK GGAFDGTMNG PFGHGYGEGA GEGIHDVEWV VGKDKPTYDE
451 IFYTLSPVNG KITGANAKKE MVKSKLPNTV LGKIWKLADV DKDGLLDDEE
501 FALANHLIKV KLEGHELPAD LPPHLVPPSK RRHE

RN 481132-72-3 CAPLUS
CN Integral membrane protein (human gene BIGM103) (9CI) (CA INDEX NAME)

SEQ
1 MAPGRAVAGL LLLAAAGLGG VAEGPGLAFS EDVLSVFGAN LSLSAAQLQH
51 LLEQMGAASR VGVPEPGQLH FNQCLTAEEI FSLHGFSNAT QITSSKFSVI
101 CPAVLQQLNF HPCEDRPKHK TRPSHSEVWG YGFLSVTIIN LASLLGLILT
151 PLIKKSYFPK ILTFFVGLAI GTLFSNAIFQ LIPEAFGFDP KVDSYVEKAV
201 AVFGGFYLLF FFERMLKMLL KTYGQNGHTH FGNDNFGPQE KTHQPKALPA
251 INGVTCYANP AVTEANGHIH FDNVSVVSLQ DGKKEPSSCT CLKGPKLSEI
301 GTIAWMITLC DALHNFIDGL AIGASCTLSL LQGLSTSIAI LCEEFPHELG
351 DFVILLNAGM STRQALLFNF LSACSCYVGL AFGILVGNNF APNIIFALAG
401 GMFLYISLAD MFPEMNDMLR EKVTGRKTDF TFFMIQNAGM LTGFTAILLI
451 TLYAGEIELE

RN 840690-75-7 CAPLUS
CN Transcription factor NF-κB-associated protein (human clone WO2004065577-SEQID-184) (9CI) (CA INDEX NAME)

SEQ
1 MAPGRAVAGL LLLAAAGLGG VAEGPGLAFS EDVLSVFGAN LSLSAAQLQH
51 LLEQMGAASR VGVPEPGQLH FNQCLTAEEI FSLHGFSNAT QITSSKFSVI
101 CPAVLQQLNF HPCEDRPKHK TRPSHSEVWG YGFLSVTIIN LASLLGLILT
151 PLIKKSYFPK ILTFFVGLAI GTLFSNAIFQ LIPEAFGFDP KVDSYVEKAV
201 AVFGGFYLLF FFERMLKMLL KTYGQNGHTH FGNDNFGPQE KTHQPKALPA
251 INGVTCYANP AVTEANGHIH FDNVSVVSLQ DGKKEPSSCT CLKGPKLSEI
301 GTIAWMITLC DALHNFIDGL AIGASCTLSL LQGLSTSIAI LCEEFPHELG
351 DFVILLNAGM STRQALLFNF LSACSCYVGL AFGILVGNNF APNIIFALAG
401 GMFLYISLAD MFPEMNDMLR EKVTGRKTDF TFFMIQNAGM LTGFTAILLI
451 TLYAGEIELE

RN 840692-26-4 CAPLUS
CN Transcription factor NF-κB-associated protein (human clone WO2004065577-SEQID-336) (9CI) (CA INDEX NAME)

SEQ
1 MFSWVSKDAR RKKEPELFQT VAEGLRQLYA QKLLPLEEHY RFHEFHSPAL
51 EDADFDNKPM VLLVXQYSTG KTTFIRHLIE QDFPGMRIGP EPTTDSFIAV
101 MHGPTEGVVP GNALVVDPRR PFRKLNAFGN AFLNRFMCAQ LPNPVLDSIS
151 IIDTPGILSG EKQRISRGYD FAAVLEWFAE RVDRIILLFD AHKLDISDEF

201 SEVIKALKNH EDKIRVVLNK ADQIETQQLM RVYGALMWSL GKIINTPEVV
251 RVYIGSFWSH PLLIPDNRKL FEAEEQDLFK DIQSLPRNAA LRKLNDLIKR
301 ARLAKVHAYI ISSLKKEMPN VFGKESKKKE LVNNLGEIYQ KIEREHQISP
351 GDFPSLRKMQ ELLQTQDFSK FQALKPKLLD TVDDMLANDI ARLMVMVRQE
401 ESLMPSQVVK GGAFDGTMNG PFGHGYGEGA GEGIHDVEWV VGKDKPTYDE
451 IFYTLSPVNG KITGANAKKE MVKSKLPNTV LGKIWKLADV DKDGLLDDEE
501 FALANHLIKV KLEGHELPAD LPPHLVPPSK RRHE

L58 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:121193 CAPLUS Full-text
DOCUMENT NUMBER: 142:214836
TITLE: Biomarkers of cyclin-dependent kinase modulation in cancer therapy
INVENTOR(S): Li, Martha; Rupnow, Brent A.; Webster, Kevin R.; Jackson, Donald G.; Wong, Tai W.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012875	A2	20050210	WO 2004-US24424	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004262369	A1	20050210	AU 2004-262369	20040729
CA 2533803	A1	20050210	CA 2004-2533803	20040729
EP 1656542	A2	20060517	EP 2004-779471	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-490890P P 20030729
WO 2004-US24424 W 20040729

ED Entered STN: 11 Feb 2005

AB Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Transcription profiling was used to identify the biomarkers. Specifically, transcription profiling of the effect of a certain cdk2 inhibitor (BMS 387032 0.5 L-tartaric acid salt) on peripheral blood mononuclear cells was first performed. Gene chips were used to quantitate the levels of gene expression on a large-scale with Affymetrix human gene chips HG-U95A, B, and C. Next, profiling of a cdk2 inhibitor-treated tumor cell line A28780 at multiple doses and time points was performed to establish a correlation of tumor site response with peripheral blood biomarkers. In order to establish the mol. target-specificity of the potential biomarkers, tumor cell line A2780 treated with anti-cdk2 oligonucleotides was also profiles. Overlapping gene

expression changes were selected for further evaluation in human ovarian carcinoma xenograft A2780 that were treated with the cdk2 inhibitor. The selected biomarkers were subjected to real-time PCR anal. in order to verify the observed changes from the gene chip anal. The biomarker comprising GenBank accession number W28729 was discovered to have the most consistent and robust regulation in response to cdk inhibition. Provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

IT **841323-39-5 841329-82-6 841329-84-8**
841329-86-0 841330-76-5 841335-28-2
841336-34-3 841339-51-3 841341-37-5
841342-88-9 841344-42-1 841348-70-7
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; biomarkers of cyclin-dependent kinase modulation in cancer therapy)

RN 841323-39-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-77) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841329-82-6 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-724) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841329-84-8 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-726) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841329-86-0 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-728) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841330-76-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-818) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841335-28-2 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1270) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841336-34-3 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1378) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841339-51-3 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1696) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841341-37-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1882) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841342-88-9 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2033) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841344-42-1 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2187) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 841348-70-7 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2615) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **841323-39-5 841329-82-6 841329-84-8**
841329-86-0 841330-76-5 841335-28-2
841336-34-3 841339-51-3 841341-37-5
841342-88-9 841344-42-1 841348-70-7
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; biomarkers of cyclin-dependent kinase modulation in cancer therapy)
RN 841323-39-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-77) (9CI) (CA INDEX NAME)

SEQ
1 PKVSGNQHRV FRLKLPDPNR FALADMSVYN PDKERLVWAC RGLEIGRGQP
51 LGVGSTGHPY FNKVKDTENS NAYITFSKDG QNTAFSKDDR LNTSFDPKQI
101 QMFIVGCTPC IGEHWDKAVP CAKNDQQTGL CPPIELKNTY IEDGDMADIG
151 FGNMNFKALQ DSRSDVSLDI VNETCKYPDF LKMQNDIYGD ACFFYARREQ
201 CYARHFFVRG GKTGDDIPGA QIDNGTYKNQ FYIPGADGQA QKTIGNAMYF
251 PTVSGSLVSS DAQLFNRPFW LQRAQGHNNG ILWANQMFIT VVDNTRNTNF
301 SISVYNQAGP LKDVADYNAE QFREYQRHVE EYEISLILQL CKVPLKAEVL
351 AQINAMNSSL LEDWQLGFVP TPDNPIQDTY RYIDSLATRC PDKNPPKEKE
401 DPYKGLHFWD VDLTERLSLD LDQYSLGRKF LFQAGLQHTT VNGTKAVSYK
451 GSNRGTKRKR KN

RN 841329-82-6 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-724) (9CI) (CA INDEX NAME)

SEQ
1 MQWAVGRRWA WAALLLAVAA VLTQVVWLWL GTQSFVFQRE EIAQLARQYA
51 GLDHELAFSR LIVELRRLHP GHVLPDEELQ WVFVNAGGWM GAMCLLHASL
101 SEYVLLFGTA LGSRGHSGRY WAEISDTIIS GTFHQWREGT TKSEVFYPGE
151 TVVHGPGEAT AVEWGPNTWM VEYGRGVIPS TLAFALADTV FSTQDFLTLF
201 YTLRSYARGL RLELTTYLFG QDP

RN 841329-84-8 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-726) (9CI) (CA INDEX NAME)

SEQ 1 MQWAVGRRWA WAALLLAVAA VLTQVVWLWL GTQSFVFQRE EIAQLARQYA
51 GLDHELAFSR LIVELRRLHP GHVLPDEELQ WVFVNAGGWM GAMCLLHASL
101 SEYVLLFGTA LGSRGHSGET VVHGPGEATA VEWGPNTWMV EYGRGVIPST
151 LAFALADTVF STQDFLTLFY TLRSYARGLR LELTTYLFGQ DP

RN 841329-86-0 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-728) (9CI) (CA INDEX NAME)

SEQ 1 MQWAVGRRWA WAALLLAVAA VLTQVVWLWL DHELAFSRLI EELQWVFVNA
51 GGWMGAMCLL HASLSEYVLL FGTALGSRGH SGRYWAEISD TIISGTFHQW
101 REGTTKSEVF YPGETVVHGP GEATAVEWGP NTWMVEYGRG VIPSTLAFAL
151 ADTVFSTQDF LTLFYTLRSY ARGLRLELTT YLFGQDP

RN 841330-76-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-818) (9CI) (CA INDEX NAME)

SEQ 1 MAHRCLRLWG RGGCWPRGLQ QLLVPGGVGP GEQPCLRTLY RFVTTQARAS
51 RNSLLTDIIA AYQRFCSRPP KGFGKYFPNG KNGKKASEPK EVMGEKKESK
101 PAATTRSSGG GGGGGGKRGG KKDDSHWWSR FQKGDIPWDD KDFRMFFLWT
151 ALFWGGVMFY LLLKRSGREI TWKDFVNNYL SKGVVDRLEV VNKRFVRVTF
201 TPGKTPVDGQ YVWFNIGSVD TFERNLETLQ QELGIEGENR VPVVYIAESD
251 GSFLLSMLPT VLIIAFLLYT IRRGPAGIGR TGRGMGGLFS VGETTAKVLK
301 DEIDVKFKDV AGCEEAKLEI MEFVNFLKNP KQYQDLGAKI PKGAILTGPP
351 GTGKTLLAKA TAGEANVPFI TVSGSEFLEM FVGVGPARVR DLFALARKNA
401 PCILFIDEID AVGRKRGRGN FGGQSEQENT LNQLLVEMDG FNTTTNVVIL
451 AGTNRPDILD PALLRPGRFD RQIFIGPPDI KGRASIFKVH LRPLKLDSTL
501 EKDKLARKLA SLTPGFSGAD VANVCNEAAL IAARHLSDSI NQKHFEQAIE
551 RVIGGLEKKT QVLQPEEKKT VAYHEAGHAV AGWYLEHADP LLKVSIIPRG
601 KGLGYAQYLP KEQYLYTKEQ LLDRMCMTLG GRASEEIFFG RITTGAQDDL
651 RKVTQSAYAQ IVQFGMNEKV GQISFDLPRQ GDMVLEKPYS EATARLIDDE
701 VRILINDAYK RTVALLTEKK ADVEKVALLL LEKEVLDKND MVELLGPRPF
751 AEKSTYEEFV EGTGSLDEDT SLPEGLKDWN KEREKEKEEP PGEKVAN

RN 841335-28-2 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1270) (9CI) (CA INDEX NAME)

SEQ 1 MARRGWRRAP LRRGVGSSPR ARRLMRPLWL LLAVGVFDWA GASDGGGGEA
51 RAMDEEIVSE KQAEESHRQD SANLLIFILL LTLTILTIWL FKHRRARFLH
101 ETGLAMIYGL LVGLVLRYGI HVPSDVNNVT LSCEVQSSPT TLLVTFDPEV
151 FFNILLPPII FYAGYSLKRR HFFRNLGSIL AYAFLGTAIS CFVIGSIMYG
201 CVTLMKVTGQ LAGDFYFTDC LLFGAIVSAT DPVTVLAIFH ELQVDVELYA
251 LLFGESVLND AVAIVLSSSI VAYQPAGDNS HTFDVTAMFK SIGIFLGIFS
301 GSFAMGAATG VVTALVTKFT KLREFQLLET GLFFLMSWST FLLAEAWGFT
351 GVVAVLFCGI TQAHYTYNNL STESQHRTKQ LFELLNFLAE NFIFSYMGLT
401 LFTFQNHVFN PTFVVGAFVA IFLGRAANIY PLSLLLNLGR RSKIGSNFQH
451 MMMFAGLRGA MAFALAIRDT ATYARQMMFS TTLLIVFFTV WVFGGGTTAM
501 LSCLHIRVGV DSDQEHLGVP ENERRTTKAE SAWLFRMWYN FDHNYLKPLL

551 THSGPPLTTT LPACCGPIAR CLTSPQAYEN QEQLKDDDSD LILNDGDISL
601 TYGDSTVNTE PATSSAPRRF MGNSSEDALD RELAFGDHEL VIRGTRLVLP
651 MDDSEPPLNL LDNTRHGPA

RN 841336-34-3 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1378) (9CI) (CA INDEX NAME)

SEQ
1 MSFLSRQQPP PPRRAGAACT LRQKLIFSPC SDCEEEEEEE EEEGSGHSTG
51 EDSAFQEPDS PLPPARSPTE PGPERRRSPG PAPGSPGELE EDLLLPGACP
101 GADEAGGGAE GDSWEEEGFG SSSPVKSPAA PYFLGSSFSP VRCGGPGDAS
151 PRGCGARRAG EGRRSPRPDH PGTPPHKTFR KLRLFDTPHT PKSLLSKARG
201 IDSSSVKLRG SSLFMDTEKS GKREFDVRQT PQVNINPFTP DSLLLHSSGQ
251 CRRRKRTYWN DSCGEDMEAS DYELEDETRP AKRITITESN MKSRYTTEFH
301 ELEKIGSGEF GSVFKCVKRL DGCIYAIKRS KKPLAGSVDE QNALREVYAH
351 AVLGQHSHVV RYFSAWAEDD HMLIQNEYCN GGSLADAISE NYRIMSYFKE
401 AELKDLLLQV GRGLRYIHSM SLVHMDIKPS NIFISRTSIP NAASEEGDED
451 DWASNKVMFK IGDLGHVTRI SSPQVEEGDS RFLANEVLQE NYTHLPKADI
501 FALALTVVCA AGAEPLPRNG DQWHEIRQGR LPRIPQVLSQ EFTELLKVMI
551 HPDPERRPSA MALVKHSVLL SASRKSAEQL RIELNAEKFK NSLLQKELKK
601 AQMAKAAAEE RALFTDRMAT RSTTQSNRTS RLIGKKMNRS VSLTIY

RN 841339-51-3 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1696) (9CI) (CA INDEX NAME)

SEQ
1 RGCSGARAAM AAGGGGSCDP LAPAGVPCAF SPHSQAYFAL ASTDGHLRVW
51 ETANNRLHQE YVPSAHLSGT CTCLAWAPAR LQAKESPQRK KRKSEAVGMS
101 NQTDLLALGT AVGSILLYST VKGELHSKLI SGGHDNRVNC IQWHQDSGCL
151 YSCSDDKHIV EWNVQTCKVK CKWKGDNSSV SSLCISPDGK MLLSAGRTIK
201 LWVLETKEVY RHFTGHATPV SSLMFTTIRP PNESQPFDGI TGLYFLSGAV
251 HDRLLNVWQV RSENKEKSAV MSFTVTDEPV YIDLTLSENK EEPVKLAVVC
301 RDGQVHLFEH ILNGYCKKPL TSNCTIQIAT PGKGKKSTPK PIPILAAGFC
351 SDKMSLLLVY GSWFQPTIER VALNSREPHM CLVRDISNCW APKVETAITK
401 VRTPVMNSEA KVLVPGIPGH HAAIKPAPPQ TEQVESKRKS GGNEVSIEER
451 LGAMDIDTHK KGKEDLQTNS FPVLLTQGLE SNDFEMLNKV LQTRNVNLIK
501 KTVLRMPLHT IIPLLQELTK RLQGHPNSAV LMVQWLKCVL TVHASYLSTL
551 PDLVPQLGTL YQLMESRVKT FQKLSHLHGK LILLITQVTA SEKTKGATSP
601 GQKAKLVYEE ESSEEESDDE IADKDSEDNW DEDEEESESE KDEDVEEEDE
651 DAEGKDEENG EDRDTASEKE LNGDSDLDPE NESEEE

RN 841341-37-5 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-1882) (9CI) (CA INDEX NAME)

SEQ
1 MASKRALVIL AKGAEEMETV IPVDVMRRAG IKVTVAGLAG KDPVQCSRDV
51 VICPDASLED AKKEGPYDVV VLPGGNLGAQ NLSESAAVKE ILKEQENRKG
101 LIAAICAGPT ALLAHEIGCG SKVTTHPLAK DKMMNGGHYT YSENRVEKDG
151 LILTSRGPGT SFEFALAIVE ALNGKEVAAQ VKAPLVLKD

RN 841342-88-9 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2033) (9CI) (CA INDEX NAME)

SEQ
1 MKTPVCSEDQ GPTREVIAQL LEDALQVESQ EQPEQAFVKP HLVSEYDIYG
51 FRTVPEDDEE EKLVAKVRAL DLKTLYLTEN QEVSTGVKWE NYFASTVNRE
101 MMCSPELKNL IRAGIPHEHR SKVWKWCVDR HTRKFKDNTE PGHFQTLLQK
151 ALEKQNPASK QIELDLLRTL PNNKHYSCPT SEGIQKLRNV LLAFSWRNPD
201 IGYCQGLNRL VAVALLYLEQ EDAFWCLVTI VEVFMPRDYY TKTLLGSQVD
251 QRVFRDLMSE KLPRLHGHFE QYKVDYTLIT FNWFLVVFVD SVVSDILFKI
301 WDSFLYEGPK VIFRFALALF KYKEEEILKL QDSMSIFKYL RYFTRTILDA
351 RKLISISFGD LNPFPLRQIR NRRAYHLEKV RLELTELEAI REDFLRERDT
401 SPDKGELVSD EEEDT

RN 841344-42-1 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2187) (9CI) (CA INDEX NAME)

SEQ
1 MFSWVSKDAR RKKEPELFQT VAEGLRQLYA QKLLPLEEHY RFHEFHSPAL
51 EDADFDNKPM VLLVGQYSTG KTTFIRHLIE QDFPGMRIGP EPTTDSFIAV
101 MHGPTEGVVP GNALVVDPRR PFRKLNRFGN AFLNRFMCAQ LPNPVLDSIS
151 IIDTPGILSG EKQRISRGYD FAAVLEWFAD CWDRIILLFD AHKQDISHEF
201 SEVIKALKNH EDKIRMVLNK ADQIETQQLM RVYGALMWSL GKIINTPEVV
251 RVYIGSFWSH PLLIPDNRKL FEAEEQDLFK DIQSLPRNAA LRKLNDLIKR
301 ARLAKVHAYI ISSLKKEMPN VFGKESKKKE LVNNLGEIYQ KIEREHQISP
351 GDFPSLRKMQ ELLQTQDFSK FQALKPKLLD TVDDMLANDI ARLMVMVRQE
401 ESLMPSQVVK GGAFDGTMNG PFGHGYGEGA GEGIDDVEWV VGKDKPSYDE
451 IFYTLSPVNG KITGANVKKE MVKSKLPNTE LGKIWKLADV DKDGLLDDEE
501 FALANHLIKV KLEGHELPAD LPPHLVPPSK RRHE

RN 841348-70-7 CAPLUS
CN Cyclin-dependent kinase modulator-regulated protein (human clone WO2005012875-SEQID-2615) (9CI) (CA INDEX NAME)

SEQ
1 MDGRTPRPQD APARRKPKAK APLPPAETKY TDVSSAADSV ESTAFIMEQK
51 ENMIDKDVEL SVVLPGDIIK STTVHGSKPM MDLLIFLCAQ YHLNPSSYTI
101 DLLSAEQNHI KFKPNTPIGM LEVEKVILKP KMLDKKKPTP IIPEKTVRVV
151 INFKKTQKTI VRVSPHASLQ ELAPIICSKC EFDPLHTLLL KDYQSQEPLD
201 LTKSLNDLGL RELYAMDVNR ESCQISQNLD IMKEKENKGF FSFFQRSKKK
251 RDQTASAPAT PLVNKHRPTF TRSNTISKPY ISNTLPSDAP KKRRAPLPPM
301 PASQSVPQDL AHIQERPASC IVKSMSVDET DKSPCEAGRV RAGSLQLSSM
351 SAGNSSLRRT KRKAPSPPSK IPPHQSDENS RVTALQPVDG VPPDSASEAN
401 SPEELSSPET FHPGLSSQEQ CTAPKLMEET SVFECPGTPE AAITSLTSGI
451 SSDYSLEEID EKEELSEVPK VEAENISPKS QDIPFVSTDI INTLKNDPDS
501 ALGNGSGEFS QNSMEEKQET KSTDGQEPHS VVYDTSNGKK VVDSIRNLKS
551 LGPNQENVQN EIIVYPENTE DNMKNGVKKT EINVEGVAKN NNIDMEVERP
601 SNSEAHETDT AISYKENHLA ASSVPDQKLN QPSAEKTKDA AIQTTPSCNS
651 FDGKHQDHNL SDSKVEECVQ TSNNNISTQH SCLSSQDSVN TSREFRSQGT
701 LIIHSEDPLT VKDPICAHGN DDLLPPVDRI DKNSTASYLK NYPLYRQDYN
751 PKPKPSNEIT REYIPKIGMT TYKIVPPKSL EISKDWQSET IEYKDDQDMH
801 ALGKKHTHEN VKETAIQTED SAISESPEEP LPNLKPKPNL RTEHQVPSSV
851 SSPDDAMVSP LKPAPKMTRD TGTAPFAPNL EEINNILESK FKSRASNAQA

```
 901 KPSSFFLQMQ KRVSGHYVTS AAAKSVHAAP NPAPKELTNK EAERDMLPSP
 951 EQTLSPLSKM PHSVPQPLVE KTDDDVIGQA PAEASPPPIA PKPVTIPASQ
1001 VSTQNLKTLK TFGAPRPYSS SGPSPFALAV VKRSQSFSKE RTESPSASAL
1051 VQPPANTEEG KTHSVNKFVD IPQLGVSDKE NNSAHNEQNS QIPTPTDGPS
1101 FTVMRQSSLT FQSSDPEQMR QSLLTAIRSG EAAAKLKRVT IPSNTISVNG
1151 RSRLSHSMSP DAQDGH
```

L58 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:809256 CAPLUS Full-text
DOCUMENT NUMBER: 142:110586
TITLE: Analysis of immune-relevant genes expressed in red sea bream (Chrysophrys major) spleen
AUTHOR(S): Chen, Song-Lin; Xu, Mei-Yu; Hu, Song-Nian; Li, Lin
CORPORATE SOURCE: Yellow Sea Fisheries Research Institute, Chinese Academy of Fisheries Sciences, Qingdao, 266071, Peop. Rep. China
SOURCE: Aquaculture (2004), 240(1-4), 115-130
CODEN: AQCLAL; ISSN: 0044-8486
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 05 Oct 2004

AB Expressed sequence tag (EST) anal. is an efficient tool for gene discovery and for profiling gene expression. In order to isolate functional genes involved in immunity in fish, a cDNA library was constructed from red sea bream (Chrysophrys major) spleen by unidirectional cloning. A total of 2010 ESTs from the library was sequenced and compared with sequences in the GenBank database. Of the 2010 ESTs, 320 ESTs (15.9%) were identified as orthologs of known gene from other organisms by BLAST searches, whereas 1690 ESTs (84.1%) appeared to be unknown and are likely to represent newly described genes. These identified clones were derived from at least 81 genes, which were categorized into 8 categories: 9 in cell structure/motility (11.1%), 14 in metabolism (17.3%), 8 in cell defense/immunity (10%), 5 in cell division (6.2%), 7 in cell signal transduction/communication (8.6%), 30 in gene/protein expression (37%), 5 Hb (6.2%), and 3 genes lacking enough information to be classified (3.7%). Several important cDNAs involved in immune functions, such as Ig light chain (IgL), MHC class IIα, MHC class IIβ, and RAP2c, were identified in red sea bream and compared for their structure with those from other organisms. Alignment showed that the red sea bream IgL precursor was closer to that of spotted wolfish than to that of yellowtail, Europe sea bass, orange spotted grouper, Atlantic salmon, channel catfish, fugu, and sterlet. Phylogenetic anal. indicated that the red sea bream MHC IIα and MHC IIβ were more related to those from striped sea bass than to those from cichlid, flounder, salmonids, zebrafish, and carp. High identity (over 92%) in deduced amino acid sequence of RAP2c between red sea bream and mammals implied that RAP2c gene was highly conserved during evolution.

IT **623876-76-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; immune-relevant genes expressed in red sea bream (Chrysophrys major) spleen)
RN 623876-76-6 CAPLUS
CN Mitogen-activated protein kinase 1-interacting protein 1 (Pagrus major) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **623876-76-6**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; immune-relevant genes expressed in red sea bream (Chrysophrys major) spleen)
RN 623876-76-6 CAPLUS
CN Mitogen-activated protein kinase 1-interacting protein 1 (Pagrus major) (9CI) (CA INDEX NAME)

SEQ 1 MADDLKRYLY KQLQSVEGLH AIVVTDRDGV PVIKVANDNA PVHALRPGFL
51 STFALATDQG SKLGLSKNKS IICYYNTYQI VQFNRLPLVI SFIASSNANT
101 GLIMSLEKEL APLIEELRQV VEVT

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:802820 CAPLUS Full-text
DOCUMENT NUMBER: 141:312934
TITLE: Vaccines comprising polynucleotide encoding Notch signalling modulator and antigen or antigenic determinant for medical treatment
INVENTOR(S): Champion, Brian Robert; Ragno, Silvia
PATENT ASSIGNEE(S): Lorantis Limited, UK
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083372	A2	20040930	WO 2004-GB1229	20040322
WO 2004083372	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006172011	A1	20060803	US 2005-232404	20050921
PRIORITY APPLN. INFO.:			GB 2003-6582 A	20030321
			GB 2003-6583 A	20030321
			GB 2003-6621 A	20030322
			GB 2003-6622 A	20030322
			GB 2003-6624 A	20030322
			GB 2003-6626 A	20030322
			GB 2003-6640 A	20030322
			GB 2003-6644 A	20030322
			GB 2003-6650 A	20030322
			GB 2003-6651 A	20030322
			GB 2003-6654 A	20030322

WO 2004-GB1229 A2 20040322

ED Entered STN: 01 Oct 2004

AB The invention provides a particle capable of being inserted into or taken up by a cell comprising (i) a polynucleotide coding for a modulator of Notch signaling; and (ii) a polynucleotide coding for an antigen or antigenic determinant thereof. The Notch signaling modulator is Delta or Serrate/Jagged protein, fragment, derivative, homolog, analog or allelic variant. The antigen is an allergen, autoantigen, MHC antigen, or tumor antigen. The cell is immune cell, antigen-presenting cell, dendritic cell or Langerhans cell. Methods for using the particles are also described.

IT **767363-94-0**
RL: PRP (Properties)
(unclaimed sequence; vaccines comprising polynucleotide encoding Notch signaling modulator and antigen or antigenic determinant for medical treatment)

RN 767363-94-0 CAPLUS

CN 131: PN: WO2004083372 PAGE: 162 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **767363-94-0**
RL: PRP (Properties)
(unclaimed sequence; vaccines comprising polynucleotide encoding Notch signaling modulator and antigen or antigenic determinant for medical treatment)

RN 767363-94-0 CAPLUS

CN 131: PN: WO2004083372 PAGE: 162 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ
```
  1 MEESVNQMQP LNEKQIANSQ DGYVWQVTDM NRLHRFLCFG SEGGTYYIKE
 51 QKLGLENAEA LIRLIEDGRG CEVIQEIKSF SQEGRTTKQE PMLFALAICS
101 QCSDISTKQA AFKAVSEVCR IPTHLFTFIQ FKKDLKESMK CGMWGRALRK
151 AIADWYNEKG GMALALAVTK YKQRNGWSHK DLLRLSHLKP SSEGLAIVTK
201 YITKGWKEVH ELYKEKALSV ETEKLLKYLE AVEKVKRTRD ELEVIHLIEE
251 HRLVREHLLT NHLKSKEVWK ALLQEMPLTA LLRNLGKMTA NSVLEPGNSE
301 VSLVCEKLCN EKLLKKARIH PFHILIALET YKTGHGLRGK LKWRPDEEIL
351 KALDAAFYKT FKTVEPTGKR FLLAVDVSAS MNQRVLGSIL NASTVAAAMC
401 MVVTRTEKDS YVVAFSDEMV PCPVTTDMTL QQVLMAMSQI PAGGTDCSLP
451 MIWAQKTNTP ADVFIVFTDN ETFAGGVHPA IALREYRKKM DIPAKLIVCG
501 MTSNGFTIAD PDDRALQNTL LNKSF
```

L58 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:634055 CAPLUS Full-text

DOCUMENT NUMBER: 141:168996

TITLE: Polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy

INVENTOR(S): Nadler, Steven G.; Neubauer, Michael G.; Feder, John N.; Carman, Julie

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004065577 A2 20040805 WO 2004-US798 20040113
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
PRIORITY APPLN. INFO.: US 2003-440068P 20030114
US 2003-469757P 20030512

ED Entered STN: 06 Aug 2004

AB Polynucleotide and polypeptide sequences are identified that are associated with, regulated in, and/or regulate the NF-κB pathway in human THP-1 cell. The identification of such polynucleotides and polypeptides were identified utilizing subtraction library technol., PCR expression profiling, and microarray technol., and verified as being of functional relevance by antisense oligonucleotide methodol. and gene knockout studies. These polypeptides and proteins are an advancement toward discovering and identifying new drug targets for the treatment of NF-κB pathway-related diseases, disorders, and conditions. The invention further relates to compns. and methods for the treatment of diseases or disorders associated with the NF-κB signaling pathway using the sequences of the invention.

IT **459727-84-5**, Protein (human gene HPAST) **481132-72-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy)
RN 459727-84-5 CAPLUS
CN Protein (human gene HPAST) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 481132-72-3 CAPLUS
CN Integral membrane protein (human gene BIGM103) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **459727-84-5**, Protein (human gene HPAST) **481132-72-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; polynucleotides and polypeptides associated with the NF-κB signaling pathway in human THP-1 cells and their use in diagnosis and therapy)
RN 459727-84-5 CAPLUS
CN Protein (human gene HPAST) (9CI) (CA INDEX NAME)

SEQ
1 MFSWVSKDAR RKKEPELFQT VAEGLRQLYA QKLLPLEEHY RFHEFHSPAL
51 EDADFDNKPM VLLVXQYSTG KTTFIRHLIE QDFPGMRIGP EPTTDSFIAV
101 MHGPTEGVVP GNALVVDPRR PFRKLNAFGN AFLNRFMCAQ LPNPVLDSIS
151 IIDTPGILSG EKQRISRGYD FAAVLEWFAE RVDRIILLFD AHKLDISDEF
201 SEVIKALKNH EDKIRVVLNK ADQIETQQLM RVYGALMWSL GKIINTPEVV
251 RVYIGSFWSH PLLIPDNRKL FEAEEQDLFK DIQSLPRNAA LRKLNDLIKR
301 ARLAKVHAYI ISSLKKEMPN VFGKESKKKE LVNNLGEIYQ KIEREHQISP
351 GDFPSLRKMQ ELLQTQDFSK FQALKPKLLD TVDDMLANDI ARLMVMVRQE
401 ESLMPSQVVK GGAFDGTMNG PFGHGYGEGA GEGIHDVEWV VGKDKPTYDE
451 IFYTLSPVNG KITGANAKKE MVKSKLPNTV LGKIWKLADV DKDGLLDDEE
501 FALANHLIKV KLEGHELPAD LPPHLVPPSK RRHE

RN 481132-72-3 CAPLUS
CN Integral membrane protein (human gene BIGM103) (9CI) (CA INDEX NAME)

SEQ 1 MAPGRAVAGL LLLAAAGLGG VAEGPGLAFS EDVLSVFGAN LSLSAAQLQH
51 LLEQMGAASR VGVPEPGQLH FNQCLTAEEI FSLHGFSNAT QITSSKFSVI
101 CPAVLQQLNF HPCEDRPKHK TRPSHSEVWG YGFLSVTIIN LASLLGLILT
151 PLIKKSYFPK ILTFFVGLAI GTLFSNAIFQ LIPEAFGFDP KVDSYVEKAV
201 AVFGGFYLLF FFERMLKMLL KTYGQNGHTH FGNDNFGPQE KTHQPKALPA
251 INGVTCYANP AVTEANGHIH FDNVSVVSLQ DGKKEPSSCT CLKGPKLSEI
301 GTIAWMITLC DALHNFIDGL AIGASCTLSL LQGLSTSIAI LCEEFPHELG
351 DFVILLNAGM STRQALLFNF LSACSCYVGL AFGILVGNNF APNIIFALAG
401 GMFLYISLAD MFPEMNDMLR EKVTGRKTDF TFFMIQNAGM LTGFTAILLI
451 TLYAGEIELE

L58 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:633546 CAPLUS Full-text
DOCUMENT NUMBER: 141:179617
TITLE: Treatment of autoimmune diseases using an activator for the notch signaling pathway
INVENTOR(S): Champion, Brian Robert; Ragno, Silvia; Young, Lesley Lynn
PATENT ASSIGNEE(S): Lorantis Limited, UK
SOURCE: PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064863	A1	20040805	WO 2004-GB263	20040123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
WO 2003087159	A2	20031023	WO 2003-GB301525	20030404
WO 2003087159	A3	20040205		
WO 2003087159	A8	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004013179	A1	20040212	WO 2003-GB303285	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004060262		A2	20040722	WO 2004-GB46	20040107
WO 2004060262		A3	20041209		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1585543		A1	20051019	EP 2004-704657	20040123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006517533		T	20060727	JP 2006-500232	20040123
WO 2004082710		A1	20040930	WO 2004-GB1252	20040322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1646400		A1	20060419	EP 2004-722319	20040322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006204508		A1	20060914	US 2005-188417	20050725
US 2006205823		A1	20060914	US 2005-231494	20050921
PRIORITY APPLN. INFO.:				GB 2003-1510	A 20030123
				GB 2003-1512	A 20030123
				GB 2003-1513	A 20030123
				GB 2003-1515	A 20030123
				GB 2003-1518	A 20030123
				GB 2003-1519	A 20030123
				GB 2003-1521	A 20030123
				GB 2003-1522	A 20030123
				GB 2003-1524	A 20030123
				GB 2003-1526	A 20030123
				GB 2003-1527	A 20030123
				GB 2003-1529	A 20030123
				WO 2003-GB1525	A 20030404
				GB 2003-12062	A 20030524
				WO 2003-GB3285	A 20030801
				GB 2003-23130	A 20031003
				WO 2004-GB46	A 20040107
				GB 2002-7929	A 20020405
				GB 2002-7930	A 20020405
				GB 2002-12282	A 20020528
				GB 2002-12283	A 20020528
				WO 2002-GB3397	A 20020725
				WO 2002-GB3426	A 20020725
				GB 2002-18068	A 20020803
				GB 2002-20849	A 20020907
				GB 2002-20912	A 20020910
				GB 2002-20913	A 20020910
				WO 2002-GB5133	A 20021113
				WO 2002-GB5137	A 20021113

GB 2003-234	A	20030107
GB 2003-6582	A	20030321
GB 2003-6583	A	20030321
GB 2003-6621	A	20030322
GB 2003-6622	A	20030322
GB 2003-6624	A	20030322
GB 2003-6626	A	20030322
GB 2003-6640	A	20030322
GB 2003-6644	A	20030322
GB 2003-6650	A	20030322
GB 2003-6651	A	20030322
GB 2003-6654	A	20030322
WO 2004-GB263	W	20040123
WO 2004-GB1252	W	20040322

ED Entered STN: 06 Aug 2004

AB A product is disclosed comprising a modulator of the Notch signaling pathway; and an autoantigen or bystander antigen, or a polynucleotide coding for an autoantigen or bystander antigen; as a combined preparation for simultaneous, contemporaneous, sep. or sequential use for modulation of immune response. The invention relates to modulators of notch signalling pathway for T cell activation, and therapeutic use in immunosuppression. In the examples of the invention, a fusion protein comprising the extracellular domain of human Delta1 ligand fused to the Fc domain of human IgG4.

IT **733172-50-4**
RL: PRP (Properties)
(unclaimed sequence; treatment of autoimmune diseases using an activator for the notch signaling pathway)

RN 733172-50-4 CAPLUS

CN 114: PN: WO2004064863 PAGE: 112-113 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **733172-50-4**
RL: PRP (Properties)
(unclaimed sequence; treatment of autoimmune diseases using an activator for the notch signaling pathway)

RN 733172-50-4 CAPLUS

CN 114: PN: WO2004064863 PAGE: 112-113 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ
```
  1 MEESVNQMQP LNEKQIANSQ DGYVWQVTDM NRLHRFLCFG SEGGTYYIKE
 51 QKLGLENAEA LIRLIEDGRG CEVIQEIKSF SQEGRTTKQE PMLFALAICS
101 QCSDISTKQA AFKAVSEVCR IPTHLFTFIQ FKKDLKESMK CGMWGRALRK
151 AIADWYNEKG GMALALAVTK YKQRNGWSHK DLLRLSHLKP SSEGLAIVTK
201 YITKGWKEVH ELYKEKALSV ETEKLLKYLE AVEKVKRTRD ELEVIHLIEE
251 HRLVREHLLT NHLKSKEVWK ALLQEMPLTA LLRNLGKMTA NSVLEPGNSE
301 VSLVCEKLCN EKLLKKARIH PFHILIALET YKTGHGLRGK LKWRPDEEIL
351 KALDAAFYKT FKTVEPTGKR FLLAVDVSAS MNQRVLGSIL NASTVAAAMC
401 MVVTRTEKDS YVVAFSDEMV PCPVTTDMTL QQVLMAMSQI PAGGTDCSLP
451 MIWAQKTNTP ADVFIVFTDN ETFAGGVHPA IALREYRKKM DIPAKLIVCG
501 MTSNGFTIAD PDDRALQNTL LNKSF
```

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:612479 CAPLUS Full-text

DOCUMENT NUMBER: 141:138524
TITLE: Gene expression profiles and microarrays for colon cancer and their use for cancer diagnosis and therapeutics
INVENTOR(S): Eveleigh, Deepa; Bigwood, Douglas; Taylor, Ian
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004146921	A1	20040729	US 2004-764425	20040123
CA 2514187	A1	20040812	CA 2004-2514187	20040123
WO 2004066941	A2	20040812	WO 2004-US2188	20040123
WO 2004066941	A3	20060803		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1603514	A2	20051214	EP 2004-704977	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-442582P P 20030124
WO 2004-US2188 W 20040123

ED Entered STN: 30 Jul 2004

AB The present invention relates to gene expression profiles for colon cancer, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using the expression profiles and microarrays. The invention also provides methods and compns. for diagnostic assays for detecting cancer and therapeutic methods and compns. for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer. [The present invention claims a total of 96 nucleic acid sequences and 95 protein sequences and provides their GenBank or RefSeq accession nos., but the Sequence Listing was not made available on publication of the patent application.].

IT **727432-36-2**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profiles and microarrays for colon cancer and their use for cancer diagnosis and therapeutics)
RN 727432-36-2 CAPLUS
CN Colon tumor-associated protein (human clone US20040146921-SEQID-189) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **727432-36-2**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profiles and microarrays for colon cancer and their use for cancer diagnosis and therapeutics)

RN 727432-36-2 CAPLUS
CN Colon tumor-associated protein (human clone US20040146921-SEQID-189) (9CI) (CA INDEX NAME)

SEQ
1 MEYEWKPDEQ GLQQILQLLK ESQSPDTTIQ RTVQQKLEQL NQYPDFNNYL
51 IFVLTKLKSE DEPTRSLSGL ILKNNVKAHF QNFPNGVTDF IKSECLNNIG
101 DSSPLIRATV GILITTIASK GELQNWPDLL PKLCSLLDSE DYNTCEGAFG
151 ALQKICEDSA EILDSDVLDR PLNIMIPKFL QFFKHSSPKI RSHAVACVNQ
201 FIISRTQALM LHIDSFIENL FALAGDEEPE VRKNVCRALV MLLEVRMDRL
251 LPHMHNIVEY MLQRTQDQDE NVALEACEFW LTLAEQPICK DVLVRHLPKL
301 IPVLVNGMKY SDIDIILLKG DVEEDETIPD SEQDIRPRFH RSRTVAQQHD
351 EDGIEEEDDD DDEIDDDDTI SDWNLRKCSA AALDVLANVY RDELLPHILP
401 LLKELLFHHE WVVKESGILV LGAIAEGCMQ GMIPYLPELI PHLIQCLSDK
451 KALVRSITCW TLSRYAHWVV SQPPDTYLKP LMTELLKRIL DSNKRVQEAA
501 CSAFATLEEE ACTELVPYLA YILDTLVFAF SKYQHKNLLI LYDAIGTLAD
551 SVGHHLNKPE YIQMLMPPLI QKWNMLKDED KDLFPLLECL SSVATALQSG
601 FLPYCEPVYQ RCVNLVQKTL AQAMLNNAQP DQYEAPDKDF MIVALDLLSG
651 LAEGLGGNIE QLVARSNILT LMYQCMQDKM PEVRQSSFAL LGDLTKACFQ
701 HVKPCIADFM PILGTNLNPE FISVCNNATW AIGEISIQMG IEMQPYIPMV
751 LHQLVEIINR PNTPKTLLEN TAITIGRLGY VCPQEVAPML QQFIRPWCTS
801 LRNIRDNEEK DSAFRGICTM ISVNPSGVIQ DFIFFCDAVA SWINPKDDLR
851 DMFCKILHGF KNQVGDENWR RFSDQFPLPL KERLAAFYGV

L58 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:589374 CAPLUS Full-text
DOCUMENT NUMBER: 141:134061
TITLE: Tumor-associated nucleic acids and encoded proteins as therapeutic targets in cancer
INVENTOR(S): Morris, David W.; Malandro, Marc S.
PATENT ASSIGNEE(S): Sagres Discovery, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060304	A2	20040722	WO 2003-US41389	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006040262	A1	20060223	US 2002-330773	20021227
CA 2511817	A1	20040722	CA 2003-2511817	20031222
AU 2003303638	A1	20040729	AU 2003-303638	20031222
EP 1587476	A2	20051026	EP 2003-814974	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

JP 2006518991	T	20060824	JP 2004-565747		20031222
US 2006166213	A1	20060727	US 2005-540898		20051213
PRIORITY APPLN. INFO.:			US 2002-330773	A	20021227
			WO 2003-US41389	W	20031222

ED Entered STN: 23 Jul 2004

AB The present invention relates to novel sequences for use in detection, diagnosis, and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. CA sequences were initially identified by infection of mice with a retrovirus such as murine leukemia virus (MLV, resulting in lymphomas) or mouse mammary tumor virus (MMTV, resulting in mammary adenocarcinoma), and identifying up- or down-regulated sequences in cancer tissue as compared to normal tissue of the same differentiation type. The CA sequences in mice and their human homologs are using Panther software designed to detect homologs and enable prediction of mol. function through a system for protein functional classification. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer, diagnostic compns. and methods for the detection of cancer, and monoclonal and polyclonal antibodies specific for the CA polypeptides.

IT **724902-56-1 724904-27-2 724906-39-2**
724906-42-7
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; tumor-associated nucleic acids and encoded proteins as therapeutic targets in cancer)

RN 724902-56-1 CAPLUS
CN Tumor-associated protein (mouse clone mP09-006) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 724904-27-2 CAPLUS
CN Tumor-associated protein (human clone hP1-10-027) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 724906-39-2 CAPLUS
CN Tumor-associated protein (mouse clone mP1-11-021) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 724906-42-7 CAPLUS
CN Tumor-associated protein (human clone hP1-11-021) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **724902-56-1 724904-27-2 724906-39-2**
724906-42-7
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; tumor-associated nucleic acids and encoded proteins as therapeutic targets in cancer)

RN 724902-56-1 CAPLUS
CN Tumor-associated protein (mouse clone mP09-006) (9CI) (CA INDEX NAME)

SEQ
```
      1 GSGRRTRPRP LSDYGQLAGR SLSIPEDAIA ADPPDEDHVD RMHPASVTTT
     51 SQDPCAPSGS CRGGRRRRPI SVIGGVSFYG NTQVEDVENL LVQPAARPPV
    101 PAHQVPPYKA VSARLRPFTF SQSTPIGLDR VGRRRQMKTS NVSSDGGAES
    151 SALVDDNGSE EDFSYEELCQ ANPRYLQPGG EQLAINELIS DGSVVCAEAL
    201 WDHVTMDDQE LGFKAGDVIQ VLEASNKDWW WGRNEDKEAW FPASFVRLRV
    251 NQEELPENCS SSHGEEQDED TSKARHKHPE SQQQMRTNVI QEIMNTERVY
    301 IKHLKDICEG YIRQCRKHTG MFTVAQLATI FGNIEDIYKF QRKFLKDLEK
    351 QYNKEEPHLS EIGSCFLEHQ EGFAIYSEYC NNHPGACVEL SNLMKHSKYR
```

401 HFFEACRLLQ QMIDIALDGF LLTPVQKICK YPLQLAELLK YTTQEHGDYN
451 NIKAAYEAMK NVACLINERK RKLESIDKIA RWQVSIVGWE GLDILDRSSE
501 LIHSGELTKI TRQGKSQQRI FFLFDHQLVS CKKDLLRRDM LYYKGRMDMD
551 EVELVDVEDG RDKDWSLSLR NAFKLVSKAT DEVHLFCARK QEDKARWLQA
601 YADERRRVQE DQQMGMEIPE NQKKLAMLNA QKAGHGKSKG YNSCPVAPPH
651 QSLPPLHQRH ITVPTSIPQQ QVFALAEPKR KPSIFWHTFH KLTPFRK

RN 724904-27-2 CAPLUS
CN Tumor-associated protein (human clone hP1-10-027) (9CI) (CA INDEX NAME)

SEQ 1 MPSRKFADGE VVRGRWPGSS LYYEVEILSH DSTSQLYTVK YKDGTELELK
51 ENDIKPLTSF RQRKGGSTSS SPSRRRGSRS RSRSRSPGRP PKSARRSASA
101 SHQADIKEAR REVEVKLTPL ILKPFGNSIS RYNGEPEHIE RNDAPHKNTQ
151 EKFNLSQESS YIATQYSLRP RREEVKLKEI DSKEEKYVAK ELAVRTFEVT
201 PIRAKDLEFG GVPGVFLIMF GLPVFLFLLL LMCKQKDPSL LNFPPPLPAL
251 YELWETRVFG VYLLWFLIQV LFYLLPIGKV VEGTPLIDGR RLKYRLNGFY
301 AFILTSAVIG TSLFQGVEFH YVYSHFLQFA LAATVFCVVL SVYLYMRSLK
351 APRNDLSPAS SGNAVYDFFI GRELNPRIGT FDLKYFCELR PGLIGWVVIN
401 LVMLLAEMKI QDRAVPSLAM ILVNSFQLLY VVDALWNEEA LLTTMDIIHD
451 GFGFMLAFGD LVWVPFIYSF QAFYLVSHPN EVSWPMASLI IVLKLCGYVI
501 FRGANSQKNA FRKNPSDPKL AHLKTIHTST GKNLLVSGWW GFVRHPNYLG
551 DLIMALAWSL PCGFNHILPY FYIIYFTMLL VHREARDEYH CKKKYGVAWE
601 KYCQRVPYRI FPYIY

RN 724906-39-2 CAPLUS
CN Tumor-associated protein (mouse clone mP1-11-021) (9CI) (CA INDEX NAME)

SEQ 1 LSIMAQTHGS KQQAQRLEQG AESLRHGAQA QSRENNVSLS TVSHADEPSQ
51 RDESSRLTVR MENTYQLGPT KPFPVATVNH ILEDVLTTYL QEAQYDPEFC
101 RQMTKTISEV IKTQVKELVI PRYKLIVIVY IGQRDDQSIV IGSRCLWNPK
151 SDTVSSYTFK NSTFFALANV YAVYFE

RN 724906-42-7 CAPLUS
CN Tumor-associated protein (human clone hP1-11-021) (9CI) (CA INDEX NAME)

SEQ 1 MMMSDNAKGR AAHSWKKRGS ISSLSNHEFW RKEIHGRIKD SMSTVSYMEE
51 PSQRDDISRL TVQMENTYQL GPPKHFPVVT VNHILKDVVT SYLQVEEYEP
101 ELCRQMTKTI SEVIKAQVKD LMIPRYKLIV IVHIGQLNRQ SILIGSRCLW
151 DPKSDTFSSY VFRNSSLFAL ANVYAVYLE

L58 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:533779 CAPLUS Full-text
DOCUMENT NUMBER: 141:87776
TITLE: Cancer-associated nucleic acids, proteins and antibodies for diagnosis and treatment of cancer
INVENTOR(S): Morris, David W.; Malandro, Marc S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 105 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004126762	A1	20040701	US 2002-322281	20021217
CA 2479719	A1	20031002	CA 2003-2479719	20030317
CA 2479731	A1	20031002	CA 2003-2479731	20030317
WO 2003079977	A2	20031002	WO 2003-US8071	20030317
WO 2003079977	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003080853	A1	20031002	WO 2003-US8188	20030317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003225826	A1	20031008	AU 2003-225826	20030317
AU 2003230669	A1	20031008	AU 2003-230669	20030317
EP 1490500	A1	20041229	EP 2003-723759	20030317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
EP 1490690	A2	20041229	EP 2003-745117	20030317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005520536	T	20050714	JP 2003-577810	20030317
JP 2005520551	T	20050714	JP 2003-578577	20030317
US 2006194265	A1	20060831	US 2003-669920	20030923
CA 2508944	A1	20040715	CA 2003-2508944	20031215
WO 2004058146	A2	20040715	WO 2003-US40081	20031215
WO 2004058146	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003299645	A1	20040722	AU 2003-299645	20031215
EP 1581542	A2	20051005	EP 2003-799929	20031215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2006154250	A1	20060713	US 2005-539228		20051028
PRIORITY APPLN. INFO.:			US 2001-4113	B2	20011023
			US 2001-52482	B2	20011108
			US 2001-997722	B2	20011130
			US 2001-34650	A2	20011220
			US 2002-85117	B2	20020227
			US 2002-87192	A2	20020301
			US 2002-105612	A	20020320
			US 2002-105613	A	20020320
			US 2002-322281	A2	20021217
			US 2002-322696	A2	20021217
			WO 2003-US8071	W	20030317
			WO 2003-US8188	W	20030317
			WO 2003-US40081	W	20031215

ED Entered STN: 02 Jul 2004

AB The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The tumors are mammary adenocarcinoma and hematopoietic malignancies (primarily T- or B-cell lymphomas) induced in mice using either mouse mammary tumor virus (MMTV) or murine leukemia virus (MLV). The present invention provides CA polypeptides associated with cancer and provides diagnostic compns. and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compns. and methods for screening, prevention and treatment of cancer.

IT **716836-00-9P 716836-03-2P 716836-82-7P**
716836-85-0P
RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; mammary adenocarcinoma and hematopoietic malignancy-associated nucleic acids, proteins and antibodies for diagnosis and treatment of cancer)

RN 716836-00-9 CAPLUS
CN Tumor-associated protein (mouse clone mP07-070) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 716836-03-2 CAPLUS
CN Tumor-associated protein (human clone hP07-070) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 716836-82-7 CAPLUS
CN Tumor-associated protein (mouse clone mP07-082) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 716836-85-0 CAPLUS
CN Tumor-associated protein (human clone hP07-082) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **716836-00-9P 716836-03-2P 716836-82-7P**
716836-85-0P
RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; mammary adenocarcinoma and hematopoietic malignancy-associated nucleic acids, proteins and antibodies for diagnosis and treatment of cancer)

RN 716836-00-9 CAPLUS
CN Tumor-associated protein (mouse clone mP07-070) (9CI) (CA INDEX NAME)

SEQ
```
  1 RTEASSRERP CLRVSALRTP SGRPVAPAAR PCVRAAAALR RGRPGTEGSS
 51 SLPAPAALVV AVAVVVVVVS AVAWAMANYI HVPPGSPEVP KLDVTVQDQE
101 EQRCRDGALS LLRHLRPHWD PREVTLQLFT DGITNKLIAC YVGDTMEDVV
151 LVRIYGNKTE LLVDRDEEVK SFRVLQAHGC APQLYCTFNN GLCYEFIQGE
201 ALDPQHVCNP AIFRLIARQL AKIHAIHAHN GWIPKSNLWL KMGKYFSLIP
251 TGFADENINK RFLSEIPSPQ LLQEEMTWMK ELLSSLGSPV VLCHNDLLCK
301 NIIYNEKQGD VQFIDYEYSG YNYLAYDIGN HFNEFAGVSD VDYSLYPDRE
351 LQGQWLRSYL EAYKEYKGFG SDVTEKEVET LFIQVNQFAL ASHFFWGLWA
401 LIQAKYSTIE FDFLGYAVVR FNQYFKMKPE VTALKMPE
```

RN 716836-03-2 CAPLUS
CN Tumor-associated protein (human clone hP07-070) (9CI) (CA INDEX NAME)

SEQ
```
  1 HLRPHWDPQE VTLQLFTDGI TNKLIGCYVG NTMEDVVLVR IYGNKTELLV
 51 DRDEEVKSFR VLQAHGCAPQ LYCTFNNGLC YEFIQGEALD PKHVCNPAIF
101 RLIARQLAKI HAIHAHNGWI PKSNLWLKMG KYFSLIPTGF ADEDINKRFL
151 SDIPSSQILQ EEMTWMKEIL SNLGSPVVLC HNDLLCKNII YNEKQGDVQF
201 IDYEYSGYNY LAYDIGNHFN EFAGVSDVDY SLYPDRELQS QWLRAYLEAY
251 KEFKGFGTEV TEKEVEILFI QVNQFALASH FFWGLWALIQ AKYSTIEFDF
301 LGYAIVRFNQ YFKMKPEVTA LKVPE
```

RN 716836-82-7 CAPLUS
CN Tumor-associated protein (mouse clone mP07-082) (9CI) (CA INDEX NAME)

SEQ
```
  1 MELKRLGVSW RFLMVLVLIL QSLSALDFDP YRVLGVSRTA SQADIKKAYK
 51 KLAREWHPDK NKDPGAEDRF IQISKAYEEK RTNYDHYGDA GENQGYQKQQ
101 REHRFRHFHE NFYFDESFFH FPFNAERRDS GDEKYLLHFS HYVNEVLPES
151 FKRPYLIKIT SDWCFSCIHI EPVWKEVVQE LEGLGVGIGV VHAGYERRLA
201 HHLGAHSTPS ILGVISGKIT FFHNAVVHEN LRQFVESLLP GNLVEKVTNK
251 NYVRFLSGWQ QENKPHALLF GQTPAVPLMY KLTAFAYKDY VSFGYVYVGL
301 RGVEEMTRQY NVNLYTPTML IFKEHINKPA DVIQARGLKK QVIEDFIAQN
351 KYLLASRLTS QRLFHELCPV KRSHRQRKYC VVLLTAETNK VSKPFEAFLS
401 FALANTQDTV RFVHVYSNRQ QEFASTLLPD MEAFQGKSGV SILERRNTAG
451 RVVFKTLEDP WTGSESDKFV LLGYLDQLRK DPAFLSSEAV LPDLTDELAP
501 VSIRVQKNGP AGGVGQCSWL KARSRGCGLT AAFASRREMM PLLSLIFSAL
551 FILFGTVMVQ AFSKIPKKGF VEVTELTDVT YTSNLVRLRP GHMNVVLILS
601 NSTKTSLLQK FALEVYTFTG SSSLHFSFLT LDKHREWLEY LLEFAQDAAP
651 IPNQYDKHFM ERDYTGYVLA LNGHKKYFCL FKPLKTVDEE TVASCDPDSS
701 RGKPSCGLGP KPLKGKLSKL SLWMERLLEG SLQRFYIPSW PELD
```

RN 716836-85-0 CAPLUS
CN Tumor-associated protein (human clone hP07-082) (9CI) (CA INDEX NAME)

SEQ
```
  1 ILSNEEKRSN YDQYGDAGEN QGYQKQQQQR EYRFRHFHEN FYFDESFFHF
```

```
  51 PFNSERRDSI DEKYLLHFSH YVNEVVPDSF KKPYLIKITS DWCFSCIHIE
 101 PVWKEVIQEL EELGVGIGVV HAGYERRLAH HLGAHSTPSI LGIINGKISF
 151 FHNAVVRENL RQFVESLLPG NLVEKVTNKN YVRFLSGWQQ ENKPHVLLFD
 201 QTPIVPLLYK LTAFAYKDYL SFGYVYVGLR GTEEMTRRYN INIYAPTLLV
 251 FKEHINRPAD VIQARGMKKQ IIDDFITRNK YLLAARLTSQ KLFHELCPVK
 301 RSHRQRKYCV VLLTAETTKL SKPFEAFLSF ALANTQDTVR FVHVYSNRQQ
 351 EFADTLLPDS EAFQGKSAVS ILERRNTAGR VVYKTLEDPW IGSESDKFIL
 401 LGYLDQLRKD PALLSSEAVL PDLTDELAPV FLLRWFYSAS DYISDCWDSI
 451 FHNNWREMMP LLSLIFSALF ILFGTVIVQA FSDSNDERES SPPEKEEAQE
 501 KTGKTEPSFT KENSSKIPKK GFVEVTELTD VTYTSNLVRL RPGHMNVVLI
 551 LSNSTKTSLL QKFALEVYTF TGSSCLHFSF LSLDKHREWL EYLLEFAQDA
 601 APIPNQYDKH FMERDYTGYV LALNGHKKYF CLFKPQKTVE EEEAIGSCSD
 651 VDSSLYLGES RGKPSCGLGS RPIKGKLSKL SLWMERLLEG SLQRFYIPSW
 701 PELD
```

L58 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:269752 CAPLUS Full-text
DOCUMENT NUMBER: 140:302325
TITLE: Human sarcoma-associated NY-SAR antigens, antibodies, genes and polynucleotides and **conjugates** for cancer diagnosis and therapy
INVENTOR(S): Scanlan, Matthew J.; Lee, Sang-Yull; Old, Lloyd J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 147 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004063101	A1	20040401	US 2002-260708	20020930
WO 2004031354	A2	20040415	WO 2003-US30870	20030930
WO 2004031354	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003287016	A1	20040423	AU 2003-287016	20030930
EP 1572965	A2	20050914	EP 2003-777536	20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-260708 A 20020930
WO 2003-US30870 W 20030930

ED Entered STN: 02 Apr 2004
AB The invention relates to sarcoma-associated antigens and the nucleic acid mols. that encode them. The invention further relates to the use of the nucleic acid mols., polypeptides and fragments thereof associated with sarcoma in methods and compns. for the diagnosis and treatment of diseases, such as

cancer More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.

IT **676376-92-4P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human sarcoma-associated NY-SAR antigens, antibodies, genes and polynucleotides and **conjugates** for cancer diagnosis and therapy)
RN 676376-92-4 CAPLUS
CN Sarcoma-associated antigen NY-SAR-50 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **676376-92-4P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human sarcoma-associated NY-SAR antigens, antibodies, genes and polynucleotides and **conjugates** for cancer diagnosis and therapy)
RN 676376-92-4 CAPLUS
CN Sarcoma-associated antigen NY-SAR-50 (human) (9CI) (CA INDEX NAME)

SEQ
```
  1 MSVGFIGAGQ LAFALAKGFT AAGVLAAHKI MASSPDMDLA TVSALRKMGV
 51 KLTPHNKETV QHSDVLFLAV KPHIIPFILD EIGADIEDRH IVVSCAAGVT
101 ISSIEKKLSA FRPAPRVIRC MTNTPVVVRE GATVYATGTH AQVEDGRLME
151 QLLSTVGFCT EVEEDLIDAV TGLSGSGPAY AFTALDALAD GGVKMGLPRR
201 LAVRLGAQAL LGAAKMLLHS EQHPGQLKDN VSSPGGATIH ALHVLESGGF
251 RSLLINAVEA SCIRTRELQS MADQEQVSPA AIKKTILDKV KLDSPAGTAL
301 SPSGHTKLLP RSLAPAGKD
```

L58 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796870 CAPLUS Full-text
DOCUMENT NUMBER: 139:303009
TITLE: Sequences of novel human genes related to colon cancer and uses for treatment and diagnosis of colon carcinomas
INVENTOR(S): MacLachlan, Karen; Gately, Dennis
PATENT ASSIGNEE(S): IDEC Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083074	A2	20031009	WO 2003-US9534	20030328

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003222103	A1	20031013	AU 2003-222103	20030328
US 2006089493	A1	20060427	US 2005-509131	20050920
PRIORITY APPLN. INFO.:			US 2002-367727P	P 20020328
			US 2002-381328P	P 20020520
			US 2002-386747P	P 20020610
			US 2002-427564P	P 20021120
			US 2002-376727P	P 20020430
			WO 2003-US9534	W 20030328

ED Entered STN: 10 Oct 2003

AB The present invention discloses novel human genes related to colon cancer and their uses for treatment and diagnosis of colon carcinomas. Specifically, the nucleic acids and proteins are overexpressed in colon or colorectal tumor tissues, and are useful as diagnostic and therapeutic targets. The invention also relates to development of novel therapies for treatment of cancer, such as colon cancer, involving the administration of anti-sense oligonucleotides corresponding to gene targets that are expressed by certain colon or colorectal cancers.

IT **611270-76-9P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; sequences of novel human genes related to colon cancer and uses for treatment and diagnosis of colon carcinomas)

RN 611270-76-9 CAPLUS

CN Protein (human clone chr15.41.013.a colon neoplasm related gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **611270-76-9P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; sequences of novel human genes related to colon cancer and uses for treatment and diagnosis of colon carcinomas)

RN 611270-76-9 CAPLUS

CN Protein (human clone chr15.41.013.a colon neoplasm related gene) (9CI) (CA INDEX NAME)

SEQ
1 MTLWNGVLPF YPQPRHAAGF SVPLLIVILV FLALAASFLL ILPGIRGHSR
51 WFWLVRVLLS LFIGAEIVAV HFSAEWFVGT VNTNTSYKAF SAARVTARVR
101 LLVGLEGINI TLTGTPVHQL NETIDYNEQF TWRLKENYAA EYANALEKGL
151 PDPVLYLAEK FTPSSPCGLY HQYHLAGHYA SATLWVAFCF WLLSNVLLST
201 PAPLYGGLAL LTTGAFALFG VFALASISSV PLCPLRLGSS ALTTQYGAAF
251 WVTLATGEDR ENGPRGLRVE TGFTPGVLCL FLGGAVAGKQ CPPGLGQESS
301 RKGTERCWRE ASDIRRHQGK SPGAICK

L58 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:551280 CAPLUS Full-text
DOCUMENT NUMBER:	139:112733
TITLE:	Methods for production of recombinant glycoproteins with mammalian-type carbohydrate structures and their use for production of immunoglobulins
INVENTOR(S):	Wildt, Stefan; Miele, Robert Gordon; Nett, Juergen

	Hermann; Davidson, Robert C.
PATENT ASSIGNEE(S):	Glycofi, Inc., USA
SOURCE:	PCT Int. Appl., 125 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	25
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003056914	A1	20030717	WO 2002-US41510	20021224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471551	A1	20030717	CA 2002-2471551	20021224
AU 2002358296	A1	20030724	AU 2002-358296	20021224
EP 1467615	A1	20041020	EP 2002-792535	20021224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005514021	T	20050519	JP 2003-557288	20021224
US 2005170452	A1	20050804	US 2003-500240	20021224
US 2004230042	A1	20041118	US 2003-616082	20030708
US 2005208617	A1	20050922	US 2003-680963	20031007
US 2006040353	A1	20060223	US 2005-108088	20050415
US 2006024292	A1	20060202	US 2005-187065	20050721
US 2006029604	A1	20060209	US 2005-187229	20050721
US 2006034829	A1	20060216	US 2005-187079	20050721
US 2006034830	A1	20060216	US 2005-187113	20050721
US 2006286637	A1	20061221	US 2006-429672	20060505
US 2007037248	A1	20070215	US 2006-546101	20060803

PRIORITY APPLN. INFO.:		
US 2001-344169P	P	20011227
US 2000-214358P	P	20000628
US 2000-215638P	P	20000630
US 2001-279997P	P	20010330
US 2001-892591	A2	20010627
WO 2002-US241510	W	20021224
WO 2002-US41510	W	20021224
US 2003-371877	A2	20030220
US 2003-680963	A	20031007
WO 2004-US5191	W	20040220
US 2004-554139P	P	20040317
US 2004-562424P	P	20040415
US 2004-589913P	P	20040721
US 2004-589937P	P	20040721
US 2004-590011P	P	20040721
US 2004-590030P	P	20040721
US 2004-590051P	P	20040721
US 2004-590052P	P	20040721
US 2004-639657P	P	20041223
US 2004-639698P	P	20041223
US 2005-84624	A2	20050317
US 2005-500240	A2	20050323

US 2005-108088 A2 20050415

ED Entered STN: 18 Jul 2003

AB The present invention relates to host cells having modified lipid-linked oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells have a GlcNAcMan3GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained. The invention specifically claims use of nucleic acid sequences for gene ALG3 from Pichia pastoris. The ALG3 gene encodes the enzyme which transfers a mannose residue to the Man5-GlcNac2-PP-Dol precursor. The invention also claims use of genetically engineered host cells for recombinant production of Igs. In examples of the invention, a Pichia pastoris strain with deletions of genes alg3 and och1 was constructed. This strain was transformed with the Kringle 3 domain of human plasminogen as a glycosylation substrate. Mass spectrometric anal. of N-glycans isolated from the kringle 3 glycoproteins showed GlcNAcMan3GlcNAc2 and GlcNAcMan4GlcNAc2 structures which could be further modified in vitro. Addition of N-acetylglucosamine to GlcNAcMan3GlcNAc2 by N-acetylglucosaminyltransferases II and III yields a "bisected" N-glycan, GlcNAc3Man3GlcNAc2, which has been implicated in greater antibody-dependent cellular cytotoxicity. Methods of the invention can be used to engineer a yeast strain capable of producing glycoproteins with bisected N-glycans and expressing Ig mols. with bisected N-glycans attached to asparagine residue 297 in the CH2 portion.

IT **561372-17-6**
RL: PRP (Properties)
(unclaimed sequence; methods for production of recombinant glycoproteins with mammalian-type carbohydrate structures and their use for production of Igs)

RN 561372-17-6 CAPLUS

CN 72: PN: WO03056914 FIGURE: 26 unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **561372-17-6**
RL: PRP (Properties)
(unclaimed sequence; methods for production of recombinant glycoproteins with mammalian-type carbohydrate structures and their use for production of Igs)

RN 561372-17-6 CAPLUS

CN 72: PN: WO03056914 FIGURE: 26 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ

```
  1 MPHKRTPSSS LLYARIPGIS FENSPVFDFL SPFGPAPNQW VARYIIIIFA
 51 ILIRLAVGLG SYSGFNTPPM YGDFEAQRHW MEITQHLSIE KWYFYDLQYW
101 GLDYPPLTAF HSYFFGKLGS FINPAWFALD VSRGFESVDL KSYMRATAIL
151 SELLCFIPAV IWYCRWMGLN YFNQNAIEQT IIASAILFNP SLIIIDHGHF
201 QYNSVMLGFA LLSILNLLYD NFALAAIFFV LSISFKQMAL YYSPIMFFYM
251 LSVSCWPLKN FNLLRLATIS IAVLLTFATL LLPFVLVDGM SQIGQILFRV
301 FPFSRGLFED KVANFWCTTN ILVKYKQLFT DKTLTRISLV ATLIAISPSC
351 FIIFTHPKKV LLPWAFAACS WAFYLFSFQV HEKSVLVPLM PTTLLLVEKD
401 LDIISMVCWI SNIAFFSMWP LLKRDGLALE YFVLGILSNW LIGNLNWISK
451 WLVPSFLIPG PTLSKKVPKR DTKTVVHTHW FWGSVTFVSY LGATVIQFVD
501 WLYLPPAKYP DLWVILNTTL SFACFGLFWL WINYNLYILR DFKLKDA
```

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:281945 CAPLUS Full-text
DOCUMENT NUMBER: 138:285609
TITLE: cDNA encoding CTTP transmembrane protein and their use in diagnosis and treatment of cancer
INVENTOR(S): Lasek, Amy K. W.; Baughn, Mariah R.; Azimzai, Yalda
PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of Appl. No. PCT/US00/07817.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003068311	A1	20030410	US 2002-187657	20020701
US 7105315	B2	20060912		
WO 2000056891	A2	20000928	WO 2000-US7817	20000322
WO 2000056891	A3	20010405		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2006275314	A1	20061207	US 2006-498712	20060804

PRIORITY APPLN. INFO.:		
US 1999-139565P	P	19990616
WO 2000-US7817	A2	20000322
US 1999-125537P	P	19990322
US 2002-187657	A3	20020701

ED Entered STN: 11 Apr 2003
AB The invention provides a transmembrane protein that is differentially expressed in neoplastic disorders. It also provides for the use of the protein, a cDNA encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of a neoplastic disorder.
IT **505104-88-1**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cDNA encoding CTTP transmembrane protein and their use in diagnosis and treatment of cancer)
RN 505104-88-1 CAPLUS
CN Transmembrane protein (human clone 4901066CD1 gene CTTP) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **505104-88-1**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cDNA encoding CTTP transmembrane protein and

their use in diagnosis and treatment of cancer)
RN 505104-88-1 CAPLUS
CN Transmembrane protein (human clone 4901066CD1 gene CTTP) (9CI) (CA INDEX NAME)

SEQ 1 MTLWNGVLPF YPQPRHAAGF SVPLLIVILV FLALAASFLL ILPGIRGHSR
51 WFWLVRVLLS LFIGAEIVAV HFSAEWFVGT VNTNTSYKAF SAARVTARVG
101 LLVGLEGINI TLTGTPVHQL NETIDYNEQF TWRLKENYAA EYANALEKGL
151 PDPVLYLAEK FTPSSPCGLY HQYHLAGHYA SATLWVAFCF WLLSNVLLST
201 PAPLYGGLAL LTTGAFALFG VFALASISSV PLCPLRLGSS ALTTQYGAAF
251 WVTLATGVLC LFLGGAVVSL QYVRPSALRT LLDQSAKDCS QERGGSPLIL
301 GDPLHKQAAL PDLKCITTNL

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:117980 CAPLUS Full-text
DOCUMENT NUMBER: 138:164857
TITLE: Protein and cDNA sequences of human mannosyl transferase associated with bipolar disorder and its use for diagnosing or predicting the susceptibility to bipolar disorder
INVENTOR(S): Evans, Glen A.
PATENT ASSIGNEE(S): Egea Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003012064	A2	20030213	WO 2002-US24490	20020802
WO 2003012064	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003104385	A1	20030605	US 2001-922225	20010802
CA 2454850	A1	20030213	CA 2002-2454850	20020802
EP 1421176	A2	20040526	EP 2002-768397	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005508618	T	20050407	JP 2003-517242	20020802
PRIORITY APPLN. INFO.:			US 2001-922225 A1	20010802
			WO 2002-US24490 W	20020802

ED Entered STN: 14 Feb 2003
AB The present invention provides an protein and cDNA sequences of human mannosyl transferase. Nucleic acids and fragments thereof that correspond to the

mannosyl transferase polypeptide similarly are applicable in therapeutic procedures. The invention also provides a human mannosyl transferase fusion polypeptide and a chromosome 9 fusion polypeptide, both of which result from a chromosomal 10 translocation t(9,11) (p24;q23.1). The fusion nucleic acid sequence that encodes the human mannosyl transferase fusion polypeptide and the fusion nucleic acid sequence that encodes the chromosome 9 fusion polypeptide also are provided. The fusion proteins of the invention and their encoding nucleic acids are useful in methods provided by the present invention for diagnosing or predicting the susceptibility to bipolar disorder.

IT **497216-12-3D**, Mannosyltransferase (human), Subfragments are claimed
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein and cDNA sequences of human mannosyl transferase associated with bipolar disorder and its use for diagnosing or predicting the susceptibility to bipolar disorder)
RN 497216-12-3 CAPLUS
CN Mannosyltransferase (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **497220-62-9**
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of human mannosyl transferase associated with bipolar disorder and its use for diagnosing or predicting the susceptibility to bipolar disorder)
RN 497220-62-9 CAPLUS
CN 8: PN: WO03012064 SEQID: 8 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **497216-12-3D**, Mannosyltransferase (human), Subfragments are claimed
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein and cDNA sequences of human mannosyl transferase associated with bipolar disorder and its use for diagnosing or predicting the susceptibility to bipolar disorder)
RN 497216-12-3 CAPLUS
CN Mannosyltransferase (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **497220-62-9**
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of human mannosyl transferase associated with bipolar disorder and its use for diagnosing or predicting the susceptibility to bipolar disorder)
RN 497220-62-9 CAPLUS
CN 8: PN: WO03012064 SEQID: 8 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
1 MASRGARQRL KGSGASSGDT APAADKLREL LGSREAGGAE HRTELSGNKA
51 GQVWAPEGST AFKCLLSARL CAALLSNISD CDETFNYWEP THYLIYGEGF
101 QTWEYSPAYA IRSYAYLLLH AWPAAFHARI LQTNKILVFY FLRCLLAFVS
151 CICELYFYKA VCKKFGLHVS RMMLAFLVLS TGMFCSSSAF LPSSFCMYTT
201 LIAMTGWYMD KTSIAVLGVA AGAILGWPFS AALGLPIAFD LLVMKHRWKS
251 FFHWSLMALI LFLVPVVVID SYYYGKLVIA PLNIVLYNVF TPHGPDLYGT
301 EPWYFYLING FLNFNVAFAL ALLVLPLTSL MEYLLQRFH

L58 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:42122 CAPLUS Full-text
DOCUMENT NUMBER: 138:84592
TITLE: Mutations in FZD4 gene encoding frizzled 4 receptor associated with familial exudative vitreoretinopathy and their use in diagnosis and therapy
INVENTOR(S): MacDonald, Marcia L.; Goldberg, Yigal P.; Hayden, Michael R.
PATENT ASSIGNEE(S): Xenon Genetics, Inc., Can.; University of British Columbia
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004045	A2	20030116	WO 2002-CA1016	20020705
WO 2003004045	A3	20030530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-303285P P 20010705
US 2001-340409P P 20011029
US 2002-360352P P 20020228

ED Entered STN: 17 Jan 2003
AB Mutations in frizzled 4 receptor genes, such as FZD4, associated with hereditary human visual disorders, such as familial exudative vitreoretinopathy ("FEVR") are disclosed. Methods of use of Wnt and/or Wnt receptor genes and proteins, including in assays for therapeutic agents useful in treating such diseases and/or ameliorating their effects as well as methods of diagnosing diseases and disorders caused by mutations in these genes are provided.
IT **480694-47-1**, Protein (human gene WNT11)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; mutations in FZD4 gene encoding frizzled 4 receptor associated with familial exudative vitreoretinopathy and their use in diagnosis and therapy)
RN 480694-47-1 CAPLUS
CN Protein (human gene WNT11) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **480694-47-1**, Protein (human gene WNT11)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; mutations in FZD4 gene encoding frizzled 4 receptor associated with familial exudative vitreoretinopathy and their use in diagnosis and therapy)
RN 480694-47-1 CAPLUS
CN Protein (human gene WNT11) (9CI) (CA INDEX NAME)

```
SEQ      1 MRARPQVCEA LLFALALQTG VCYGIKWLAL SKTPSALALN QTQHCKQLEG
        51 LVSAQVQLCR SNLELMHTVV HAAREVMKAC RRAFADMRWN CSSIELAPNY
       101 LLDLERGTRE SAFVYALSAA TISHAIARAC TSGDLPGCSC GPVPGEPPGP
       151 GNRWGRCADN LSYGLLMGAK FSDAPMKVKK TGSQANKLMR LHNSEVGRQA
       201 LRASLEMKCK CHGVSGSCSI RTCWKGLQEL QDVAADLKTR YLSATKVVHR
       251 PMGTRKHLVP KDLDIRPVKD WELVYLQSSP DFCMKNEKVG SHGTQDRQCN
       301 KTSNGSDSCD LMCCGRGYNP YTDRVVERCH CKYHWCCYVT CRRCERTVER
       351 YVCK
```

L58 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:832948 CAPLUS Full-text

DOCUMENT NUMBER: 137:351508

TITLE: Methods of producing or identifying intracellular antibodies (intrabodies) in eukaryotic cells for therapeutic uses

INVENTOR(S): Zauderer, Maurice; Wei, Chungwen; Smith, Ernest S.

PATENT ASSIGNEE(S): University of Rochester Medical Center, USA

SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002086096	A2	20021031	WO 2002-US1677		20020123
WO 2002086096	A3	20031009			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002338446	A1	20021105	AU 2002-338446		20020123
US 2003104402	A1	20030605	US 2002-52942		20020123
PRIORITY APPLN. INFO.:			US 2001-263225P	P	20010123
			US 2001-263200P	P	20010124
			US 2001-271422P	P	20010227
			US 2001-298095P	P	20010615
			WO 2002-US1677	W	20020123

ED Entered STN: 01 Nov 2002

AB The present invention relates to a high efficiency method of expressing intrabodies or intracellular Ig mols. in eukaryotic cells. The invention is further drawn to a method of producing intracellular Ig libraries, particularly using the trimol. recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for intracellular Ig mols. and fragments thereof. The invention also provides kits for producing, screening and selecting intracellular Ig mols. Finally, the invention provides intracellular Ig mols. and fragments thereof, produced by the methods provided herein.

IT **474564-70-0**
RL: PRP (Properties)
(unclaimed protein sequence; methods of producing or identifying intracellular antibodies (intrabodies) in eukaryotic cells for therapeutic uses)
RN 474564-70-0 CAPLUS
CN L-Isoleucine, L-methionyl-L-leucyl-L-isoleucyl-L-prolyl-L-isoleucyl-L-alanylglycyl-L-phenylalanyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanylglycyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl-L-valyl-L-leucyl-L-isoleucyl-L-alanyl-L-tyrosyl-L-leucyl-L-isoleucylglycyl-L-arginyl-L-lysyl-L-arginyl-L-seryl-L-histidyl-L-alanylglycyl-L-tyrosyl-L-glutaminyl-L-threonyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **474564-70-0**
RL: PRP (Properties)
(unclaimed protein sequence; methods of producing or identifying intracellular antibodies (intrabodies) in eukaryotic cells for therapeutic uses)
RN 474564-70-0 CAPLUS
CN L-Isoleucine, L-methionyl-L-leucyl-L-isoleucyl-L-prolyl-L-isoleucyl-L-alanylglycyl-L-phenylalanyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanylglycyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl-L-valyl-L-leucyl-L-isoleucyl-L-alanyl-L-tyrosyl-L-leucyl-L-isoleucylglycyl-L-arginyl-L-lysyl-L-arginyl-L-seryl-L-histidyl-L-alanylglycyl-L-tyrosyl-L-glutaminyl-L-threonyl- (9CI) (CA INDEX NAME)

SEQ 1 MLIPIAGFFA LAGLVLIVLI AYLIGRKRSH AGYQTI

L58 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:368690 CAPLUS Full-text
DOCUMENT NUMBER: 136:381354
TITLE: Novel markers for diagnosis and therapy of cutaneous T cell lymphoma
INVENTOR(S): Eichmueller, Stefan; Schadendorf, Dirk; Usener, Dirk
PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffenlichen Rechts, Germany
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038803	A2	20020516	WO 2001-DE4229	20011108
WO 2002038803	A3	20030717		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10055285	A1	20020606	DE 2000-10055285	20001108
AU 2002018977	A5	20020521	AU 2002-18977	20011108
EP 1349871	A2	20031008	EP 2001-993706	20011108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004197782	A1	20041007	US 2003-416330	20031215
PRIORITY APPLN. INFO.:			DE 2000-10055285 A	20001108
			WO 2001-DE4229 W	20011108

ED Entered STN: 18 May 2002

AB The invention relates to novel markers for tumors, preferably cutaneous T cell lymphoma (CTCL). The invention further relates to the application of the above for the diagnosis and therapy of tumor-related diseases, preferably CTCL. Thus, CTCL-associated cDNAs corresponding to 19 different genes were identified, 5 being novel. Of the remaining cDNAs, some displayed sequence homol. to SCP-1, one to NP220, and one to RAP140.

IT **425446-46-4**

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; novel markers for diagnosis and therapy of cutaneous T cell lymphoma)

RN 425446-46-4 CAPLUS

CN Protein GBP-TA (human skin T-cell lymphoma-associated) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **425446-46-4**

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; novel markers for diagnosis and therapy of cutaneous T cell lymphoma)

RN 425446-46-4 CAPLUS

CN Protein GBP-TA (human skin T-cell lymphoma-associated) (9CI) (CA INDEX NAME)

SEQ
```
  1 MALEIHMSDP MCLIENFNEQ LKVNQEALEI LSAITQPVVV VAIVGLYRTG
 51 KSYLMNKLAG KNKGFSVAST VQSHTKGIWI WCVPHPNWPN HTLVLLDTEG
101 LGDVEKADNK NDIQIFALAL LLSSTFVYNT VNKIDQGAID LLHNVTELTD
151 LLKARNSPDL DRVEDPADSA SFFPDLVWTL RDFCLGLEID GQLVTPDEYL
201 ENSLRPKQGS DQRVQNFNLP RLCIQKFFPK KKCFIFDLPA HQKKLAQLET
251 LPDDELEPEF VQQVTEFCSY IFSHSMTKTL PGGIMVNGSR LKNLVLTYVN
301 AISSGDLPCI ENAVLALAQR ENSAAVQKAI AHYDQQMGQK VQLPMETLQE
351 LLDLHRTSER EAIEVFMKNS FKDVDQSFQK ELETLLDAKQ NDICKRNLEA
401 SSDYCSALLK DIFGPLEEAV KQGIYSKPGG HNLFIQKTEE LKAKYYREPR
451 KGIQAEEVLQ KYLKSKESVS HAILQTDQAL TETEKKKKEA QVKAEAEKAE
501 AQRLAAIQRQ NEQMMQERER LHQEQVRQME IAKQNWLAEQ QKMQEQQMQE
551 QAAQLSTTFQ AQNRSLLSEL QHAQRTVNND DPCVLL
```

L58 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:553599 CAPLUS Full-text

DOCUMENT NUMBER: 133:159917

TITLE: Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease

INVENTOR(S): Tanzi, Rudolph E.; Kovacs, Dora M.; Saunders, Aleister J.

PATENT ASSIGNEE(S): General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046246	A1	20000810	WO 2000-US2412	20000202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6472140	B1	20021029	US 1999-241606	19990202
EP 1153036	A1	20011114	EP 2000-907091	20000202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002541770	T	20021210	JP 2000-597316	20000202

PRIORITY APPLN. INFO.:			
US 1999-241606	A	19990202
US 1997-57655P	P	19970905
US 1998-93297P	P	19980717
US 1998-148503	A2	19980904
WO 2000-US2412	W	20000202

ED Entered STN: 11 Aug 2000

AB The disclosed invention relates to the finding that the A2M-2 deletion mutation, which is a predisposing factor for Alzheimer's Disease, leads to the production of altered α2M RNA transcripts and proteins. Based on this finding, the invention provides for new therapeutic agents for AD, including mols. having Aβ and low d. lipoprotein receptor-related protein (LRP) binding domains, peptides, nucleic acid mols., antisense oligonucleotides, and viral vectors for gene therapy. In addition, the invention relates to pharmaceutical compns. containing these therapeutic agents, methods of using these therapeutic agents to combat Alzheimer's Disease, and methods of screening for therapeutic agents that can combat Alzheimer's Disease.

IT **287743-14-0**, α2-Macroglobulin (human)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; α2-macroglobulin therapies and drug screening methods for Alzheimer's disease)

RN 287743-14-0 CAPLUS

CN α2-Macroglobulin (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **287743-14-0**, α2-Macroglobulin (human)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; α2-macroglobulin therapies and drug screening methods for Alzheimer's disease)

RN 287743-14-0 CAPLUS

CN α2-Macroglobulin (human) (9CI) (CA INDEX NAME)

```
SEQ      1 MGKNKLLHPS LVLLLLVLLP TDASVSGKPQ YMVLVPSLLH TETTEKGCVL
        51 LSYLNETVTV SASLESVRGN RSLFTDLEAE NDVLHCVAFA VPKSSSNEEV
       101 MFLTVQVKGP TQEFKKRTTV MVKNEDSLVF VQTDKSIYKP GQTVKFRVVS
       151 MDENFHPLNE LIPLVYIQDP KGNRIAQWQS FQLEGGLKQF SFPLSSEPFQ
       201 GSYKVVVQKK SGGRTEHPFT VEEFVLPKFE VQVTVPKIIT ILEEEMNVSV
       251 CGLYTYGKPV PGHVTVSICR KYSDASDCHG EDSQAFCEKF SGQLNSHGCF
       301 YQQVKTKVFQ LKRKEYEMKL HTEAQIQEEG TVVELTGRQS SEITRTITKL
       351 SFVKVDSHFR QGIPFFGQVR LVDGKGVPIP NKVIFIRGNE ANYYSNATTD
       401 EHGLVQFSIN TTNVMGTSLT VRVNYKDRSP CYGYQWVSEE HEEAHHTAYL
       451 VFSPSKSFVH LEPMSHELPC GHTQTVQAHY ILNGGTLLGL KKLSFYYLIM
       501 AKGGIVRTGT HGLLVKQEDM KGHFSISIPV KSDIAPVARL LIYAVLPTGD
       551 VIGDSAKYDV ENCLANKVDL SFSPSQSLPA SHAHLRVTAA PQSVCALRAV
       601 DQSVLLMKPD AELSASSVYN LLPEKDLTGF PGPLNDQDDE DCINRHNVYI
       651 NGITYTPVSS TNEKDMYSFL EDMGLKAFTN SKIRKPKMCP QLQQYEMHGP
       701 EGLRVGFYES DVMGRGHARL VHVEEPHTET VRKYFPETWI WDLVVVNSAG
       751 VAEVGVTVPD TITEWKAGAF CLSEDAGLGI SSTASLRAFQ PFFVELTMPY
       801 SVIRGEAFTL KATVLNYLPK CIRVSVQLEA SPAFLAVPVE KEQAPHCICA
       851 NGRQTVSWAV TPKSLGNVNF TVSAEALESQ ELCGTEVPSV PEHGRKDTVI
       901 KPLLVEPEGL EKETTFNSLL CPSGGEVSEE LSLKLPPNVV EESARASVSV
       951 LGDILGSAMQ NTQNLLQMPY GCGEQNMVLF APNIYVLDYL NETQQLTPEI
      1001 KSKAIGYLNT GYQRQLNYKH YDGSYSTFGE RYGRNQGNTW LTAFVLKTFA
      1051 QARAYIFIDE AHITQALIWL SQRQKDNGCF RSSGSLLNNA IKGGVEDEVT
      1101 LSAYITIALL EIPLTVTHPV VRNALFCLES AWKTAQEGDH GSHVYTKALL
      1151 AYAFALAGNQ DKRKEVLKSL NEEAVKKDNS VHWERPQKPK APVGHFYEPQ
      1201 APSAEVEMTS YVLLAYLTAQ PAPTSEDLTS ATNIVKWITK QQNAQGGFSS
      1251 TQDTVVALHA LSKYGAATFT RTGKAAQVTI QSSGTFSSKF QVDNNNRLLL
      1301 QQVSLPELPG EYSMKVTGEG CVYLQTSLKY NILPEKEEFP FALGVQTLPQ
      1351 TCDEPKAHTS FQISLSVSYT GSRSASNMAI VDVKMVSGFI PLKPTVKMLE
      1401 RSNHVSRTEV SSNHVLIYLD KVSNQTLSLF FTVLQDVPVR DLKPAIVKVY
      1451 DYYETDEFAI AEYNAPCSKD LGNA
```

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:452338 CAPLUS Full-text
DOCUMENT NUMBER: 133:85150
TITLE: Protein and cDNA sequences of a Rho GTPase-activating protein, designated PARG, which interacts with PTPL1 phosphatase, and therapeutic uses thereof
INVENTOR(S): Saras, Jan; Franzen, Petra; Aspenstrom, Pontus; Hellman, Ulf; Gonez, Leonel Jorge; Heldin, Carl-Henrik
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA
SOURCE: U.S., 54 pp., Cont.-in-part of U.S. Ser. No. 805,583, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6083721	A	20000704	US 1998-80855	19980518
US 6475775	B1	20021105	US 2000-566076	20000508
US 2003166232	A1	20030904	US 2002-177980	20020621
PRIORITY APPLN. INFO.:			US 1997-805583 B2	19970225
			US 1998-80855 A3	19980518

US 2000-566076 A3 20000508

ED Entered STN: 05 Jul 2000

AB The invention provides protein and cDNA sequences of a Rho GTPase-activating protein, designated PARG, which interacts with PTPL1 phosphatase. PARG is a 150 kDa protein that comprises a GAP domain, a ZPII domain, a cysteine-rich domain, and a PDZ domain. The GAP domain displays strong activity towards Rho, and the C-terminal tail of PARG specifically interacts with the fourth PDZ domain of PTPL1. The invention also relates to methods of modulating Rho GTPase signal transduction, treating cancers, and to drug screening assays.

IT **158651-88-8**
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of a Rho GTPase-activating protein, designated PARG, which interacts with PTPL1 phosphatase, and therapeutic uses thereof)

RN 158651-88-8 CAPLUS

CN Phosphatase, phosphoprotein (phosphotyrosine) (human clone p6B isoenzyme L1) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **158651-88-8**
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of a Rho GTPase-activating protein, designated PARG, which interacts with PTPL1 phosphatase, and therapeutic uses thereof)

RN 158651-88-8 CAPLUS

CN Phosphatase, phosphoprotein (phosphotyrosine) (human clone p6B isoenzyme L1) (9CI) (CA INDEX NAME)

SEQ

```
      1 MHVSLAEALE VRGGPLQEEE IWAVLNQSAE SLQELFRKVS LADPAALGFI
     51 ISPWSLLLLP SGSVSFTDEN ISNQDLRAFT APEVLQNQSL TSLSDVEKIH
    101 IYSLGMTLYW GADYEVPQSQ PIKLGDHLNS ILLGMCEDVI YARVSVRTVL
    151 DACSAHIRNS NCAPSFSYVK HLVKLVLGNL SGTDQLSCNS EQKPDRSQAI
    201 RDRLRGKGLP TGRSSTSDVL DIQKPPLSHQ TFLNKGLSKS MGFLSIKDTQ
    251 DENYFKDILS DNSGREDSEN TFSPYQFKTS GPEKKPIPGI DVLSKKKIWA
    301 SSMDLLCTAD RDFSSGETAT YRRCHPEAVT VRTSTTPRKK EARYSDGSIA
    351 LDIFGPQKMD PIYHTRELPT SSAISSALDR IRERQKKLQV LREAMNVEEP
    401 VRRYKTYHGD VFSTSSESPS IISSESDFRQ VRRSEASKRF ESSSGLPGVD
    451 ETLSQGQSQR PSRQYETPFE GNLINQEIML KRQEEELMQL QAKMALRQSR
    501 LSLYPGDTIK ASMLDITRDP LREIALETAM TQRKLRNFFG PEFVKMTIEP
    551 FISLDLPRSI LTKKGKNEDN RRKVNIMLLN GQRLELTCDT KTICKDVFDM
    601 VVAHIGLVEH HLFALATLKD NEYFFVDPDL KLTKVAPEGW KEEPKKKTKA
    651 TVNFTLFFRI KFFMDDVSLI QHTLTCHQYY LQLRKDILEE RMHCDDETSL
    701 LLASLALQAE YGDYQPEVHG VSYFRMEHYL PARVMEKLDL SYIKEELPKL
    751 HNTYVGASEK ETELEFLKVC QRLTEYGVHF HRVHPEKKSQ TGILLGVCSK
    801 GVLVFEVHNG VRTLVLRFPW RETKKISFSK KKITLQNTSD GIKHGFQTDN
    851 SKICQYLLHL CSYQHKFQLQ MRARQSNQDA QDIERASFRS LNLQAESVRG
    901 FNMGRAISTG SLASSTLNKL AVRPLSVQAE ILKRLSCSEL SLYQPLQNSS
    951 KEKNDKASWE EKPREMSKSY HDLSQASLYP HRKNVIVNME PPPQTVAELV
   1001 GKPSHQMSRS DAESLAGVTK LNNSKSVASL NRSPERRKHE SDSSSIEDPG
   1051 QAYVLDVLHK RWSIVSSPER EITLVNLKKD AKYGLGFQII GGEKMGRLDL
   1101 GIFISSVAPG GPADFHGCLK PGDRLISVNS VSLEGVSHHA AIEILQNAPE
   1151 DVTLVISQPK EKISKVPSTP VHLTNEMKNY MKKSSYMQDS AIDSSSKDHH
   1201 WSRGTLRHIS ENSFGPSGGL REGSLSSQDS RTESASLSQS QVNGFFASHL
   1251 GDQTWQESQH GSPSPSVISK ATEKETFTDS NQSKTKKPGI SDVTDYSDRG
   1301 DSDMDEATYS SSQDHQTPKQ ESSSSVNTSN KMNFKTFSSS PPKPGDIFEV
   1351 ELAKNDNSLG ISVTGGVNTS VRHGGIYVKA VIPQGAAESD GRIHKGDRVL
   1401 AVNGVSLEGA THKQAVETLR NTGQVVHLLL EKGQSPTSKE HVPVTPQCTL
   1451 SDQNAQGQGP EKVKKTTQVK DYSFVTEENT FEVKLFKNSS GLGFSFSRED
   1501 NLIPEQINAS IVRVKKLFAG QPAAESGKID VGDVILKVNG ASLKGLSQQE
```

```
1551 VISALRGTAP EVFLLLCRPP PGVLPEIDTA LLTPLQSPAQ VLPNSSKDSS
1601 QPSCVEQSTS SDENEMSDKS KKQCKSPSRR DSYSDSSGSG EDDLVTAPAN
1651 ISNSTWSSAL HQTLSNMVSQ AQSHHEAPKS QEDTICTMFY YPQKIPNKPE
1701 FEDSNPSPLP PDMAPGQSYQ PQSESASSSS MDKYHIHHIS EPTRQENWTP
1751 LKNDLENHLE DFELEVELLI TLIKSEKASL GFTVTKGNQR IGCYVHDVIQ
1801 DPAKSDGRLK PGDRLIKVND TDVTNMTHTD AVNLLRAASK TVRLVIGRVL
1851 ELPRIPMLPH LLPDITLTCN KEELGFSLCG GHDSLYQVVY ISDINPRSVA
1901 AIEGNLQLLD VIHYVNGVST QGMTLEEVNR ALDMSLPSLV LKATRNDLPV
1951 VPSSKRSAVS APKSTKGNGS YSVGSCSQPA LTPNDSFSTV AGEEINEISY
2001 PKGKCSTYQI KGSPNLTLPK ESYIQEDDIY DDSQEAEVIQ SLLDVVDEEA
2051 QNLLNENNAA GYSCGPGTLK MNGKLSEERT EDTDCDGSPL PEYFTEATKM
2101 NGCEEYCEEK VKSESLIQKP QEKKTDDDEI TWGNDELPIE RTNHEDSDKD
2151 HSFLTNDELA VLPVVKVLPS GKYTGANLKS VIRVLRGLLD QGIPSKELEN
2201 LQELKPLDQC LIGQTKENRR KNRYKNILPY DATRVPLGDE GGYINASFIK
2251 IPVGKEEFVY IACQGPLPTT VGDFWQMIWE QKSTVIAMMT QEVEGEKIKC
2301 QRYWPNILGK TTMVSNRLRL ALVRMQQLKG FVVRAMTLED IQTREVRHIS
2351 HLNFTAWPDH DTPSQPDDLL TFISYMRHIH RSGPIITHCS AGIGRSGTLI
2401 CIDVVLGLIS QDLDFDISDL VRCMRLQRHG MVQTEDQYIF CYQVILYVLT
2451 RLQAEEEQKQ QPQLLK
```

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:672481 CAPLUS Full-text
DOCUMENT NUMBER: 129:293890
TITLE: **Ligand**/lytic peptide compositions and methods of use
INVENTOR(S): Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William B.; Koonce, Kenneth L.; Foil, Lane D.
PATENT ASSIGNEE(S): Demeter Biotechnologies, Ltd., USA; Louisiana State University and Agricultural and Mechanical College
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842364	A1	19981001	WO 1998-US6013	19980326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865879	A	19981020	AU 1998-65879	19980326
EP 988048	A1	20000329	EP 1998-912077	19980326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CA 2302392	A1	19990311	CA 1998-2302392	19980901
WO 9911282	A1	19990311	WO 1998-US18117	19980901
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP,				

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9892138	A	19990322	AU 1998-92138	19980901
JP 2001514231	T	20010911	JP 2000-508384	19980901
US 6680058	B1	20040120	US 2000-486143	20000222
PRIORITY APPLN. INFO.:			US 1997-41009P P	19970327
			US 1997-869153 A	19970604
			US 1997-57456P P	19970903
			WO 1998-US6013 W	19980326
			WO 1998-US18117 W	19980901

ED Entered STN: 23 Oct 1998

AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compds. are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components - the ligand and the lytic peptide - may optionally be administered as a fusion peptide, or they may be administered sep., with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compds. may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

IT **133084-63-6**, Hecate
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)

RN 133084-63-6 CAPLUS

CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



PAGE 5-A



IT **214142-46-8 214142-48-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)
RN 214142-46-8 CAPLUS
CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 214142-48-0 CAPLUS
CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **133084-63-6**, Hecate
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)
RN 133084-63-6 CAPLUS
CN L-Leucine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-

L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



PAGE 5-A



IT **214142-46-8 214142-48-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**ligand**/lytic peptide compns. for contraceptive and therapeutic use)

RN 214142-46-8 CAPLUS

CN L-Leucine, L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycyl-L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 QHWSYGLRPG FALALKALKK ALKKLKKALK KAL

RN 214142-48-0 CAPLUS

CN Glycine, L-phenylalanyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 FALALKALKK ALKKLKKALK KALQHWSYGL RPG

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT